var title_f23_39_24176="Skin biopsy adult Stills";
var content_f23_39_24176=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F56878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F56878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin biospy from adult onset Still's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This skin biopsy demonstrates some mild perivascular inflammation and dermal edema in an area of skin involved with the rash of adult Still's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa Mandl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24176=[""].join("\n");
var outline_f23_39_24176=null;
var title_f23_39_24177="Uric acid crystals in the urine";
var content_f23_39_24177=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F61827%7ENEPH%2F73642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F61827%7ENEPH%2F73642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uric acid crystals in the urine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment loaded with uric acid crystals. These crystals are pleomorphic, most often appearing as rhombic plates or rosettes. They are yellow or reddish-brown and form only in an acid urine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harvard Medical School.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uric acid crystals under polarized light",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urine sediment showing uric acid crystals viewed under polarized light.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24177=[""].join("\n");
var outline_f23_39_24177=null;
var title_f23_39_24178="Pathologic skin picking back";
var content_f23_39_24178=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Psychogenic excoriations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Excoriated and lichenified lesions with postinflammatory hyperpigmentation. Note the relative sparing of the less accessible scapular areas in typical \"butterfly distribution\".",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24178=[""].join("\n");
var outline_f23_39_24178=null;
var title_f23_39_24179="Cheilitis PI";
var content_f23_39_24179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F77776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F77776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Cheilitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cheilitis means inflammation of the lips. There are different types of cheilitis. Photo A shows \"actinic\" cheilitis, which causes the lips to be red and scaly. Photo B shows \"angular\" cheilitis, which causes cracking and redness in the corners of the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24179=[""].join("\n");
var outline_f23_39_24179=null;
var title_f23_39_24180="Ceftriaxone: Patient drug information";
var content_f23_39_24180=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ceftriaxone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     see \"Ceftriaxone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=see_link\">",
"     see \"Ceftriaxone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F148198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rocephin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F148199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ceftriaxone for Injection;",
"     </li>",
"     <li>",
"      Ceftriaxone Sodium for Injection BP;",
"     </li>",
"     <li>",
"      Rocephin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not give to a newborn whose skin or eyes are yellow or who has high bilirubin levels in the blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ceftriaxone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11907 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-2EEB765D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24180=[""].join("\n");
var outline_f23_39_24180=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148198\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F148199\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015374\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015373\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015378\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015379\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015381\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015376\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015377\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015382\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015383\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=related_link\">",
"      Ceftriaxone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/19/312?source=related_link\">",
"      Ceftriaxone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_39_24181="Hepatitis B immune globulin: Pediatric drug information";
var content_f23_39_24181=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Hepatitis B immune globulin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"    see \"Hepatitis B immune globulin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/42/28323?source=see_link\">",
"    see \"Hepatitis B immune globulin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HepaGam B&reg;;",
"     </li>",
"     <li>",
"      HyperHEP B&trade; S/D;",
"     </li>",
"     <li>",
"      Nabi-HB&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HepaGam B&reg;;",
"     </li>",
"     <li>",
"      HyperHEP B&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2649544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immune Globulin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Perinatal exposure, prophylaxis",
"     </b>",
"     (CDC, 2005):",
"     <b>",
"      Note:",
"     </b>",
"     HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neonates born to  HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-positive mothers:",
"     </i>",
"     I.M.: 0.5 mL as soon after birth as possible (within 12 hours; efficacy decreases significantly if treatment is delayed &gt;48 hours); hepatitis B vaccine series to begin at the same time; if this series is delayed for as long as 3 months, the HBIG dose may be repeated (Saari, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Neonates born to mothers with unknown HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag status at birth:",
"     </i>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Birth weight &lt;2 kg: 0.5 mL within 12 hours of birth (along with hepatitis B vaccine) if unable to determine maternal HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag status within that time",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Birth weight &ge;2 kg: 0.5 mL within 7 days of birth while awaiting maternal HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag results; if mother is determined to be HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag positive, administer dose as soon as possible.",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2649554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=see_link\">",
"      see \"Hepatitis B immune globulin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Note:",
"     </b>",
"     For exposure prophylaxis, HBIG may be administered at the same time (but at a different site) or up to 1 month preceding hepatitis B vaccination without impairing the active immune response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Perinatal exposure, prophylaxis",
"     </b>",
"     (CDC, 2005):",
"     <i>",
"      Infants born to HB",
"      <sub>",
"       s",
"      </sub>",
"      Ag-positive mothers:",
"     </i>",
"     I.M.: 0.5 mL as a repeat of birth dose if the hepatitis B vaccination series is delayed for as long as 3 months (hepatitis B vaccine should also be administered at the same time/different site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Postexposure, prophylaxis:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants &lt;12 months: I.M.: 0.5 mL as soon as possible after exposure (eg, mother or primary caregiver with acute HBV infection); initiate hepatitis B vaccine series",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 months and Adolescents: I.M.: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28-30 days after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Postexposure, prophylaxis:",
"     </b>",
"     I.M.: 0.06 mL/kg as soon as possible after exposure (ie, within 24 hours of needlestick, ocular, or mucosal exposure or within 14 days of sexual exposure); repeat at 28-30 days after exposure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of hepatitis B recurrence in liver transplant patients:",
"     </b>",
"     I.V.: HepaGam B&trade;: 20,000 international units/dose according to the following schedule:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Anhepatic phase (initial dose): One dose given with the liver transplant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Week 1 postop: One dose daily for 7 days (days 1-7)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Weeks 2-12 postop: One dose every 2 weeks starting on day 14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Month 4 onward: One dose monthly starting on month 4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose adjustment:  Adjust dose to reach anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     levels of 500 int. units/L within the first week after transplantation. In patients with surgical bleeding, abdominal fluid drainage &gt;500 mL or those undergoing plasmapheresis, administer 10,000 int. units/dose every 6 hours until target anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     levels are reached.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosing adjustments provided in the manufacturer labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HepaGam B&reg;: Anti-HBs &gt; 312 units/mL (1 mL, 5 mL) [contains maltose, polysorbate 80]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperHEP B&trade; S/D: Anti-HBs &gt; 220 units/mL (0.5 mL, 1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nabi-HB&reg;: Anti-HBs &gt; 312 units/mL (1 mL, 5 mL) [contains polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2649555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: Inject only in the anterolateral aspects of the upper thigh or the deltoid muscle; multiple injections may be necessary when the dosage is a large volume (postexposure prophylaxis). Do not administer hepatitis vaccine and HBIG in same syringe (vaccine will be neutralized); hepatitis vaccine may be administered at the same time at a separate site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: HepaGam B&trade;: Administer at 2 mL/minute. Decrease infusion to &lt;1 mL/minute for patient discomfort or infusion-related adverse events. Actual volume of dosage is dependent upon potency labeled on each individual vial. Nabi-HB&reg;: Although not FDA approved for this purpose, Nabi-HB&reg; has been administered intravenously in hepatitis B-positive liver transplant adult patients (Dickson, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2649551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze; use within 6 hours of puncturing the vial. HyperHEP  B&trade; S/D: May be exposed to room temperature for a cumulative 7 days (Cohen, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2649545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.M.: HepaGam  B&reg;, HyperHEP B&trade; S/D, Nabi-HB&reg;: Provide prophylactic post-exposure passive immunity to hepatitis B following perinatal exposure of infants born to HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive mothers (FDA approved in neonates and infants); provide prophylactic postexposure passive immunity to hepatitis B following acute exposure to blood containing hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag), sexual exposure to HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive persons, or household exposure to persons with acute HBV infection (FDA approved in infants, children, and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: HepaGam B&reg;: Prevention of hepatitis B virus recurrence after liver transplantation in HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag-positive transplant patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hepatitis B immune globulin is not indicated for treatment of active hepatitis B infection and is ineffective in the treatment of chronic active hepatitis B infection.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6052749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       HBIG may be confused with BabyBIG",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F178949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reported with postexposure prophylaxis; frequency not defined. Adverse events reported in liver transplant patients included tremor and hypotension, were associated with a single infusion during the first week of treatment, and did not recur with additional infusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Central nervous system: Dizziness, fainting, headache, lightheadedness, malaise",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, bruising, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: WBC decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Ache, erythema, pain, and/or tenderness at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, joint stiffness, myalgia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cold symptoms",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, flu-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2649547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to hepatitis B immune globulin  or any component; severe allergy to gamma globulin or anti-immunoglobulin therapies. Additional contraindication: HepaGam B&reg;: Postexposure prophylaxis in patients with severe thrombocytopenia or other coagulation disorders which would contraindicate I.M. injections (administer only if benefit outweighs the risk)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2649632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; administer with caution in patients with IgA deficiency or a prior history of systemic allergic reactions following the administration of human immunoglobulin preparations. When administered I.V., do not exceed recommended infusion rates; may increase risk of adverse events (eg, hypotension, chills, dizziness, headache, pyrexia, cold sweat); patients should be monitored for adverse events during and after the infusion. Thrombotic events have been reported with administration of intravenous immune globulin; use with caution in patients of advanced age, with a history of atherosclerosis or cardiovascular and/or thrombotic risk factors, patients with impaired cardiac output, coagulation disorders, prolonged immobilization, or patients with known/suspected hyperviscosity. Consider a baseline assessment of blood viscosity in patients at risk for hyperviscosity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products may contain maltose, which may result in falsely-elevated blood glucose readings.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2649548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product of human plasma; may potentially contain infectious agents which could transmit disease. Screening of donors, as well as testing and/or inactivation or removal of certain viruses, reduces this risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Although extremely rare, severe hypersensitivity reactions including anaphylaxis may occur; epinephrine (1:1000) and other anaphylactic treatment agents should be readily available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Injection may contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986;",
"     <i>",
"      MMWR",
"     </i>",
"     , 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2530309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Use of HBIG is not contraindicated in pregnant women and may be used for postexposure prophylaxis when indicated (CDC, 2001). In addition, use of HBIG has been evaluated to reduce maternal to fetal transmission of hepatis B virus during pregnancy (ACOG, 2007)",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5203731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver transplant patients: anti-HB levels; infusion-related adverse events",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2649552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hepatitis  B immune globulin (HBIG) is a nonpyrogenic sterile solution containing immunoglobulin G (IgG) specific to hepatitis B surface antigen (HB",
"     <sub>",
"      s",
"     </sub>",
"     Ag). HBIG differs from immune globulin in the amount of anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     . Immune globulin is prepared from plasma that is not preselected for anti-HBs content. HBIG is prepared from plasma preselected for high titer anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     . In the U.S., HBIG has an anti-HB",
"     <sub>",
"      s",
"     </sub>",
"     high titer &gt;1:100,000 by IRA.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5203730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: Postexposure prophylaxis: 3-6 months",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2649553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Slow",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 17-25 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: 2-10 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;A Comprehensive Immunization Strategy to Eliminate Transmission of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part I: Immunization of Infants, Children, and Adolescents,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2005, 54(RR-16):1-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), U.S. Public Health Service, \"Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2001, 50(RR-11):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/11442229/pubmed\" id=\"11442229\" target=\"_blank\">",
"        11442229",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickson RC, Terrault NA, Ishitani M, et al, &ldquo;Protective Antibody Levels and Dose Requirements for IV 5% Nabi Hepatitis B Immune Globulin Combined With Lamivudine in Liver Transplantation for Hepatitis B-Induced End Stage Liver Disease,&rdquo;",
"      <i>",
"       Liver Transpl",
"      </i>",
"      , 2006,  12(1):124-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/16382463/pubmed\" id=\"16382463\" target=\"_blank\">",
"        16382463",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saari TN and American Academy of Pediatrics Committee on Infectious Diseases, \"Immunization of Preterm and Low Birth Weight Infants. American Academy of Pediatrics Committee on Infectious Diseases,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2003, 112(1 Pt 1):193-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/39/24181/abstract-text/12837889/pubmed\" id=\"12837889\" target=\"_blank\">",
"        12837889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13229 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24181=[""].join("\n");
var outline_f23_39_24181=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178933\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178934\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649544\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442598\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649554\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178920\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178907\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649555\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649551\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649545\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6052749\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178949\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649547\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649632\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649548\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299441\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178915\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178917\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2530309\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5203731\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649552\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5203730\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2649553\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28437?source=related_link\">",
"      Hepatitis B immune globulin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/42/28323?source=related_link\">",
"      Hepatitis B immune globulin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_39_24182="Nesidioblastosis Light";
var content_f23_39_24182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nesidioblastosis: Findings on histopathology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive insulin immunostaining of a hypertrophied islet (upper right) and two beta cells budding from an acinar duct (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of F John Service, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24182=[""].join("\n");
var outline_f23_39_24182=null;
var title_f23_39_24183="Lexicomp clinical abbreviations";
var content_f23_39_24183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F57469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F57469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lexicomp clinical abbreviations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abbreviation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meaning",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abbreviation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meaning",
"       </td>",
"       <td class=\"subtitle1\">",
"        Abbreviation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Meaning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Abbreviations, acronyms, and symbols that may be used in Lexicomp*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &frac12;NS",
"       </td>",
"       <td>",
"        0.45 percent sodium chloride",
"       </td>",
"       <td class=\"centered\">",
"        EF",
"       </td>",
"       <td>",
"        Ejection fraction",
"       </td>",
"       <td class=\"centered\">",
"        NS",
"       </td>",
"       <td>",
"        Normal saline (0.9 percent sodium chloride)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        5-HT",
"       </td>",
"       <td>",
"        5-hydroxytryptamine (serotonin)",
"       </td>",
"       <td class=\"centered\">",
"        EG",
"       </td>",
"       <td>",
"        Ethylene glycol",
"       </td>",
"       <td class=\"centered\">",
"        NSAID",
"       </td>",
"       <td>",
"        Nonsteroidal anti-inflammatory drug",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AAP",
"       </td>",
"       <td>",
"        American Academy of Pediatrics",
"       </td>",
"       <td class=\"centered\">",
"        EGA",
"       </td>",
"       <td>",
"        Estimated gestational age",
"       </td>",
"       <td class=\"centered\">",
"        NSF",
"       </td>",
"       <td>",
"        Nephrogenic systemic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AAPC",
"       </td>",
"       <td>",
"        Antibiotic-associated pseudomembranous colitis",
"       </td>",
"       <td class=\"centered\">",
"        EIA",
"       </td>",
"       <td>",
"        Enzyme immunoassay",
"       </td>",
"       <td class=\"centered\">",
"        NSTEMI",
"       </td>",
"       <td>",
"        Non-ST-elevation myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ABG",
"       </td>",
"       <td>",
"        Arterial blood gases",
"       </td>",
"       <td class=\"centered\">",
"        ELBW",
"       </td>",
"       <td>",
"        Extremely low birth weight",
"       </td>",
"       <td class=\"centered\">",
"        NYHA",
"       </td>",
"       <td>",
"        New York Heart Association",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ABMT",
"       </td>",
"       <td>",
"        Autologous bone marrow transplant",
"       </td>",
"       <td class=\"centered\">",
"        ELISA",
"       </td>",
"       <td>",
"        Enzyme-linked immunosorbent assay",
"       </td>",
"       <td class=\"centered\">",
"        OA",
"       </td>",
"       <td>",
"        Osteoarthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ABW",
"       </td>",
"       <td>",
"        Adjusted body weight",
"       </td>",
"       <td class=\"centered\">",
"        EPS",
"       </td>",
"       <td>",
"        Extrapyramidal side effects",
"       </td>",
"       <td class=\"centered\">",
"        OCD",
"       </td>",
"       <td>",
"        Obsessive-compulsive disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AACT",
"       </td>",
"       <td>",
"        American Academy of Clinical Toxicology",
"       </td>",
"       <td class=\"centered\">",
"        ESR",
"       </td>",
"       <td>",
"        Erythrocyte sedimentation rate",
"       </td>",
"       <td class=\"centered\">",
"        OHSS",
"       </td>",
"       <td>",
"        Ovarian hyperstimulation syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ACC",
"       </td>",
"       <td>",
"        American College of Cardiology",
"       </td>",
"       <td class=\"centered\">",
"        ESRD",
"       </td>",
"       <td>",
"        End stage renal disease",
"       </td>",
"       <td class=\"centered\">",
"        O.R.",
"       </td>",
"       <td>",
"        Operating room",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ACE",
"       </td>",
"       <td>",
"        Angiotensin-converting enzyme",
"       </td>",
"       <td class=\"centered\">",
"        E.T.",
"       </td>",
"       <td>",
"        Endotracheal",
"       </td>",
"       <td class=\"centered\">",
"        OTC",
"       </td>",
"       <td>",
"        Over-the-counter (nonprescription)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ACLS",
"       </td>",
"       <td>",
"        Advanced cardiac life support",
"       </td>",
"       <td class=\"centered\">",
"        EtOH",
"       </td>",
"       <td>",
"        Alcohol",
"       </td>",
"       <td class=\"centered\">",
"        PABA",
"       </td>",
"       <td>",
"        Para-aminobenzoic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ACOG",
"       </td>",
"       <td>",
"        American College of Obstetricians and Gynecologists",
"       </td>",
"       <td class=\"centered\">",
"        FDA",
"       </td>",
"       <td>",
"        Food and Drug Administration (United States)",
"       </td>",
"       <td class=\"centered\">",
"        PACTG",
"       </td>",
"       <td>",
"        Pediatric AIDS Clinical Trials Group",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ACTH",
"       </td>",
"       <td>",
"        Adrenocorticotrophic hormone",
"       </td>",
"       <td class=\"centered\">",
"        FEV1",
"       </td>",
"       <td>",
"        Forced expiratory volume exhaled after 1 second",
"       </td>",
"       <td class=\"centered\">",
"        PALS",
"       </td>",
"       <td>",
"        Pediatric advanced life support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ADH",
"       </td>",
"       <td>",
"        Antidiuretic hormone",
"       </td>",
"       <td class=\"centered\">",
"        FSH",
"       </td>",
"       <td>",
"        Follicle-stimulating hormone",
"       </td>",
"       <td class=\"centered\">",
"        PAT",
"       </td>",
"       <td>",
"        Paroxysmal atrial tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ADHD",
"       </td>",
"       <td>",
"        Attention-deficit/hyperactivity disorder",
"       </td>",
"       <td class=\"centered\">",
"        FTT",
"       </td>",
"       <td>",
"        Failure to thrive",
"       </td>",
"       <td class=\"centered\">",
"        PCA",
"       </td>",
"       <td>",
"        Patient-controlled analgesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ADI",
"       </td>",
"       <td>",
"        Adequate daily intake",
"       </td>",
"       <td class=\"centered\">",
"        FVC",
"       </td>",
"       <td>",
"        Forced vital capacity",
"       </td>",
"       <td class=\"centered\">",
"        PCP",
"       </td>",
"       <td>",
"        Pneumocystis jiroveci pneumonia (also called Pneumocystis carinii pneumonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ADLs",
"       </td>",
"       <td>",
"        Activities of daily living",
"       </td>",
"       <td class=\"centered\">",
"        G-6-PD, G6PD",
"       </td>",
"       <td>",
"        Glucose-6-phosphate dehydrogenase",
"       </td>",
"       <td class=\"centered\">",
"        PCWP",
"       </td>",
"       <td>",
"        Pulmonary capillary wedge pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AED",
"       </td>",
"       <td>",
"        Antiepileptic drug",
"       </td>",
"       <td class=\"centered\">",
"        GA",
"       </td>",
"       <td>",
"        Gestational age",
"       </td>",
"       <td class=\"centered\">",
"        PD",
"       </td>",
"       <td>",
"        Parkinson's disease; peritoneal dialysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AHA",
"       </td>",
"       <td>",
"        American Heart Association",
"       </td>",
"       <td class=\"centered\">",
"        GABA",
"       </td>",
"       <td>",
"        Gamma-aminobutyric acid",
"       </td>",
"       <td class=\"centered\">",
"        PDA",
"       </td>",
"       <td>",
"        Patent ductus arteriosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AHCPR",
"       </td>",
"       <td>",
"        Agency for Health Care Policy and Research",
"       </td>",
"       <td class=\"centered\">",
"        GAD",
"       </td>",
"       <td>",
"        Generalized anxiety disorder",
"       </td>",
"       <td class=\"centered\">",
"        PDE-5",
"       </td>",
"       <td>",
"        Phosphodiesterase-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AIDS",
"       </td>",
"       <td>",
"        Acquired immunodeficiency syndrome",
"       </td>",
"       <td class=\"centered\">",
"        GE",
"       </td>",
"       <td>",
"        Gastroesophageal",
"       </td>",
"       <td class=\"centered\">",
"        PE",
"       </td>",
"       <td>",
"        Pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AIMS",
"       </td>",
"       <td>",
"        Abnormal Involuntary Movement Scale",
"       </td>",
"       <td class=\"centered\">",
"        GERD",
"       </td>",
"       <td>",
"        Gastroesophageal reflux disease",
"       </td>",
"       <td class=\"centered\">",
"        PEG tube",
"       </td>",
"       <td>",
"        Percutaneous endoscopic gastrostomy tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ALL",
"       </td>",
"       <td>",
"        Acute lymphoblastic leukemia",
"       </td>",
"       <td class=\"centered\">",
"        GFR",
"       </td>",
"       <td>",
"        Glomerular filtration rate",
"       </td>",
"       <td class=\"centered\">",
"        P-gp",
"       </td>",
"       <td>",
"        P-glycoprotein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ALS",
"       </td>",
"       <td>",
"        Amyotrophic lateral sclerosis",
"       </td>",
"       <td class=\"centered\">",
"        GGT",
"       </td>",
"       <td>",
"        Gamma-glutamyltransferase",
"       </td>",
"       <td class=\"centered\">",
"        PHN",
"       </td>",
"       <td>",
"        Post-herpetic neuralgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ALT",
"       </td>",
"       <td>",
"        Alanine aminotransferase (formerly called SGPT)",
"       </td>",
"       <td class=\"centered\">",
"        GI",
"       </td>",
"       <td>",
"        Gastrointestinal",
"       </td>",
"       <td class=\"centered\">",
"        PICU",
"       </td>",
"       <td>",
"        Pediatric Intensive Care Unit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AMA",
"       </td>",
"       <td>",
"        American Medical Association",
"       </td>",
"       <td class=\"centered\">",
"        GU",
"       </td>",
"       <td>",
"        Genitourinary",
"       </td>",
"       <td class=\"centered\">",
"        PID",
"       </td>",
"       <td>",
"        Pelvic inflammatory disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AML",
"       </td>",
"       <td>",
"        Acute myeloblastic leukemia",
"       </td>",
"       <td class=\"centered\">",
"        GVHD",
"       </td>",
"       <td>",
"        Graft versus host disease",
"       </td>",
"       <td class=\"centered\">",
"        PIP",
"       </td>",
"       <td>",
"        Peak inspiratory pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ANA",
"       </td>",
"       <td>",
"        Antinuclear antibodies",
"       </td>",
"       <td class=\"centered\">",
"        HAM-A",
"       </td>",
"       <td>",
"        Hamilton Anxiety Scale",
"       </td>",
"       <td class=\"centered\">",
"        PMA",
"       </td>",
"       <td>",
"        Postmenstrual age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ANC",
"       </td>",
"       <td>",
"        Absolute neutrophil count",
"       </td>",
"       <td class=\"centered\">",
"        HAM-D",
"       </td>",
"       <td>",
"        Hamilton Depression Scale",
"       </td>",
"       <td class=\"centered\">",
"        PMDD",
"       </td>",
"       <td>",
"        Premenstrual dysphoric disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ANLL",
"       </td>",
"       <td>",
"        Acute nonlymphoblastic leukemia",
"       </td>",
"       <td class=\"centered\">",
"        HARS",
"       </td>",
"       <td>",
"        HIV-associated adipose redistribution",
"       </td>",
"       <td class=\"centered\">",
"        PNA",
"       </td>",
"       <td>",
"        Postnatal age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        aPTT",
"       </td>",
"       <td>",
"        Activated partial thromboplastin time",
"       </td>",
"       <td class=\"centered\">",
"        Hct",
"       </td>",
"       <td>",
"        Hematocrit",
"       </td>",
"       <td class=\"centered\">",
"        PONV",
"       </td>",
"       <td>",
"        Postoperative nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ARB",
"       </td>",
"       <td>",
"        Angiotensin receptor blocker",
"       </td>",
"       <td class=\"centered\">",
"        HDL-C",
"       </td>",
"       <td>",
"        High density lipoprotein cholesterol",
"       </td>",
"       <td class=\"centered\">",
"        PPHN",
"       </td>",
"       <td>",
"        Persistent pulmonary hypertension of the neonate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ARDS",
"       </td>",
"       <td>",
"        Acute respiratory distress syndrome",
"       </td>",
"       <td class=\"centered\">",
"        HF",
"       </td>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td class=\"centered\">",
"        PPN",
"       </td>",
"       <td>",
"        Peripheral parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ASA-PS",
"       </td>",
"       <td>",
"        <p>",
"         American Society of Anesthesiologists - Physical Status",
"        </p>",
"        <p>",
"         P1: Normal, healthy patient",
"        </p>",
"        <p>",
"         P2: Patient having mild systemic disease",
"        </p>",
"        <p>",
"         P3: Patient having severe systemic disease",
"        </p>",
"        <p>",
"         P4: Patient having severe systemic disease which is a constant threat to life",
"        </p>",
"        <p>",
"         P5: Moribund patient; not expected to survive without the procedure",
"        </p>",
"        P6: Patient declared brain-dead; organs being removed for donor purposes",
"       </td>",
"       <td class=\"centered\">",
"        HFA",
"       </td>",
"       <td>",
"        Hydrofluoroalkane",
"       </td>",
"       <td class=\"centered\">",
"        PROM",
"       </td>",
"       <td>",
"        Premature rupture of membranes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AST",
"       </td>",
"       <td>",
"        Aspartate aminotransferase (formerly called SGOT)",
"       </td>",
"       <td class=\"centered\">",
"        HFSA",
"       </td>",
"       <td>",
"        Heart Failure Society of America",
"       </td>",
"       <td class=\"centered\">",
"        PSVT",
"       </td>",
"       <td>",
"        Paroxysmal supraventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ATP",
"       </td>",
"       <td>",
"        Adenosine triphosphate",
"       </td>",
"       <td class=\"centered\">",
"        Hgb",
"       </td>",
"       <td>",
"        Hemoglobin",
"       </td>",
"       <td class=\"centered\">",
"        PT",
"       </td>",
"       <td>",
"        Prothrombin time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AUC",
"       </td>",
"       <td>",
"        Area under the curve (area under the serum concentration-time curve)",
"       </td>",
"       <td class=\"centered\">",
"        HIV",
"       </td>",
"       <td>",
"        Human immunodeficiency virus",
"       </td>",
"       <td class=\"centered\">",
"        PTH",
"       </td>",
"       <td>",
"        Parathyroid hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        A-V",
"       </td>",
"       <td>",
"        Atrial-ventricular",
"       </td>",
"       <td class=\"centered\">",
"        HMG-CoA",
"       </td>",
"       <td>",
"        3-hydroxy-3-methylglutaryl-coenzyme A",
"       </td>",
"       <td class=\"centered\">",
"        PTSD",
"       </td>",
"       <td>",
"        Post-traumatic stress disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BDI",
"       </td>",
"       <td>",
"        Beck Depression Inventory",
"       </td>",
"       <td class=\"centered\">",
"        HOCM",
"       </td>",
"       <td>",
"        Hypertrophic obstructive cardiomyopathy",
"       </td>",
"       <td class=\"centered\">",
"        PTT",
"       </td>",
"       <td>",
"        Partial thromboplastin time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BEC",
"       </td>",
"       <td>",
"        Blood ethanol concentration",
"       </td>",
"       <td class=\"centered\">",
"        HPA",
"       </td>",
"       <td>",
"        Hypothalamic-pituitary-adrenal",
"       </td>",
"       <td class=\"centered\">",
"        PUD",
"       </td>",
"       <td>",
"        Peptic ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BLS",
"       </td>",
"       <td>",
"        Basic life support",
"       </td>",
"       <td class=\"centered\">",
"        HPLC",
"       </td>",
"       <td>",
"        High performance liquid chromatography",
"       </td>",
"       <td class=\"centered\">",
"        PVC",
"       </td>",
"       <td>",
"        Premature ventricular contraction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BMI",
"       </td>",
"       <td>",
"        Body mass index",
"       </td>",
"       <td class=\"centered\">",
"        HSV",
"       </td>",
"       <td>",
"        Herpes simplex virus",
"       </td>",
"       <td class=\"centered\">",
"        PVD",
"       </td>",
"       <td>",
"        Peripheral vascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BMT",
"       </td>",
"       <td>",
"        Bone marrow transplant",
"       </td>",
"       <td class=\"centered\">",
"        HTN",
"       </td>",
"       <td>",
"        Hypertension",
"       </td>",
"       <td class=\"centered\">",
"        PVR",
"       </td>",
"       <td>",
"        Peripheral vascular resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BP",
"       </td>",
"       <td>",
"        Blood pressure",
"       </td>",
"       <td class=\"centered\">",
"        HUS",
"       </td>",
"       <td>",
"        Hemolytic uremic syndrome",
"       </td>",
"       <td class=\"centered\">",
"        QTc",
"       </td>",
"       <td>",
"        Corrected QT interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BPD",
"       </td>",
"       <td>",
"        Bronchopulmonary disease or dysplasia",
"       </td>",
"       <td class=\"centered\">",
"        IBD",
"       </td>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"       <td class=\"centered\">",
"        QTc-F",
"       </td>",
"       <td>",
"        Corrected QT interval by Fredricia's formula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BPH",
"       </td>",
"       <td>",
"        Benign prostatic hyperplasia",
"       </td>",
"       <td class=\"centered\">",
"        IBS",
"       </td>",
"       <td>",
"        Irritable bowel syndrome",
"       </td>",
"       <td class=\"centered\">",
"        RA",
"       </td>",
"       <td>",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BPRS",
"       </td>",
"       <td>",
"        Brief Psychiatric Rating Scale",
"       </td>",
"       <td class=\"centered\">",
"        IBW",
"       </td>",
"       <td>",
"        Ideal body weight",
"       </td>",
"       <td class=\"centered\">",
"        RAP",
"       </td>",
"       <td>",
"        Right arterial pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BSA",
"       </td>",
"       <td>",
"        Body surface area",
"       </td>",
"       <td class=\"centered\">",
"        ICD",
"       </td>",
"       <td>",
"        Implantable cardioverter defibrillator",
"       </td>",
"       <td class=\"centered\">",
"        RDA",
"       </td>",
"       <td>",
"        Recommended daily allowance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        BUN",
"       </td>",
"       <td>",
"        Blood urea nitrogen",
"       </td>",
"       <td class=\"centered\">",
"        ICH",
"       </td>",
"       <td>",
"        Intracranial hemorrhage",
"       </td>",
"       <td class=\"centered\">",
"        REM",
"       </td>",
"       <td>",
"        Rapid eye movement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CABG",
"       </td>",
"       <td>",
"        Coronary artery bypass graft",
"       </td>",
"       <td class=\"centered\">",
"        ICP",
"       </td>",
"       <td>",
"        Intracranial pressure",
"       </td>",
"       <td class=\"centered\">",
"        REMS",
"       </td>",
"       <td>",
"        Risk evaluation and mitigation strategies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CAD",
"       </td>",
"       <td>",
"        Coronary artery disease",
"       </td>",
"       <td class=\"centered\">",
"        IDDM",
"       </td>",
"       <td>",
"        Insulin-dependent diabetes mellitus",
"       </td>",
"       <td class=\"centered\">",
"        RIA",
"       </td>",
"       <td>",
"        Radioimmunoassay",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CADD",
"       </td>",
"       <td>",
"        Computer ambulatory drug delivery",
"       </td>",
"       <td class=\"centered\">",
"        IDSA",
"       </td>",
"       <td>",
"        Infectious Diseases Society of America",
"       </td>",
"       <td class=\"centered\">",
"        RNA",
"       </td>",
"       <td>",
"        Ribonucleic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cAMP",
"       </td>",
"       <td>",
"        Cyclic adenosine monophosphate",
"       </td>",
"       <td class=\"centered\">",
"        IgG",
"       </td>",
"       <td>",
"        Immune globulin G",
"       </td>",
"       <td class=\"centered\">",
"        RPLS",
"       </td>",
"       <td>",
"        Reversible posterior leukoencephalopathy syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CAN",
"       </td>",
"       <td>",
"        Canadian",
"       </td>",
"       <td class=\"centered\">",
"        IHSS",
"       </td>",
"       <td>",
"        Idiopathic hypertrophic subaortic stenosis",
"       </td>",
"       <td class=\"centered\">",
"        RSV",
"       </td>",
"       <td>",
"        Respiratory syncytial virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CAPD",
"       </td>",
"       <td>",
"        Continuous ambulatory peritoneal dialysis",
"       </td>",
"       <td class=\"centered\">",
"        I.M.",
"       </td>",
"       <td>",
"        Intramuscular",
"       </td>",
"       <td class=\"centered\">",
"        SA",
"       </td>",
"       <td>",
"        Sinoatrial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CAS",
"       </td>",
"       <td>",
"        Chemical abstract service",
"       </td>",
"       <td class=\"centered\">",
"        ILCOR",
"       </td>",
"       <td>",
"        International Liaison Committee on Resuscitation",
"       </td>",
"       <td class=\"centered\">",
"        SAD",
"       </td>",
"       <td>",
"        Seasonal affective disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CBC",
"       </td>",
"       <td>",
"        Complete blood count",
"       </td>",
"       <td class=\"centered\">",
"        INR",
"       </td>",
"       <td>",
"        International normalized ratio",
"       </td>",
"       <td class=\"centered\">",
"        SAH",
"       </td>",
"       <td>",
"        Subarachnoid hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CBT",
"       </td>",
"       <td>",
"        Cognitive behavioral therapy",
"       </td>",
"       <td class=\"centered\">",
"        Int. unit",
"       </td>",
"       <td>",
"        International unit",
"       </td>",
"       <td class=\"centered\">",
"        SBE",
"       </td>",
"       <td>",
"        Subacute bacterial endocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CDC",
"       </td>",
"       <td>",
"        Centers for Disease Control and Prevention",
"       </td>",
"       <td class=\"centered\">",
"        I.O.",
"       </td>",
"       <td>",
"        Intraosseous",
"       </td>",
"       <td class=\"centered\">",
"        SBP",
"       </td>",
"       <td>",
"        Systolic blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CF",
"       </td>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"       <td class=\"centered\">",
"        I &amp; O",
"       </td>",
"       <td>",
"        Input and output",
"       </td>",
"       <td class=\"centered\">",
"        Scr",
"       </td>",
"       <td>",
"        Serum creatinine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CFC",
"       </td>",
"       <td>",
"        Chlorofluorocarbons",
"       </td>",
"       <td class=\"centered\">",
"        IOP",
"       </td>",
"       <td>",
"        Intraocular pressure",
"       </td>",
"       <td class=\"centered\">",
"        SERM",
"       </td>",
"       <td>",
"        Selective estrogen receptor modulator",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CGI",
"       </td>",
"       <td>",
"        Clinical Global Impression",
"       </td>",
"       <td class=\"centered\">",
"        IQ",
"       </td>",
"       <td>",
"        Intelligence quotient",
"       </td>",
"       <td class=\"centered\">",
"        SGA",
"       </td>",
"       <td>",
"        Small for gestational age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CHD",
"       </td>",
"       <td>",
"        Coronary heart disease",
"       </td>",
"       <td class=\"centered\">",
"        I.T.",
"       </td>",
"       <td>",
"        Intrathecal",
"       </td>",
"       <td class=\"centered\">",
"        SGOT",
"       </td>",
"       <td>",
"        Serum glutamic oxaloacetic aminotransferase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CHF",
"       </td>",
"       <td>",
"        Congestive heart failure; chronic heart failure",
"       </td>",
"       <td class=\"centered\">",
"        ITP",
"       </td>",
"       <td>",
"        Idiopathic thrombocytopenic purpura",
"       </td>",
"       <td class=\"centered\">",
"        SGPT",
"       </td>",
"       <td>",
"        Serum glutamic pyruvate transaminase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CI",
"       </td>",
"       <td>",
"        Cardiac index",
"       </td>",
"       <td class=\"centered\">",
"        IUGR",
"       </td>",
"       <td>",
"        Intrauterine growth retardation",
"       </td>",
"       <td class=\"centered\">",
"        SI",
"       </td>",
"       <td>",
"        International System of Units or Systeme international d'Unites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CIE",
"       </td>",
"       <td>",
"        Chemotherapy-induced emesis",
"       </td>",
"       <td class=\"centered\">",
"        I.V.",
"       </td>",
"       <td>",
"        Intravenous",
"       </td>",
"       <td class=\"centered\">",
"        SIADH",
"       </td>",
"       <td>",
"        Syndrome of inappropriate antidiuretic hormone secretion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C-II",
"       </td>",
"       <td>",
"        Schedule two controlled substance",
"       </td>",
"       <td class=\"centered\">",
"        IVH",
"       </td>",
"       <td>",
"        Intraventricular hemorrhage",
"       </td>",
"       <td class=\"centered\">",
"        SLE",
"       </td>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C-III",
"       </td>",
"       <td>",
"        Schedule three controlled substance",
"       </td>",
"       <td class=\"centered\">",
"        IVP",
"       </td>",
"       <td>",
"        Intravenous push",
"       </td>",
"       <td class=\"centered\">",
"        SLEDD",
"       </td>",
"       <td>",
"        Sustained low-efficiency daily diafiltration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C-IV",
"       </td>",
"       <td>",
"        Schedule four controlled substance",
"       </td>",
"       <td class=\"centered\">",
"        IVPB",
"       </td>",
"       <td>",
"        Intravenous piggyback",
"       </td>",
"       <td class=\"centered\">",
"        SNRI",
"       </td>",
"       <td>",
"        Serotonin norepinephrine reuptake inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C-V",
"       </td>",
"       <td>",
"        Schedule five controlled substance",
"       </td>",
"       <td class=\"centered\">",
"        JIA",
"       </td>",
"       <td>",
"        Juvenile idiopathic arthritis",
"       </td>",
"       <td class=\"centered\">",
"        SSKI",
"       </td>",
"       <td>",
"        Saturated solution of potassium iodide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CIV",
"       </td>",
"       <td>",
"        Continuous I.V. infusion",
"       </td>",
"       <td class=\"centered\">",
"        JNC",
"       </td>",
"       <td>",
"        Joint National Committee",
"       </td>",
"       <td class=\"centered\">",
"        SSRIs",
"       </td>",
"       <td>",
"        Selective serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Cl",
"        <sub>",
"         cr",
"        </sub>",
"       </td>",
"       <td>",
"        Creatinine clearance",
"       </td>",
"       <td class=\"centered\">",
"        JRA",
"       </td>",
"       <td>",
"        Juvenile rheumatoid arthritis",
"       </td>",
"       <td class=\"centered\">",
"        STD",
"       </td>",
"       <td>",
"        Sexually transmitted disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CLL",
"       </td>",
"       <td>",
"        Chronic lymphocytic leukemia",
"       </td>",
"       <td class=\"centered\">",
"        kg",
"       </td>",
"       <td>",
"        Kilogram",
"       </td>",
"       <td class=\"centered\">",
"        STEMI",
"       </td>",
"       <td>",
"        ST-elevation myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C",
"        <sub>",
"         max",
"        </sub>",
"       </td>",
"       <td>",
"        Maximum plasma concentration",
"       </td>",
"       <td class=\"centered\">",
"        KIU",
"       </td>",
"       <td>",
"        Kallikrein inhibitor unit",
"       </td>",
"       <td class=\"centered\">",
"        SVR",
"       </td>",
"       <td>",
"        Systemic vascular resistance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C",
"        <sub>",
"         min",
"        </sub>",
"       </td>",
"       <td>",
"        Minimum plasma concentration",
"       </td>",
"       <td class=\"centered\">",
"        KOH",
"       </td>",
"       <td>",
"        Potassium hydroxide",
"       </td>",
"       <td class=\"centered\">",
"        SVT",
"       </td>",
"       <td>",
"        Supraventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CML",
"       </td>",
"       <td>",
"        Chronic myelogenous leukemia",
"       </td>",
"       <td class=\"centered\">",
"        LAMM",
"       </td>",
"       <td>",
"        L-&alpha;-acetyl methadol",
"       </td>",
"       <td class=\"centered\">",
"        SWFI",
"       </td>",
"       <td>",
"        Sterile water for injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CMV",
"       </td>",
"       <td>",
"        Cytomegalovirus",
"       </td>",
"       <td class=\"centered\">",
"        LDH",
"       </td>",
"       <td>",
"        Lactate dehydrogenase",
"       </td>",
"       <td class=\"centered\">",
"        SWI",
"       </td>",
"       <td>",
"        Sterile water for injection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CNS",
"       </td>",
"       <td>",
"        Central nervous system or coagulase negative staphylococcus",
"       </td>",
"       <td class=\"centered\">",
"        LDL-C",
"       </td>",
"       <td>",
"        Low density lipoprotein cholesterol",
"       </td>",
"       <td class=\"centered\">",
"        T&frac12;",
"       </td>",
"       <td>",
"        Half-life",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        COLD",
"       </td>",
"       <td>",
"        Chronic obstructive lung disease",
"       </td>",
"       <td class=\"centered\">",
"        LE",
"       </td>",
"       <td>",
"        Lupus erythematosus",
"       </td>",
"       <td class=\"centered\">",
"        T",
"        <sub>",
"         3",
"        </sub>",
"       </td>",
"       <td>",
"        Triiodothyronine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        COPD",
"       </td>",
"       <td>",
"        Chronic obstructive pulmonary disease",
"       </td>",
"       <td class=\"centered\">",
"        LFT",
"       </td>",
"       <td>",
"        Liver function test",
"       </td>",
"       <td class=\"centered\">",
"        T",
"        <sub>",
"         4",
"        </sub>",
"       </td>",
"       <td>",
"        Thyroxine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        COX",
"       </td>",
"       <td>",
"        Cyclooxygenase",
"       </td>",
"       <td class=\"centered\">",
"        LGA",
"       </td>",
"       <td>",
"        Large for gestational age",
"       </td>",
"       <td class=\"centered\">",
"        TB",
"       </td>",
"       <td>",
"        Tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CPK",
"       </td>",
"       <td>",
"        Creatine phosphokinase",
"       </td>",
"       <td class=\"centered\">",
"        LH",
"       </td>",
"       <td>",
"        Luteinizing hormone",
"       </td>",
"       <td class=\"centered\">",
"        TC",
"       </td>",
"       <td>",
"        Total cholesterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CPR",
"       </td>",
"       <td>",
"        Cardiopulmonary resuscitation",
"       </td>",
"       <td class=\"centered\">",
"        LP",
"       </td>",
"       <td>",
"        Lumbar posture",
"       </td>",
"       <td class=\"centered\">",
"        TCA",
"       </td>",
"       <td>",
"        Tricyclic antidepressant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CRF",
"       </td>",
"       <td>",
"        Chronic renal failure",
"       </td>",
"       <td class=\"centered\">",
"        LR",
"       </td>",
"       <td>",
"        Lactated Ringer's solution",
"       </td>",
"       <td class=\"centered\">",
"        TD",
"       </td>",
"       <td>",
"        Tardive dyskinesia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CRP",
"       </td>",
"       <td>",
"        C-reactive protein",
"       </td>",
"       <td class=\"centered\">",
"        LV",
"       </td>",
"       <td>",
"        Left ventricular",
"       </td>",
"       <td class=\"centered\">",
"        TG",
"       </td>",
"       <td>",
"        Triglyceride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CRRT",
"       </td>",
"       <td>",
"        Continuous renal replacement therapy",
"       </td>",
"       <td class=\"centered\">",
"        LVEF",
"       </td>",
"       <td>",
"        Left ventricular ejection fraction",
"       </td>",
"       <td class=\"centered\">",
"        TIA",
"       </td>",
"       <td>",
"        Transient ischemic attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CSF",
"       </td>",
"       <td>",
"        Cerebrospinal fluid",
"       </td>",
"       <td class=\"centered\">",
"        LVH",
"       </td>",
"       <td>",
"        Left ventricular hypertrophy",
"       </td>",
"       <td class=\"centered\">",
"        TIBC",
"       </td>",
"       <td>",
"        Total iron binding capacity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CSII",
"       </td>",
"       <td>",
"        Continuous subcutaneous insulin infusion",
"       </td>",
"       <td class=\"centered\">",
"        MAC",
"       </td>",
"       <td>",
"        Mycobacterium avium complex",
"       </td>",
"       <td class=\"centered\">",
"        TMA",
"       </td>",
"       <td>",
"        Thrombotic microangiopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CT",
"       </td>",
"       <td>",
"        Computed tomography",
"       </td>",
"       <td class=\"centered\">",
"        MADRS",
"       </td>",
"       <td>",
"        Montgomery Asbery Depression Rating Scale",
"       </td>",
"       <td class=\"centered\">",
"        T",
"        <sub>",
"         max",
"        </sub>",
"       </td>",
"       <td>",
"        Time to maximum observed concentration, plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CVA",
"       </td>",
"       <td>",
"        Cerebrovascular accident",
"       </td>",
"       <td class=\"centered\">",
"        MAO",
"       </td>",
"       <td>",
"        Monoamine oxidase",
"       </td>",
"       <td class=\"centered\">",
"        TNF",
"       </td>",
"       <td>",
"        Tumor necrosis factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CVP",
"       </td>",
"       <td>",
"        Central venous pressure",
"       </td>",
"       <td class=\"centered\">",
"        MAOIs",
"       </td>",
"       <td>",
"        Monamine oxidase inhibitors",
"       </td>",
"       <td class=\"centered\">",
"        TPN",
"       </td>",
"       <td>",
"        Total parenteral nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CVVH",
"       </td>",
"       <td>",
"        Continuous venovenous hemofiltration",
"       </td>",
"       <td class=\"centered\">",
"        MAP",
"       </td>",
"       <td>",
"        Mean arterial pressure",
"       </td>",
"       <td class=\"centered\">",
"        TSH",
"       </td>",
"       <td>",
"        Thyroid stimulating hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CVVHD",
"       </td>",
"       <td>",
"        Continuous venovenous hemodialysis",
"       </td>",
"       <td class=\"centered\">",
"        MDD",
"       </td>",
"       <td>",
"        Major depressive disorder",
"       </td>",
"       <td class=\"centered\">",
"        TT",
"       </td>",
"       <td>",
"        Thrombin time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CVVHDF",
"       </td>",
"       <td>",
"        Continuous venovenous hemodiafiltration",
"       </td>",
"       <td class=\"centered\">",
"        MDRD",
"       </td>",
"       <td>",
"        Modification of diet in renal disease",
"       </td>",
"       <td class=\"centered\">",
"        UA",
"       </td>",
"       <td>",
"        Urine analysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        CYP",
"       </td>",
"       <td>",
"        Cytochrome",
"       </td>",
"       <td class=\"centered\">",
"        MDRSP",
"       </td>",
"       <td>",
"        Multidrug resistant streptococcus pneumoniae",
"       </td>",
"       <td class=\"centered\">",
"        UC",
"       </td>",
"       <td>",
"        Ulcerative colitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         5",
"        </sub>",
"        &frac14;NS",
"       </td>",
"       <td>",
"        Dextrose 5 percent in sodium chloride 0.2 percent",
"       </td>",
"       <td class=\"centered\">",
"        MI",
"       </td>",
"       <td>",
"        Myocardial infarction",
"       </td>",
"       <td class=\"centered\">",
"        ULN",
"       </td>",
"       <td>",
"        Upper limits of normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         5",
"        </sub>",
"        &frac12;NS",
"       </td>",
"       <td>",
"        Dextrose 5 percent in sodium chloride 0.45 percent",
"       </td>",
"       <td class=\"centered\">",
"        MMSE",
"       </td>",
"       <td>",
"        Mini mental status examination",
"       </td>",
"       <td class=\"centered\">",
"        URI",
"       </td>",
"       <td>",
"        Upper respiratory infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         5",
"        </sub>",
"        LR",
"       </td>",
"       <td>",
"        Dextrose 5 percent in lactated Ringer's",
"       </td>",
"       <td class=\"centered\">",
"        M/P",
"       </td>",
"       <td>",
"        Milk to plasma ratio",
"       </td>",
"       <td class=\"centered\">",
"        USAN",
"       </td>",
"       <td>",
"        United States Adopted Names",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         5",
"        </sub>",
"        NS",
"       </td>",
"       <td>",
"        Dextrose 5 percent in sodium chloride 0.9 percent",
"       </td>",
"       <td class=\"centered\">",
"        MPS I",
"       </td>",
"       <td>",
"        Mucopolysaccharidosis I",
"       </td>",
"       <td class=\"centered\">",
"        USP",
"       </td>",
"       <td>",
"        United States Pharmacopeia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         5",
"        </sub>",
"        W",
"       </td>",
"       <td>",
"        Dextrose 5 percent in water",
"       </td>",
"       <td class=\"centered\">",
"        MRHD",
"       </td>",
"       <td>",
"        Maximum recommended human dose",
"       </td>",
"       <td class=\"centered\">",
"        UTI",
"       </td>",
"       <td>",
"        Urinary tract infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        D",
"        <sub>",
"         10",
"        </sub>",
"        W",
"       </td>",
"       <td>",
"        Dextrose 10 percent in water",
"       </td>",
"       <td class=\"centered\">",
"        MRI",
"       </td>",
"       <td>",
"        Magnetic resonance imaging",
"       </td>",
"       <td class=\"centered\">",
"        UV",
"       </td>",
"       <td>",
"        Ultraviolet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DBP",
"       </td>",
"       <td>",
"        Diastolic blood pressure",
"       </td>",
"       <td class=\"centered\">",
"        MRSA",
"       </td>",
"       <td>",
"        Methicillin-resistant Staphylococcus aureus",
"       </td>",
"       <td class=\"centered\">",
"        V",
"        <sub>",
"         d",
"        </sub>",
"       </td>",
"       <td>",
"        Volume of distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DEHP",
"       </td>",
"       <td>",
"        Di(3-ethylhexyl)phthalate",
"       </td>",
"       <td class=\"centered\">",
"        MUGA",
"       </td>",
"       <td>",
"        Multiple gated acquisition scan",
"       </td>",
"       <td class=\"centered\">",
"        V",
"        <sub>",
"         dss",
"        </sub>",
"       </td>",
"       <td>",
"        Volume of distribution at steady-state",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DIC",
"       </td>",
"       <td>",
"        Disseminated intravascular coagulation",
"       </td>",
"       <td class=\"centered\">",
"        NAEPP",
"       </td>",
"       <td>",
"        National Asthma Education and Prevention Program",
"       </td>",
"       <td class=\"centered\">",
"        VEGF",
"       </td>",
"       <td>",
"        Vascular endothelial growth factor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DLco",
"       </td>",
"       <td>",
"        Pulmonary diffusion capacity for carbon monoxide",
"       </td>",
"       <td class=\"centered\">",
"        NAS",
"       </td>",
"       <td>",
"        Neonatal abstinence syndrome",
"       </td>",
"       <td class=\"centered\">",
"        VF",
"       </td>",
"       <td>",
"        Ventricular fibrillation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DM",
"       </td>",
"       <td>",
"        Diabetes mellitus",
"       </td>",
"       <td class=\"centered\">",
"        NCI",
"       </td>",
"       <td>",
"        National Cancer Institute",
"       </td>",
"       <td class=\"centered\">",
"        VLBW",
"       </td>",
"       <td>",
"        Very low birth weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DMARD",
"       </td>",
"       <td>",
"        Disease modifying antirheumatic drug",
"       </td>",
"       <td class=\"centered\">",
"        ND",
"       </td>",
"       <td>",
"        Nasoduodenal",
"       </td>",
"       <td class=\"centered\">",
"        VMA",
"       </td>",
"       <td>",
"        Vanillylmandelic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DNA",
"       </td>",
"       <td>",
"        Deoxyribonucleic acid",
"       </td>",
"       <td class=\"centered\">",
"        NF",
"       </td>",
"       <td>",
"        National Formulary",
"       </td>",
"       <td class=\"centered\">",
"        VT",
"       </td>",
"       <td>",
"        Ventricular tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DSC",
"       </td>",
"       <td>",
"        Discontinued",
"       </td>",
"       <td class=\"centered\">",
"        NFD",
"       </td>",
"       <td>",
"        Nephrogenic fibrosing dermopathy",
"       </td>",
"       <td class=\"centered\">",
"        VTE",
"       </td>",
"       <td>",
"        Venous thromboembolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DSM-IV",
"       </td>",
"       <td>",
"        Diagnostic and Statistical Manual",
"       </td>",
"       <td class=\"centered\">",
"        NG",
"       </td>",
"       <td>",
"        Nasogastric",
"       </td>",
"       <td class=\"centered\">",
"        vWD",
"       </td>",
"       <td>",
"        Von Willebrand disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        DVT",
"       </td>",
"       <td>",
"        Deep vein thrombosis",
"       </td>",
"       <td class=\"centered\">",
"        NIDDM",
"       </td>",
"       <td>",
"        Noninsulin-dependent diabetes mellitus",
"       </td>",
"       <td class=\"centered\">",
"        VZV",
"       </td>",
"       <td>",
"        Varicella zoster virus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        EBV",
"       </td>",
"       <td>",
"        Epstein-Barr virus",
"       </td>",
"       <td class=\"centered\">",
"        NIH",
"       </td>",
"       <td>",
"        National Institute of Health",
"       </td>",
"       <td class=\"centered\">",
"        WHO",
"       </td>",
"       <td>",
"        World Health Organization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ECG",
"       </td>",
"       <td>",
"        Electrocardiogram",
"       </td>",
"       <td class=\"centered\">",
"        NKA",
"       </td>",
"       <td>",
"        No known allergies",
"       </td>",
"       <td class=\"centered\">",
"        w/v",
"       </td>",
"       <td>",
"        Weight for volume",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ECHO",
"       </td>",
"       <td>",
"        Echocardiogram",
"       </td>",
"       <td class=\"centered\">",
"        NKDA",
"       </td>",
"       <td>",
"        No known drug allergies",
"       </td>",
"       <td class=\"centered\">",
"        w/w",
"       </td>",
"       <td>",
"        Weight for weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ECMO",
"       </td>",
"       <td>",
"        Extracorporeal membrane oxygenation",
"       </td>",
"       <td class=\"centered\">",
"        NMDA",
"       </td>",
"       <td>",
"        N-methyl-d-aspartate",
"       </td>",
"       <td class=\"centered\">",
"        YBOC",
"       </td>",
"       <td>",
"        Yale Brown Obsessive-Compulsive Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ECT",
"       </td>",
"       <td>",
"        Electroconvulsive therapy",
"       </td>",
"       <td class=\"centered\">",
"        NMS",
"       </td>",
"       <td>",
"        Neuroleptic malignant syndrome",
"       </td>",
"       <td class=\"centered\">",
"        YMRS",
"       </td>",
"       <td>",
"        Young Mania Rating Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ED",
"       </td>",
"       <td>",
"        Emergency department",
"       </td>",
"       <td class=\"centered\">",
"        NNRTI",
"       </td>",
"       <td>",
"        Non-nucleoside reverse transcriptase inhibitor",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\">",
"        EEG",
"       </td>",
"       <td>",
"        Electroencephalogram",
"       </td>",
"       <td class=\"centered\">",
"        NRTI",
"       </td>",
"       <td>",
"        Nucleoside reverse transcriptase inhibitor",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Common weights, measures, or apothecary abbreviations that may be used in Lexicomp*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &lt;",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Less than",
"       </td>",
"       <td class=\"centered\">",
"        F",
"       </td>",
"       <td>",
"        Fahrenheit",
"       </td>",
"       <td class=\"centered\">",
"        o.u.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Each eye",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &gt;",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Greater than",
"       </td>",
"       <td class=\"centered\">",
"        f, ft",
"       </td>",
"       <td>",
"        Make, let be made",
"       </td>",
"       <td class=\"centered\">",
"        pc, post cib",
"       </td>",
"       <td>",
"        After meals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &le;",
"       </td>",
"       <td>",
"        Less than or equal to",
"       </td>",
"       <td class=\"centered\">",
"        g",
"       </td>",
"       <td>",
"        Gram",
"       </td>",
"       <td class=\"centered\">",
"        PM",
"       </td>",
"       <td>",
"        Afternoon or evening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        &ge;",
"       </td>",
"       <td>",
"        Greater than or equal to",
"       </td>",
"       <td class=\"centered\">",
"        gr",
"       </td>",
"       <td>",
"        Grain",
"       </td>",
"       <td class=\"centered\">",
"        P.O.",
"       </td>",
"       <td>",
"        By mouth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ac",
"       </td>",
"       <td>",
"        Before meals or food",
"       </td>",
"       <td class=\"centered\">",
"        gtt",
"       </td>",
"       <td>",
"        One drop",
"       </td>",
"       <td class=\"centered\">",
"        P.R.",
"       </td>",
"       <td>",
"        Rectally",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ad",
"       </td>",
"       <td>",
"        To, up to",
"       </td>",
"       <td class=\"centered\">",
"        h",
"       </td>",
"       <td>",
"        Hour",
"       </td>",
"       <td class=\"centered\">",
"        prn",
"       </td>",
"       <td>",
"        As needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ad lib",
"       </td>",
"       <td>",
"        At pleasure",
"       </td>",
"       <td class=\"centered\">",
"        hs",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        At bedtime",
"       </td>",
"       <td class=\"centered\">",
"        pulv",
"       </td>",
"       <td>",
"        A powder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AM",
"       </td>",
"       <td>",
"        Morning",
"       </td>",
"       <td class=\"centered\">",
"        kcal",
"       </td>",
"       <td>",
"        Kilocalorie",
"       </td>",
"       <td class=\"centered\">",
"        q",
"       </td>",
"       <td>",
"        Every",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        AMA",
"       </td>",
"       <td>",
"        Against medical advice",
"       </td>",
"       <td class=\"centered\">",
"        kg",
"       </td>",
"       <td>",
"        Kilogram",
"       </td>",
"       <td class=\"centered\">",
"        qad",
"       </td>",
"       <td>",
"        Every other day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        amp",
"       </td>",
"       <td>",
"        Ampul",
"       </td>",
"       <td class=\"centered\">",
"        L",
"       </td>",
"       <td>",
"        Liter",
"       </td>",
"       <td class=\"centered\">",
"        qd",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Every day, daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        amt",
"       </td>",
"       <td>",
"        Amount",
"       </td>",
"       <td class=\"centered\">",
"        liq",
"       </td>",
"       <td>",
"        A liquor, solution",
"       </td>",
"       <td class=\"centered\">",
"        qh",
"       </td>",
"       <td>",
"        Every hour",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        aq",
"       </td>",
"       <td>",
"        Water",
"       </td>",
"       <td class=\"centered\">",
"        M",
"       </td>",
"       <td>",
"        Molar",
"       </td>",
"       <td class=\"centered\">",
"        qid",
"       </td>",
"       <td>",
"        Four times a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        aq. dest.",
"       </td>",
"       <td>",
"        Distilled water",
"       </td>",
"       <td class=\"centered\">",
"        mcg",
"       </td>",
"       <td>",
"        Microgram",
"       </td>",
"       <td class=\"centered\">",
"        qod",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Every other day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ASAP",
"       </td>",
"       <td>",
"        As soon as possible",
"       </td>",
"       <td class=\"centered\">",
"        m. dict",
"       </td>",
"       <td>",
"        As directed",
"       </td>",
"       <td class=\"centered\">",
"        qs",
"       </td>",
"       <td>",
"        A sufficient quantity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        a.u.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Each ear",
"       </td>",
"       <td class=\"centered\">",
"        mEq",
"       </td>",
"       <td>",
"        Milliequivalent",
"       </td>",
"       <td class=\"centered\">",
"        qs ad",
"       </td>",
"       <td>",
"        A sufficient quantity to make",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        bid",
"       </td>",
"       <td>",
"        Twice daily",
"       </td>",
"       <td class=\"centered\">",
"        mg",
"       </td>",
"       <td>",
"        Milligram",
"       </td>",
"       <td class=\"centered\">",
"        Rx",
"       </td>",
"       <td>",
"        Take, a recipe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        bm",
"       </td>",
"       <td>",
"        Bowel movement",
"       </td>",
"       <td class=\"centered\">",
"        microL",
"       </td>",
"       <td>",
"        Microliter",
"       </td>",
"       <td class=\"centered\">",
"        S.L.",
"       </td>",
"       <td>",
"        Sublingual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        C",
"       </td>",
"       <td>",
"        Celsius, centigrade",
"       </td>",
"       <td class=\"centered\">",
"        min",
"       </td>",
"       <td>",
"        Minute",
"       </td>",
"       <td class=\"centered\">",
"        stat",
"       </td>",
"       <td>",
"        At once, immediately",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cal",
"       </td>",
"       <td>",
"        Calorie",
"       </td>",
"       <td class=\"centered\">",
"        mL",
"       </td>",
"       <td>",
"        Milliliter",
"       </td>",
"       <td class=\"centered\">",
"        SubQ",
"       </td>",
"       <td>",
"        Subcutaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cap",
"       </td>",
"       <td>",
"        Capsule",
"       </td>",
"       <td class=\"centered\">",
"        mm",
"       </td>",
"       <td>",
"        Millimeter",
"       </td>",
"       <td class=\"centered\">",
"        supp",
"       </td>",
"       <td>",
"        Suppository",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cc",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Cubic centimeter",
"       </td>",
"       <td class=\"centered\">",
"        mM",
"       </td>",
"       <td>",
"        Millimole",
"       </td>",
"       <td class=\"centered\">",
"        syr",
"       </td>",
"       <td>",
"        Syrup",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cm",
"       </td>",
"       <td>",
"        Centimeter",
"       </td>",
"       <td class=\"centered\">",
"        mm Hg",
"       </td>",
"       <td>",
"        Millimeters of mercury",
"       </td>",
"       <td class=\"centered\">",
"        tab",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        comp",
"       </td>",
"       <td>",
"        Compound",
"       </td>",
"       <td class=\"centered\">",
"        mo",
"       </td>",
"       <td>",
"        Month",
"       </td>",
"       <td class=\"centered\">",
"        tal",
"       </td>",
"       <td>",
"        Such",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        cont",
"       </td>",
"       <td>",
"        Continue",
"       </td>",
"       <td class=\"centered\">",
"        mOsm",
"       </td>",
"       <td>",
"        Milliosmoles",
"       </td>",
"       <td class=\"centered\">",
"        tid",
"       </td>",
"       <td>",
"        Three times a day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        d",
"       </td>",
"       <td>",
"        Day",
"       </td>",
"       <td class=\"centered\">",
"        ng",
"       </td>",
"       <td>",
"        Nanogram",
"       </td>",
"       <td class=\"centered\">",
"        tr, tinct",
"       </td>",
"       <td>",
"        Tincture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        d/c",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Discharge",
"       </td>",
"       <td class=\"centered\">",
"        nmol",
"       </td>",
"       <td>",
"        Nanomole",
"       </td>",
"       <td class=\"centered\">",
"        trit",
"       </td>",
"       <td>",
"        Triturate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        dil",
"       </td>",
"       <td>",
"        Dilute",
"       </td>",
"       <td class=\"centered\">",
"        no.",
"       </td>",
"       <td>",
"        Number",
"       </td>",
"       <td class=\"centered\">",
"        tsp",
"       </td>",
"       <td>",
"        Teaspoon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        disp",
"       </td>",
"       <td>",
"        Dispense",
"       </td>",
"       <td class=\"centered\">",
"        noc",
"       </td>",
"       <td>",
"        In the night",
"       </td>",
"       <td class=\"centered\">",
"        u.d.",
"       </td>",
"       <td>",
"        As directed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        div",
"       </td>",
"       <td>",
"        Divide",
"       </td>",
"       <td class=\"centered\">",
"        non rep",
"       </td>",
"       <td>",
"        Do not repeat, no refills",
"       </td>",
"       <td class=\"centered\">",
"        ung",
"       </td>",
"       <td>",
"        Ointment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        dtd",
"       </td>",
"       <td>",
"        Give of such a dose",
"       </td>",
"       <td class=\"centered\">",
"        NPO",
"       </td>",
"       <td>",
"        Nothing by mouth",
"       </td>",
"       <td class=\"centered\">",
"        v.o.",
"       </td>",
"       <td>",
"        Verbal order",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        Dx",
"       </td>",
"       <td>",
"        Diagnosis",
"       </td>",
"       <td class=\"centered\">",
"        NV",
"       </td>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"       <td class=\"centered\">",
"        w.a.",
"       </td>",
"       <td>",
"        While awake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        elix, el",
"       </td>",
"       <td>",
"        Elixir",
"       </td>",
"       <td class=\"centered\">",
"        O, Oct",
"       </td>",
"       <td>",
"        One pint",
"       </td>",
"       <td class=\"centered\">",
"        x3",
"       </td>",
"       <td>",
"        Three times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        emp",
"       </td>",
"       <td>",
"        As directed",
"       </td>",
"       <td class=\"centered\">",
"        o.d.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Right eye",
"       </td>",
"       <td class=\"centered\">",
"        x4",
"       </td>",
"       <td>",
"        Four times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        et",
"       </td>",
"       <td>",
"        And",
"       </td>",
"       <td class=\"centered\">",
"        o.l.",
"       </td>",
"       <td>",
"        Left eye",
"       </td>",
"       <td class=\"centered\">",
"        y",
"       </td>",
"       <td>",
"        Year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        ex aq",
"       </td>",
"       <td>",
"        In water",
"       </td>",
"       <td class=\"centered\">",
"        o.s.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Left eye",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Additional abbreviations used and defined within a specific drug monograph or text piece may only apply to that text. Definitions for the two letter country codes used in \"International Brand Names\" field of Lexicomp are available at the International Standards Organization (ISO) website:",
"     <a href=\"file://www.iso.org/iso/home/standards/country_codes/iso-3166-1_decoding_table.htm\" target=\"_blank\">",
"      file://www.iso.org/iso/home/standards/country_codes/iso-3166-1_decoding_table.htm",
"     </a>",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      These abbreviations are considered error-prone according to the Institute for Safe Medicine Practices.",
"      <sup>",
"       [1]",
"      </sup>",
"      <br>",
"       &Delta; Healthcare organizations accredited by the Joint Commission are required to prohibit the use of these abbreviations in orders and medication-related documentation.",
"       <sup>",
"        [2]",
"       </sup>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       The Institute for Safe Medication Practices (ISMP) list of Error-Prone Abbreviations, Symbols, and Dose Designations. Available at",
"       <a href=\"file://www.ismp.org/Tools/errorproneabbreviations.pdf\" target=\"_blank\">",
"        file://www.ismp.org/Tools/errorproneabbreviations.pdf",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       The Joint Commission Official \"Do Not Use\" list. Available at",
"       <a href=\"file://www.jointcommission.org/assets/1/18/Do_Not_Use_List.pdf\" target=\"_blank\">",
"        file://www.jointcommission.org/assets/1/18/Do_Not_Use_List.pdf",
"       </a>",
"       .",
"      </li>",
"     </ol>",
"     <br/>",
"     Reproduced with permission from: Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24183=[""].join("\n");
var outline_f23_39_24183=null;
var title_f23_39_24184="Hypoglycemia in adults without diabetes mellitus: Diagnostic approach";
var content_f23_39_24184=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24184/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24184/contributors\">",
"     F John Service, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24184/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24184/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24184/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24184/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/39/24184/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia is an uncommon clinical problem in patients not being treated for diabetes mellitus. It can occur in the fasting or postprandial state. In any case of hypoglycemia, regardless of the cause, the diagnosis can usually be established by appropriate blood tests at the time of the spontaneous occurrence of hypoglycemia, if such an event occurs in the presence of medical personnel (",
"    <a class=\"graphic graphic_table graphicRef73797 \" href=\"UTD.htm?22/21/22877\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If the patient is not symptomatic when seen, the diagnostic strategy is to replicate conditions in which hypoglycemia would be expected if a hypoglycemic disorder exists. A prolonged supervised fast, which can last as long as 72 hours, has been the best established and probably most reliable test for the evaluation of hypoglycemia occurring in the food-deprived state. For patients with postprandial hypoglycemia, however, a mixed meal test is the preferred provocative procedure.",
"   </p>",
"   <p>",
"    This topic will review the approach to the nondiabetic patient with hypoglycemia. The clinical manifestations, diagnosis, and causes of hypoglycemia, in general, are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52892 \" href=\"UTD.htm?7/27/7612\">",
"     table 3",
"    </a>",
"    ). The evaluation and management of hypoglycemia in patients with drug-treated diabetes mellitus is also reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22071?source=see_link\">",
"     \"Diagnostic dilemmas in hypoglycemia: Illustrative cases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"     \"Management of hypoglycemia during treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a hypoglycemic disorder in a person without diabetes should not be suspected solely on the basis of a low plasma glucose concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The association of symptoms reinforces the biologic significance of the low blood glucose. Furthermore, healthy individuals may have low glucose concentrations without symptoms after prolonged fasting. In addition, sympathoadrenal and neuroglycopenic symptoms may be highly suggestive of hypoglycemia, but they cannot be ascribed to hypoglycemia with confidence unless the glucose concentration is low at the same time. Normal glucose concentrations measured when the patient is free of those symptoms does not exclude the possibility of hypoglycemia at the time of those earlier symptoms. Thus, it is important to confirm the presence of a hypoglycemic disorder before performing various tests to determine the etiology of hypoglycemia. Documentation of Whipple's triad helps to establish the existence of a hypoglycemic disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whipple's triad includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms consistent with hypoglycemia",
"     </li>",
"     <li>",
"      A low plasma glucose concentration measured with a precise method (not a home glucose monitor) when symptoms are present",
"     </li>",
"     <li>",
"      Relief of those symptoms after the plasma glucose level is raised",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only those patients in whom Whipple's triad is documented require evaluation and management of hypoglycemia. Given documentation of Whipple's triad, detailed laboratory evaluation is usually required in a healthy-appearing patient, whereas hypoglycemia may be readily recognized as part of the underlying illness or its treatment in an ill or medicated patient (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link&amp;anchor=H2#H2\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoglycemia is sometimes detected serendipitously. A low plasma glucose concentration in the absence of symptoms of hypoglycemia suggests the possibility of artifactual hypoglycemia. However, a distinctly low plasma glucose concentration measured in a reliable laboratory cannot be ignored. The measurement should be repeated using a collection tube that contains an inhibitor of glycolysis, and processing should not be delayed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link&amp;anchor=H18546202#H18546202\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although low blood glucose values measured using reflectance meters suggest the presence of hypoglycemia, these methods are not reliable to diagnose hypoglycemia in the absence of insulin or insulin secretagogue treatment of diabetes. Thus, a patient who has a single low blood glucose value measured by a meter but no symptoms of hypoglycemia probably does not need further evaluation; on the other hand, evaluation is indicated in a patient who has repeated low values.",
"   </p>",
"   <p>",
"    Patients who have only sympathoadrenal symptoms but normal concurrent plasma glucose concentrations have a low probability of having a hypoglycemic disorder and do not require a comprehensive evaluation for a hypoglycemic disorder. This combination is most common in patients with postprandial symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3255?source=see_link\">",
"     \"Postprandial (reactive) hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     APPROACH TO TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our approach to the evaluation and management of hypoglycemia in nondiabetic adults is outlined below. Because hypoglycemic disorders are uncommon in persons without diabetes, this approach is largely based upon clinical experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/2\">",
"     2",
"    </a>",
"    ]. It is consistent with the 2009 Endocrine Society guidelines for the evaluation and management of hypoglycemic disorders in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first step is to review the patient's history in detail, including the nature and timing of symptoms (particularly in relationship to meals), existence of underlying illnesses or conditions, medications taken by the individual and by family members, and social history. Clinical evidence for adrenal insufficiency or nonislet cell tumor should be considered. In a patient with documented hypoglycemia, the cause may be apparent from the history and physical examination (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    ). In a seemingly well individual, the cause is less apparent and may be due to hyperinsulinism or factitious hypoglycemia. When the cause of hypoglycemia is not evident, detailed laboratory evaluation is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a hypoglycemic disorder in a person without diabetes should not be inferred solely on the basis of a low plasma glucose concentration, unless the value is severely depressed (&lt;40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2",
"    <span class=\"nowrap\">",
"     mmol/L]).",
"    </span>",
"    To rule out artifactual hypoglycemia in such cases, the measurement should be repeated using a collection tube that contains an inhibitor of glycolysis, and processing should not be delayed.",
"   </p>",
"   <p>",
"    The purpose of the initial laboratory evaluation is to document Whipple's triad [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/2\">",
"     2",
"    </a>",
"    ]. Should Whipple's triad have been demonstrated previously, the goal of testing is to assess the role of insulin in the genesis of the hypoglycemia.",
"   </p>",
"   <p>",
"    If the patient is not symptomatic when seen, the diagnostic strategy is to seek Whipple's triad under conditions in which hypoglycemia would be expected if a hypoglycemic disorder exists. In a patient who presents with a self-diagnosis of hypoglycemia, one strategy is to measure plasma glucose concentrations at the time of symptoms and then decide if the glucose values and the history are sufficiently suggestive to warrant additional evaluation. If the symptoms occur primarily in the fasting state, that evaluation should be performed during a fast (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Fasting evaluation'",
"    </a>",
"    below). However, if there is a compelling history of postprandial symptoms, it is reasonable to seek Whipple's triad with frequent timed plasma glucose measurements and recording of any symptoms after a mixed meal. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Postprandial evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who are fortuitously observed during an episode of symptoms and are found to have hypoglycemia at that time should have the following blood tests (",
"    <a class=\"graphic graphic_table graphicRef73797 \" href=\"UTD.htm?22/21/22877\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Glucose",
"     </li>",
"     <li>",
"      Insulin",
"     </li>",
"     <li>",
"      C-peptide",
"     </li>",
"     <li>",
"      Beta-hydroxybutyrate",
"     </li>",
"     <li>",
"      Proinsulin",
"     </li>",
"     <li>",
"      Sulfonylurea and meglitinide screen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The interpretation of these results is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ) and described below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Interpretation of data'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Determining the cause of hypoglycemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with endogenous hyperinsulinism, insulin antibodies should be measured to distinguish insulin autoimmune hypoglycemia from other causes of hyperinsulinism (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ). Insulin antibodies do not need to be drawn during hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fasting evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are patients in whom symptoms occur after only a short period of food withdrawal. In such patients, continued observation in the office or clinic, especially if they have fasted overnight, may result in an episode of symptomatic hypoglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/2\">",
"     2",
"    </a>",
"    ]. Plasma glucose should be measured repeatedly during the period of observation. If symptoms occur and hypoglycemia is documented (plasma glucose &lt;55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    the other tests described above should be performed (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ). The results may obviate the need for a provocative test, such as the 72-hour fast.",
"   </p>",
"   <p>",
"    If this approach causes neither symptoms nor hypoglycemia and if clinical suspicion remains high, the patient should undergo a 72-hour fast. (See",
"    <a class=\"local\" href=\"#H9\">",
"     '72-hour fast'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Postprandial evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If symptoms of hypoglycemia typically occur within five hours after eating, patients should be evaluated in the postprandial state (mixed meal test).",
"   </p>",
"   <p>",
"    For a mixed meal diagnostic test, the patient consumes a meal that usually leads to symptoms and is then observed for up to five hours [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/2\">",
"     2",
"    </a>",
"    ]. Samples are collected for plasma glucose, insulin, C-peptide, and proinsulin prior to ingestion of the meal and every 30 minutes thereafter for five hours. If severe symptoms occur prior to five hours, samples for the above lab tests should be collected before the administration of carbohydrates (to assess for correction of symptoms). All glucose samples are sent for analysis. The samples for insulin, C-peptide, and proinsulin should be analyzed only in those samples in which plasma glucose is &lt;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    If Whipple's triad is demonstrated, sulfonylureas, meglitinides, and antibodies to insulin should also be measured.",
"   </p>",
"   <p>",
"    Standards for the interpretation of the mixed meal test are not established. Thus, the interpretation of the test results is the same as when the tests are done during a spontaneous episode of hypoglycemia or during a 72-hour fast (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Interpretation of data'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An oral glucose tolerance test or a meal that is solely in liquid form (eg, Ensure) done in an effort to replicate postprandial symptoms should not be performed because misleading results may be obtained. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3255?source=see_link\">",
"     \"Postprandial (reactive) hypoglycemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     72-hour fast",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of the 72-hour fast is to provoke the homeostatic responses that keep blood glucose concentrations from falling to concentrations that cause symptoms in the absence of food. Increased release of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , epinephrine and, to a lesser degree, growth hormone and cortisol are the most important components of this response. All the hormonal responses begin well before the onset of symptomatic hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal subjects do not have symptomatic hypoglycemia after a prolonged fast because of a hormonally mediated increase in glucose production. Gluconeogenesis accounts for approximately 50 percent of glucose production after an overnight fast and for almost all glucose production after 42 hours or more of fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prolonged fast will result in hypoglycemia only if there is a defect in the ability to maintain normoglycemia due, for example, to an excess of insulin. The defect should be identifiable if appropriate testing is performed (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Interpretation of test results'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 72-hour fast can be initiated at home, usually after the evening meal, and continued the next day in an outpatient setting or a hospital.",
"   </p>",
"   <p>",
"    The following protocol is used at our institution (Mayo Clinic, Rochester MN) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/4\">",
"     4",
"    </a>",
"    ], whether the fast is initiated in the outpatient setting or in the hospital. A careful record should be kept of exactly what was done, what blood samples were taken, what was to be measured in each blood sample, and what symptoms occurred. It is equally important that the blood samples and laboratory slips be carefully labeled, particularly with the exact time, and that the labeling information be recorded on a flow sheet. Later interpretation of the results is possible only with this detail.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Date the onset of the fast at the time of the last intake of calories. Discontinue all nonessential medications.",
"     </li>",
"     <li>",
"      Allow the patient to drink beverages that are calorie and caffeine free.",
"     </li>",
"     <li>",
"      Ensure that the patient is active during waking hours.",
"     </li>",
"     <li>",
"      Collect blood specimens for measurement of plasma glucose, insulin, C-peptide, proinsulin, and beta hydroxybutyrate (BHOB) every six hours until the glucose concentration is below 60",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.3",
"      <span class=\"nowrap\">",
"       mmol/L);",
"      </span>",
"      at this point, the frequency of sampling should be increased to every one to two hours. Because of possible delays in the availability of the results of plasma glucose testing, a bedside reflectance meter may have to be used to measure blood glucose when frequent samples are obtained. However, the decision to end the fast should not be made on the basis of a fingerstick blood glucose value. It is essential that the clinician determine in advance the correct tubes to use for the blood samples and the correct procedures for handling and processing the samples.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although blood is collected repeatedly, we measure insulin, C-peptide, and proinsulin only in those specimens in which the plasma glucose concentration is &le;60",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.3",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    Insulin antibodies should be measured, but they do not have to be measured during hypoglycemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Test end points and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fast is ended when the plasma glucose concentration is &le;45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    the patient has symptoms or signs of hypoglycemia, 72 hours have elapsed, or when the plasma glucose concentration is less than 55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    if Whipple's triad was documented on a prior occasion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fasting for a maximum of 72 hours has been the standard test for the diagnosis of insulinoma. A 48-hour maximum has been proposed as a simpler alternative based upon a report of 127 patients with insulinoma in which adequate information was obtained for diagnosis in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/5\">",
"     5",
"    </a>",
"    ]. The fast was terminated because of hypoglycemia (plasma glucose &le;45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.5",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    in 43 percent by 12 hours, 67 percent by 24 hours, and 95 percent by 48 hours.",
"   </p>",
"   <p>",
"    However, in our series of 205 patients with insulinoma, 14 percent did not develop Whipple's triad until after 48 hours of fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, to avoid misdiagnosis, we recommend the standard 72-hour fast.",
"   </p>",
"   <p>",
"    The decision to end the fast may not be easy. Some patients have slightly low plasma glucose values, but no symptoms or signs of hypoglycemia, while others have the same symptoms during fasting that they have in ordinary life at a time when plasma glucose values are normal. In the latter patients, the symptoms cannot be attributed to hypoglycemia. To complicate matters further, young, lean, healthy women may have plasma glucose concentrations in the range of 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or even lower after prolonged periods of fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful questioning and testing for subtle symptoms or signs of hypoglycemia should be conducted repeatedly when the patient's plasma glucose is near or in the hypoglycemic range. To end the fast solely on the basis of a low plasma glucose value (except in those patients who have had Whipple's triad documented previously), in the absence of symptoms or signs of hypoglycemia, jeopardizes the possibility of discriminating between normal persons and those with hypoglycemia not mediated by insulin. A low plasma glucose value is a necessary but not sufficient finding for the diagnosis of hypoglycemia.",
"   </p>",
"   <p>",
"    The absence of symptoms or signs of hypoglycemia and lack of a low plasma glucose concentration during a 72-hour fast indicates a normal 72-hour fast, but does not preclude the existence of a hypoglycemic disorder that causes only postprandial symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Ending the fast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three steps are performed at the end of the fast:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Collect samples for plasma glucose, insulin, C-peptide, proinsulin, BHOB, and oral hypoglycemic agents",
"     </li>",
"     <li>",
"      1 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      is given intravenously and the plasma glucose measured 10, 20, and 30 minutes later",
"     </li>",
"     <li>",
"      The patient is fed",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interpretation of data",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of the data obtained at the end of the 72-hour fast is the same as that performed during the occurrence of a spontaneous hypoglycemic episode or during a postprandial evaluation (mixed meal test) (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/4,8\">",
"     4,8",
"    </a>",
"    ]. These data will help distinguish hyperinsulinemia (endogenous or exogenous) from other causes of hypoglycemia. The normal overnight fasting reference ranges usually supplied by the laboratory for plasma insulin, C-peptide, proinsulin, and beta-hydroxybutyrate (BHOB), and the response of plasma glucose to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    cannot be applied when the plasma glucose is in the hypoglycemic range. New criteria are required.",
"   </p>",
"   <p>",
"    In addition, ratios of insulin-to-glucose or of glucose-to-insulin are not helpful in the establishment of hyperinsulinemia; absolute values for insulin are preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The distribution of simultaneously measured plasma glucose and insulin concentrations in patients with surgically confirmed insulinomas and in normal subjects studied during 72-hour fasts is shown in the figure (",
"    <a class=\"graphic graphic_figure graphicRef76164 \" href=\"UTD.htm?30/14/30958\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/4\">",
"     4",
"    </a>",
"    ]. The recommended diagnostic criteria for plasma insulin, C-peptide, proinsulin, and BHOB, described below, have sensitivities and specificities of &gt;90 and &gt;70 percent, respectively, for the diagnosis of insulinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plasma insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A plasma insulin concentration of 3",
"    <span class=\"nowrap\">",
"     microU/mL",
"    </span>",
"    (20.8",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    by immunochemiluminometric assay (ICMA) when the plasma glucose concentration is below 55",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.0",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    indicates an excess of insulin and is consistent with hyperinsulinemia (eg, insulinoma) (",
"    <a class=\"graphic graphic_figure graphicRef76164 \" href=\"UTD.htm?30/14/30958\">",
"     figure 1",
"    </a>",
"    ). Unfortunately, plasma glucose concentrations fall below 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in some normal subjects and remain above 50",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    in an occasional patient with an insulinoma. This slight overlap can occur despite best efforts to require a plasma glucose of less than 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    at the end of the fast, because of the variation in plasma glucose in the hypoglycemic range. Plasma insulin by ICMA may be lowered in a hemolyzed blood sample.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Plasma C-peptide",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is essential to measure plasma C-peptide at the end of the fast; measurement of plasma proinsulin can also be helpful (",
"    <a class=\"graphic graphic_figure graphicRef80403 \" href=\"UTD.htm?35/63/36861\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Plasma C-peptide distinguishes endogenous from exogenous hyperinsulinemia. In patients in whom plasma glucose concentrations fell below 45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    there was no overlap in the values in insulinoma patients and normal subjects at a plasma C-peptide concentration of 0.2",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    (200",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    or 0.6",
"    <span class=\"nowrap\">",
"     ng/mL).",
"    </span>",
"    All insulinoma patients had higher values and all normal subjects who were hypoglycemic had lower values. For plasma proinsulin, the diagnostic criterion for insulinoma is 5",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    or greater (",
"    <a class=\"graphic graphic_figure graphicRef74225 \" href=\"UTD.htm?31/49/32541\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Plasma beta-hydroxybutyrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the antiketogenic effect of insulin, plasma beta-hydroxybutyrate (BHOB) concentrations are lower in insulinoma patients than in normal subjects. All patients with insulinoma had plasma BHOB values of 2.7",
"    <span class=\"nowrap\">",
"     mmol/L",
"    </span>",
"    or less at the end of the fast, whereas normal subjects had higher values (",
"    <a class=\"graphic graphic_figure graphicRef54835 \" href=\"UTD.htm?36/34/37421\">",
"     figure 4",
"    </a>",
"    ). A progressive rise in the concentration of BHOB after the 18-hour point of the fast is indicative of a negative fast [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The plasma BHOB value, as well as the glucose response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    , can be used to confirm the diagnosis in patients in whom the insulin and C-peptide values are in the borderline range (eg, plasma insulin concentration of &lt;3",
"    <span class=\"nowrap\">",
"     microU/mL",
"    </span>",
"    [20.8",
"    <span class=\"nowrap\">",
"     pmol/L],",
"    </span>",
"    C-peptide &lt;0.2",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    [0.6",
"    <span class=\"nowrap\">",
"     ng/mL])",
"    </span>",
"    or to indicate the action of an insulin-like factor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Glycemic response to glucagon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulin is antiglycogenolytic and hyperinsulinemia permits retention of glycogen within the liver. As a result, patients with insulin-mediated hypoglycemia respond to 1 mg of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    (a potent glycogenolytic agent) by releasing glucose. Normal subjects will have released virtually all glucose from the liver at the end of the 72-hour fast and cannot therefore respond as vigorously to intravenous glucagon as a patient with an insulinoma. At the end of the fast, patients with an insulinoma have an increase in plasma glucose of 25",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or more in 20 to 30 minutes, whereas normal subjects have a smaller increment (",
"    <a class=\"graphic graphic_figure graphicRef64700 \" href=\"UTD.htm?37/35/38461\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Determining the cause of hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;By observing the presence of symptoms and signs of hypoglycemia, and by making the above biochemical measurements, it is usually possible to distinguish among the various causes of hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lower plasma beta-hydroxybutyrate value and a vigorous plasma glucose response to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    point to hypoglycemia mediated by insulin or an insulin-like factor (",
"    <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma insulin, C-peptide, and proinsulin values are elevated in patients with insulinoma, oral hypoglycemia agent-induced hypoglycemia, and insulin autoimmune hypoglycemia.",
"      <br/>",
"      <br/>",
"      Sulfonylurea or meglitinides are present in the plasma only in oral hypoglycemic agent-induced hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=see_link\">",
"       \"Factitious hypoglycemia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The presence of insulin or insulin receptor antibodies can distinguish insulin autoimmune hypoglycemia from insulinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/16\">",
"       16",
"      </a>",
"      ]. Insulin autoimmune hypoglycemia occurs in patients who have antibodies directed to endogenous insulin or to the insulin receptor. Symptoms can occur postprandially, fasting, or in both states. In patients with insulin autoantibodies, it is presumed that insulin secreted in response to a meal binds to the antibody and then disassociates in an unregulated fashion causing hyperinsulinemia and hypoglycemia. In patients with antibodies to the insulin receptor, hypoglycemia occurs as a result of antibody activation of the receptor.",
"     </li>",
"     <li>",
"      Plasma insulin, C-peptide, and proinsulin values are also elevated in patients with noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS). NIPHS is endogenous hyperinsulinemia due to islet hypertrophy and nesidioblastosis, a form of primary islet cell hypertrophy with neodifferentiation of islet of Langerhans cells from pancreatic duct epithelium. An unusual feature of this disorder is that hypoglycemia occurs postprandially, two to four hours after a meal. Fasting hypoglycemia, characteristic of insulinoma, is rare in this disorder. Nesidioblastosis has also been described in patients with post-gastric bypass hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44614?source=see_link\">",
"       \"Noninsulinoma pancreatogenous hypoglycemia syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma insulin values are high in patients with exogenous insulin administration, whereas plasma C-peptide and proinsulin values are low.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plasma insulin, C-peptide, and proinsulin concentrations are not elevated in patients with nonislet cell tumors. Nonislet cell tumors can cause hypoglycemia via a number of mechanisms not related to hypersecretion of insulin, including tumor production of insulin-like growth factor-II or more often its precursor, and tumor burden in which the tumor cell's high metabolic needs and reduced hepatic glycogen stores are thought to be responsible for hypoglycemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11461?source=see_link\">",
"       \"Nonislet cell tumor hypoglycemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of primary hepatocellular carcinoma\", section on 'Hypoglycemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LOCALIZING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localizing studies should not be performed until endogenous insulin-mediated hypoglycemia has been demonstrated. In patients with endogenous insulin-mediated hypoglycemia, the differential diagnosis includes insulinoma,",
"    <span class=\"nowrap\">",
"     nesidioblastosis/islet",
"    </span>",
"    cell hypertrophy, oral hypoglycemic agent-induced hypoglycemia, and insulin autoimmune hypoglycemia (",
"    <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"     table 2",
"    </a>",
"    ). Negative results for circulating oral hypoglycemic agents and insulin antibodies effectively rule out oral hypoglycemic agent-induced hypoglycemia and insulin autoimmune hypoglycemia, respectively. A localizing study is required in all patients with insulin-mediated hypoglycemia, except those with positive results for insulin antibodies or circulating oral hypoglycemic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Radiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography, MRI, and transabdominal ultrasonography can detect most insulinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24184/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The choice of procedure depends upon which tests are available and local radiologic skill. Transabdominal ultrasonography is our preferred initial test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H13#H13\">",
"     \"Insulinoma\", section on 'Tumor localization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A negative imaging study does not exclude insulinoma. If an insulinoma is not visible with initial imaging, additional studies, such as endoscopic ultrasonography, sometimes with fine-needle aspiration biopsy of detected tumors, or selective arterial calcium stimulation, are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Arterial calcium stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A selective arterial calcium stimulation test with hepatic venous sampling can be performed to distinguish between a focal abnormality (insulinoma) and a diffuse process (islet cell",
"    <span class=\"nowrap\">",
"     hypertrophy/nesidioblastosis).",
"    </span>",
"    We reserve this test for complex cases of endogenous hyperinsulinemic hypoglycemia and negative radiologic localization studies.",
"   </p>",
"   <p>",
"    This test involves selective injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    into the gastroduodenal, splenic, and superior mesenteric arteries with subsequent sampling of the hepatic venous effluent for insulin. A positive result is a doubling or tripling of basal insulin concentrations. The increase in insulin occurs in samples from the artery supplying the region with hyperfunctioning islets, either an insulinoma or islet hypertrophy, which facilitates operative localization.",
"   </p>",
"   <p>",
"    In patients with insulinoma, the response is positive in one artery alone unless the tumor resides in an area fed by two arteries, or the patient has multiple insulinomas scattered throughout the pancreas (",
"    <a class=\"graphic graphic_table graphicRef77814 \" href=\"UTD.htm?42/8/43147\">",
"     table 5",
"    </a>",
"    ). In contrast, in patients with islet cell hypertrophy, positive responses are usually but not always observed after injection of multiple arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44614?source=see_link&amp;anchor=H6#H6\">",
"     \"Noninsulinoma pancreatogenous hypoglycemia syndrome\", section on 'Localization studies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22071?source=see_link\">",
"     \"Diagnostic dilemmas in hypoglycemia: Illustrative cases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=see_link\">",
"       \"Patient information: Low blood sugar in people without diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Who should be evaluated?",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only those patients in whom Whipple's triad is documented require evaluation and management of hypoglycemia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Candidates for evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with symptoms of hypoglycemia but normal plasma glucose concentrations at the same time, no further evaluation is needed.",
"     </li>",
"     <li>",
"      Although low blood glucose values measured using reflectance meters suggest the presence of hypoglycemia, these methods are not sufficiently reliable in the low range.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first step is to review the patient's history in detail, including the nature and timing of symptoms (particularly in relationship to meals), existence of underlying illnesses or conditions, medications taken by the individual and by family members, and social history. In a patient with documented hypoglycemia, the cause may be apparent from the history and physical examination (",
"      <a class=\"graphic graphic_table graphicRef78919 \" href=\"UTD.htm?17/42/18092\">",
"       table 2",
"      </a>",
"      ). When the cause of hypoglycemia is not evident, laboratory evaluation is needed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are fortuitously observed during an episode of symptoms and are found to have simultaneous hypoglycemia (fasting or postprandial), additional measurements should be performed (plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and an oral hypoglycemic agent screen) (",
"      <a class=\"graphic graphic_table graphicRef73797 \" href=\"UTD.htm?22/21/22877\">",
"       table 1",
"      </a>",
"      ). Studies at this time may obviate the need for further testing (",
"      <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient is not symptomatic when seen, the diagnostic strategy is to seek Whipple's triad under conditions in which hypoglycemia would be expected if a hypoglycemic disorder exists (either fasting or during a mixed meal test). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Fasting evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Postprandial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If neither symptoms nor hypoglycemia have been observed and if clinical suspicion remains high, the patient should undergo a 72-hour fast, which is described in detail above. (See",
"      <a class=\"local\" href=\"#H9\">",
"       '72-hour fast'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An oral glucose tolerance test done in an effort to replicate postprandial symptoms should not be performed because misleading results may be obtained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3255?source=see_link\">",
"       \"Postprandial (reactive) hypoglycemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Interpretation of test results",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interpretation of the data obtained at the end of the 72-hour fast or a mixed meal test is the same as that performed during the occurrence of a spontaneous hypoglycemic episode (",
"      <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A lower plasma beta-hydroxybutyrate value and a vigorous plasma glucose response to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/32/25093?source=see_link\">",
"       glucagon",
"      </a>",
"      point to hypoglycemia mediated by insulin or an insulin-like factor (",
"      <a class=\"graphic graphic_table graphicRef56314 \" href=\"UTD.htm?12/24/12685\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Interpretation of data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma insulin, C-peptide, and proinsulin values are elevated in patients with insulinomas, oral hypoglycemic agent-induced hypoglycemia, and insulin autoimmune hypoglycemia. Sulfonylurea or meglitinides are present in the plasma only in oral hypoglycemia agent-induced hypoglycemia. The presence of insulin or insulin receptor antibodies can distinguish insulin autoimmune hypoglycemia from insulinoma. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Determining the cause of hypoglycemia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=see_link\">",
"       \"Factitious hypoglycemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasma insulin values are higher than levels observed in insulinoma in patients with exogenous insulin administration, but plasma C-peptide and proinsulin values are low or undetectable.",
"     </li>",
"     <li>",
"      Hypoglycemia that is not mediated by insulin or an insulin-like factor is characterized by low plasma concentrations of beta-cell polypeptides. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Determining the cause of hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Illustrative cases of hypoglycemia are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22071?source=see_link\">",
"     \"Diagnostic dilemmas in hypoglycemia: Illustrative cases\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/1\">",
"      Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/2\">",
"      Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/3\">",
"      Landau BR, Wahren J, Chandramouli V, et al. Contributions of gluconeogenesis to glucose production in the fasted state. J Clin Invest 1996; 98:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/4\">",
"      Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/5\">",
"      Hirshberg B, Livi A, Bartlett DL, et al. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 2000; 85:3222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/6\">",
"      Service FJ, Natt N. The prolonged fast. J Clin Endocrinol Metab 2000; 85:3973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/7\">",
"      Merimee TJ, Fineberg SE. Homeostasis during fasting. II. Hormone substrate differences between men and women. J Clin Endocrinol Metab 1973; 37:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/8\">",
"      Fajans SS, Floyd JC Jr. Fasting hypoglycemia in adults. N Engl J Med 1976; 294:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/9\">",
"      Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 1976; 51:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/10\">",
"      Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009; 94:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/11\">",
"      Service FJ, O'Brien PC, McMahon MM, Kao PC. C-peptide during the prolonged fast in insulinoma. J Clin Endocrinol Metab 1993; 76:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/12\">",
"      O'Brien T, O'Brien PC, Service FJ. Insulin surrogates in insulinoma. J Clin Endocrinol Metab 1993; 77:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/13\">",
"      Kao PC, Taylor RL, Service FJ. Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma. J Clin Endocrinol Metab 1994; 78:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/14\">",
"      Service FJ, O'Brien PC. Increasing serum betahydroxybutyrate concentrations during the 72-hour fast: evidence against hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 2005; 90:4555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/15\">",
"      Perros P, Henderson AK, Carter DC, Toft AD. Lesson of the week. Are spontaneous hypoglycaemia, raised plasma insulin and C peptide concentrations, and abnormal pancreatic images enough to diagnose insulinoma? BMJ 1997; 314:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/16\">",
"      Lupsa BC, Chong AY, Cochran EK, et al. Autoimmune forms of hypoglycemia. Medicine (Baltimore) 2009; 88:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/17\">",
"      Grossman AB, Reznek RH. Commentary: imaging of islet-cell tumours. Best Pract Res Clin Endocrinol Metab 2005; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24184/abstract/18\">",
"      Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 2005; 19:195.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1798 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-218.189.88.190-9543B823DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24184=[""].join("\n");
var outline_f23_39_24184=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CANDIDATES FOR EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      APPROACH TO TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fasting evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Postprandial evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - 72-hour fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Test end points and duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ending the fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interpretation of data",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plasma insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Plasma C-peptide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Plasma beta-hydroxybutyrate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Glycemic response to glucagon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Determining the cause of hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LOCALIZING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Radiologic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Arterial calcium stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Who should be evaluated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Interpretation of test results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1798|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/14/30958\" title=\"figure 1\">",
"      Glucose and insulin concentrations after prolonged fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/63/36861\" title=\"figure 2\">",
"      C peptide in prolonged fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/49/32541\" title=\"figure 3\">",
"      Proinsulin in prolonged fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/34/37421\" title=\"figure 4\">",
"      B OHB in prolonged fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/35/38461\" title=\"figure 5\">",
"      Glucagon resp in prolonged fast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/21/22877\" title=\"table 1\">",
"      Rapid overview for hypoglycemia in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/42/18092\" title=\"table 2\">",
"      Causes hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/27/7612\" title=\"table 3\">",
"      Drugs that cause hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/24/12685\" title=\"table 4\">",
"      Interpretation 72 hour fast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/8/43147\" title=\"table 5\">",
"      Arterial calcium stimulation insulinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/10/34986?source=related_link\">",
"      Clinical features and diagnosis of primary hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22071?source=related_link\">",
"      Diagnostic dilemmas in hypoglycemia: Illustrative cases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/32/18951?source=related_link\">",
"      Factitious hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=related_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44614?source=related_link\">",
"      Noninsulinoma pancreatogenous hypoglycemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11461?source=related_link\">",
"      Nonislet cell tumor hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=related_link\">",
"      Patient information: Low blood sugar in people without diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/11/3255?source=related_link\">",
"      Postprandial (reactive) hypoglycemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_39_24185="Metaplastic (chronic) atrophic gastritis";
var content_f23_39_24185=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metaplastic (chronic) atrophic gastritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Pamela J Jensen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Mark Feldman, MD, MACP, AGAF, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24185/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24185/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/39/24185/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injury to the gastric mucosa is associated with epithelial cell damage and regeneration. The term gastritis is used to denote inflammation associated with mucosal injury. However, epithelial cell injury and regeneration are not always accompanied by mucosal inflammation. This distinction has caused considerable confusion since gastritis is often used to describe endoscopic or radiologic characteristics of the gastric mucosa rather than specific histologic findings. Epithelial cell damage and regeneration without associated inflammation is properly referred to as \"gastropathy\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link\">",
"     \"Classification and diagnosis of gastritis and gastropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The causes, natural history, and therapeutic implications of gastropathy differ from gastritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastropathy is usually caused by irritants such as drugs (eg, nonsteroidal antiinflammatory agents and alcohol), bile reflux, hypovolemia, and chronic congestion.",
"     </li>",
"     <li>",
"      Gastritis is usually due to infectious agents (such as Helicobacter pylori) and autoimmune and hypersensitivity reactions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most classification systems distinguish acute, short-term from chronic, long-term disease. The terms acute and chronic are also used to describe the type of inflammatory cell infiltrate. Acute inflammation is usually associated with neutrophilic infiltration, while chronic inflammation is usually characterized by mononuclear cells, chiefly lymphocytes, plasma cells and macrophages. A practical clinicopathologic framework for the classification of gastritis and gastropathy based upon these factors can be proposed (",
"    <a class=\"graphic graphic_table graphicRef73286 \" href=\"UTD.htm?38/54/39788\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the different types of metaplastic atrophic gastritis (also called chronic atrophic gastritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The other forms of gastritis and gastropathy are presented separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     METAPLASTIC ATROPHIC GASTRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term atrophic gastritis, sometimes referred to as gastric atrophy, has been used since the nineteenth century. It is still commonly used to describe chronic gastritis that, in addition to inflammation, is associated with mucosal thinning, gland loss, and changes in epithelial cell types (ie, metaplasia).",
"   </p>",
"   <p>",
"    The classification of atrophic gastritis has varied. In one system proposed by Strickland and colleagues, the designation type A and B gastritis were used to describe immune, endocrine, and functional changes in the antrum and body, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, these alphabetic designations have been used inconsistently among authors.",
"   </p>",
"   <p>",
"    A more precise classification system uses the term \"metaplastic atrophic gastritis\" to specify the presence of metaplastic epithelial changes. It recognizes two main subtypes, autoimmune and environmental (",
"    <a class=\"graphic graphic_table graphicRef73286 \" href=\"UTD.htm?38/54/39788\">",
"     table 1",
"    </a>",
"    ). The location and histologic features defining autoimmune and environmental metaplastic atrophic gastritis are similar to those of type A and B atrophic gastritis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/5,7,8\">",
"     5,7,8",
"    </a>",
"    ]. This classification system has several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metaplasia, especially of the intestinal type, is virtually a universal feature of atrophic gastritis and is often the most dependable defining morphologic feature.",
"     </li>",
"     <li>",
"      Metaplasia is highly relevant to the pathogenesis of atrophic gastritis and to its complications (eg, pernicious anemia, gastric ulcer, and gastric cancer).",
"     </li>",
"     <li>",
"      The term metaplastic atrophic gastritis makes a sharp distinction between metaplastic and nonmetaplastic forms of gastric atrophy, especially the atrophic change often noted in the oxyntic mucosa (ie, mucosa of the body and fundus), which remains in place after antrectomy for peptic ulcer.",
"     </li>",
"     <li>",
"      The emphasis given to metaplasia also provides a better frame of reference for comprehending the changes in pepsinogen concentrations and ratios, as well as gastrin concentrations that accompany gastritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link\">",
"       \"Classification and diagnosis of gastritis and gastropathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the autoimmune and environmental forms of metaplastic atrophic gastritis are pathologically, pathogenetically, and clinically distinct, they share histologic features. Two main types of gastric mucosal metaplasia are seen in both AMAG and EMAG: pseudopyloric (\"pyloric\") and intestinal. Three other types of metaplasia may be seen in chronic gastritis: pancreatic (acinar), ciliated cell, and squamous. These are uncommon and of uncertain significance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pseudopyloric metaplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudopyloric metaplasia refers to the replacement of parietal and chief cells in oxyntic glands by mucus-secreting cells of the type found in antral (ie, pyloric) mucosa. These mucus-secreting cells arise from surviving mucous neck cells or stem cells in the damaged oxyntic glands. The pseudopyloric glands have the coiled architecture seen in normal antrum, but are smaller, less numerous, contain less mucin, and do not have antral-type endocrine cells, especially G cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intestinal metaplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal metaplasia is defined by the replacement of the surface, foveolar, and glandular epithelium in the oxyntic or antral mucosa by intestinal epithelium, which is easily recognized by the presence of goblet cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/11\">",
"     11",
"    </a>",
"    ]. Intestinal metaplasia is further subdivided into three types [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I, in which the metaplastic shift is most obvious or complete, shows fully formed small intestinal epithelium, including absorptive, goblet, and Paneth's cell types.",
"     </li>",
"     <li>",
"      Types II and III metaplasia, which are incomplete, consist of goblet cells interspersed among gastric-type mucin cells (",
"      <a class=\"graphic graphic_picture graphicRef64199 \" href=\"UTD.htm?17/24/17802\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The different types of intestinal metaplasia can be distinguished in part by the mucins produced by the goblet cells. Goblet cells in type I and II metaplasia show predominantly acidic sialomucins, whereas type III metaplasia shows acidic sulfomucin. Incomplete intestinal metaplasia, especially type III, is of special interest because its presence correlates with an increased risk of gastric adenocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. The risk appears to be greatest in patients with intestinal metaplasia involving the lesser curvature from the cardia to the pylorus or the entire stomach compared with patients with a focal or antral-predominant distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Heterotopic gastric mucosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patches of gastric-type mucosa can occur anywhere in the small or large intestine (presumably from a congenital origin). However, gastric mucosa that is noted histologically in the duodenum is most often an acquired finding (ie, gastric mucous cell metaplasia). The metaplasia is typically accompanied by chronic inflammation and Brunner gland hyperplasia, which can appear grossly as multiple erythematous nodules (ie, \"nodular duodenitis\") [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/15\">",
"     15",
"    </a>",
"    ]. The metaplastic changes are caused by exposure to chronic hyperacidity originating in the stomach and predisposes to duodenal ulcer disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"     \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Distinguishing reliably between heterotopic (congenital) and acquired (metaplastic) gastric mucosa in the duodenum from the gross appearance alone is impossible, although the appearance of multiple small mucosal nodules resembling gastric body-type mucosa may be suggestive of heterotopic mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/16\">",
"     16",
"    </a>",
"    ]. At the same time, gastric-type epithelium in the more proximal duodenum (at or near the bulb, where acidity tends to be greatest) is most likely to be metaplastic.",
"   </p>",
"   <p>",
"    Histologic findings of duodenal biopsy specimens are critical for recognition of gastric heterotopia. However, making the distinction between heterotopia and metaplasia from histological specimens is also difficult. Most authorities emphasize that heterotopic lesions more often show features of complete gastric mucosa with inclusion of specialized cell types such as parietal and chief cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. These are usually absent in the metaplastic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune metaplastic atrophic gastritis (AMAG) is an inherited form of metaplastic atrophic gastritis that is associated with an immune response in the oxyntic mucosa directed against parietal cells and intrinsic factor. An association with the major histocompatibility haplotypes HLA B-8 and DR-3 has been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/18\">",
"     18",
"    </a>",
"    ]. A mouse model of autoimmune gastritis found that the antibodies are directed against the hydrogen-potassium ATPase in parietal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;AMAG is inherited as an autosomal dominant disorder that commonly affects people of northern Europe or northern European extraction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/18\">",
"     18",
"    </a>",
"    ]. The disease is three times more common among women [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/20\">",
"     20",
"    </a>",
"    ]. An association with autoimmune thyroid disease has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/21\">",
"     21",
"    </a>",
"    ]. Affected patients are at high risk for developing pernicious anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/5,20,22\">",
"     5,20,22",
"    </a>",
"    ]. In addition, asymptomatic relatives are sometimes found to have established AMAG and even pernicious anemia.",
"   </p>",
"   <p>",
"    The chronic inflammation, gland atrophy, and epithelial metaplasia of AMAG are closely paralleled by elevated serum antibodies to parietal cells and to intrinsic factor, reflecting its autoimmune origin. The loss of parietal cell mass leads to profound hypochlorhydria, while the inadequate production of intrinsic factor leads to vitamin B12 malabsorption and pernicious anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AMAG and vitamin B12 deficiency may develop several clinical consequences in addition to anemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Subacute combined degeneration of the dorsal and lateral spinal columns may occur prior to the development of anemia, particularly in the elderly [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/23\">",
"       23",
"      </a>",
"      ]. The disorder is associated with a neuropathy, which is symmetrical and affects the legs more than the arms. It begins with paresthesias and ataxia associated with loss of vibration and position sense, and can progress to severe weakness, spasticity, clonus, paraplegia, and fecal and urinary incontinence. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There may be other autoimmune disorders such as Hashimoto's thyroiditis and vitiligo [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"       \"Disorders that cause hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metaplasia, glandular atrophy, and inflammation are confined to the gastric body and fundus in patients with AMAG. In the early stages, referred to as active autoimmune gastritis, the gastric body and fundus may appear to contain multiple polyps, which, histologically, represent retained islands of uninvolved mucosa rather than being true neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In advanced or end-stage AMAG, gross examination of the stomach by endoscopy or contrast radiography may demonstrate absent or inconspicuous rugae in the gastric body and fundus. In addition, the submucosal blood vessels may be visible through the thin, atrophic, overlying mucosa. Atrophy and metaplasia are usually absent in the antrum [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The inflammation in active AMAG typically consists of diffuse or focal lymphocytic infiltration including epithelial lymphocytosis with destruction of oxyntic glands. Pseudohypertrophy of parietal cells resembling that seen during treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    may be present in the islands of surviving mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. This observation has led to the suggestion that autoantibodies against the hydrogen-potassium ATPase inhibit acid secretion, causing parietal cell pseudohypertrophy as a result of enlargement of canaliculi [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/19\">",
"     19",
"    </a>",
"    ]. This is analogous to the effect of omeprazole (which blocks the hydrogen-potassium ATPase) on parietal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In end-stage AMAG, oxyntic glands are completely or almost completely replaced by metaplastic glands. In extreme cases, the mucosa becomes villiform, closely resembling normal small intestine. The epithelial cells may appear megaloblastic in patients who have coexisting untreated pernicious anemia.",
"   </p>",
"   <p>",
"    The proportion of pseudopyloric and intestinal metaplasia within the body and fundus vary widely among patients, and either form can predominate. This variability must be taken into account when obtaining and interpreting gastric biopsy specimens. Correct anatomic localization of the biopsy to body or antrum requires that the endoscopist provide accurate information about the biopsy sites (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Where did the biopsy specimens come from?'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Metaplasia is usually absent or only slight in the antrum in AMAG, but changes consistent with chemical gastropathy are often present. The basis for this finding is not clear; it is possible that these patients are subject to excessive duodenogastric reflux.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperplastic and neoplastic lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AMAG are at increased risk for the development of gastric carcinoid tumors and adenocarcinoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypochlorhydria associated with AMAG induces hyperplasia of the G cells (the cell type responsible for producing gastrin) and hypergastrinemia. Gastrin exerts a trophic effect on endocrine cells within the metaplastic and atrophic body mucosa, which increase in number and may give rise to hyperplastic nodules both within and around the glands [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Carcinoid tumors are thought to arise from transformation of enterochromaffin-like cells (ECL cells, which are responsible for histamine secretion) within the oxyntic mucosa due to chronic stimulation by gastrin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relationship between gastrin-induced hyperplasia and carcinoid tumor formation is supported by the observation that antrectomy, with resultant loss of G cell mass and normalization of plasma gastrin concentrations, can lead to reversal of endocrine hyperplasia and reduced tumor size [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Thus, antrectomy rather than total gastrectomy, may be the optimal treatment in many if not most patients with AMAG-associated carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid tumors in AMAG patients appear grossly as mucosal nodules or polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/38\">",
"     38",
"    </a>",
"    ]. However, most nodular and polypoid lesions encountered in the gastric body and antrum in patients with AMAG are ordinary benign epithelial hyperplastic lesions. The tumors in the antrum are related to the foveolar hyperplasia of chemical gastropathy that often accompanies AMAG. These changes have no known malignant potential or direct connection with other mucosal changes in AMAG [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ECL cell hyperplasia is also observed in the hypergastrinemia associated with long-term use of proton pump inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    . However, an increased risk for the development of carcinoid tumors has not been observed during chronic treatment with these drugs in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=see_link\">",
"     \"Medical management of gastroesophageal reflux disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Gastric adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric adenocarcinoma develops in 1 to 3 percent of patients with autoimmune gastritis via intervening steps of intestinal metaplasia and dysplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/40\">",
"     40",
"    </a>",
"    ]. The magnitude of the risk is variable in the literature, with estimates ranging from 3 to 18 times greater than an age-matched population [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/41-44\">",
"     41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies suggesting an increased risk of gastric adenocarcinoma have shown the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that used follow-up data from mass screening endoscopy, the risk of developing gastric cancer during an average follow-up period of 4.4 years was increased 5.73-fold in patients who had atrophic gastritis at baseline compared with patients who did not [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/45\">",
"       45",
"      </a>",
"      ]. Another report described a similar increase in risk (5.76-fold) in patients with severe fundal atrophic gastritis diagnosed by the Congo red chromoendoscopy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/44\">",
"       44",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=see_link\">",
"       \"Chromoendoscopy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An increased risk of gastric cancer was noted in a cohort study that included 4517 men and women in Sweden who had pernicious anemia and were followed for 20 years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/43\">",
"       43",
"      </a>",
"      ]. A total of 553 cancers were diagnosed, which was higher than expected based upon the standardized incidence rates in the general population. The risk was highest for cancers of the stomach, esophagus, and pancreas (relative risk 2.9, 3.2, and 1.7, respectively). The risk of stomach cancer was highest in the first year after diagnosis of pernicious anemia.",
"     </li>",
"     <li>",
"      In a long-term study that included 80 patients with pernicious anemia, only one patient had gastric adenocarcinoma at the outset [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/39\">",
"       39",
"      </a>",
"      ]. Although varying degrees of dysplasia were present in 42 percent of patients, none progressed to adenocarcinoma during a follow-up of 6 to 10 years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/46\">",
"       46",
"      </a>",
"      ]. However, an adenoma with high-grade dysplasia and a carcinoid developed in two other patients.",
"     </li>",
"     <li>",
"      A meta-analysis looked at the risk of developing adenocarcinoma in the gastric cardia [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/47\">",
"       47",
"      </a>",
"      ]. The analysis found that atrophic gastritis was a risk factor for adenocarcinoma of the gastric cardia (RR 2.9).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the above studies, the risk of gastric cancer and the need for surveillance endoscopy was questioned in another population-based study that included 152 patients who were followed for a mean of approximately 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/48\">",
"     48",
"    </a>",
"    ]. Although these patients did not undergo regular surveillance endoscopy, only one case of gastric cancer was detected during follow-up, a rate which was not different from that expected in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H122606258\">",
"    <span class=\"h3\">",
"     Esophageal squamous cell carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between atrophic gastritis and esophageal squamous cell carcinoma (SCC) has also been noted. In a meta-analysis that included seven studies of esophageal SCC, the overall relative risk for developing esophageal SCC in patients with atrophic gastritis was 1.94 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AMAG are",
"    <strong>",
"     less likely",
"    </strong>",
"    to be infected by H. pylori than age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/49\">",
"     49",
"    </a>",
"    ]. Two possible explanations are that the metaplastic epithelium is unsuitable for H. pylori colonization, and that the associated hypochlorhydria encourages overgrowth by other bacterial species [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, chronic H. pylori gastritis and AMAG share some clinical and pathologic features. Both can be associated with an atrophic form of body gastritis and hypochlorhydria. In addition, some patients with H. pylori have circulating parietal cell autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/51\">",
"     51",
"    </a>",
"    ]. Serologic testing for H. pylori may be helpful in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"     \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is also a theory that H. pylori might serve as a trigger of AMAG and pernicious anemia. This theory was proposed in a study involving 160 patients with autoimmune gastritis who were identified by the presence of hypergastrinemia and strongly positive antiparietal antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/52\">",
"     52",
"    </a>",
"    ]. The patients fell into three groups: those with iron deficiency anemia (52 percent), those with normocytic indices (30 percent), and those with macrocytic anemia (18 percent). Progression from iron deficiency anemia to macrocytic anemia correlated strongly with age. Furthermore, the prevalence of H. pylori infection was markedly high among those younger than 20 (88 percent) declining to only 12.5 percent in those older than 60. These observations are consistent with the hypothesis that H. pylori triggers the development of autoimmune gastritis, which progresses clinically from iron deficiency anemia to clinical cobalamin deficiency over time. H. pylori infection has also been associated with iron deficiency anemia in patients without evidence of gastrointestinal blood loss by mechanisms that are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=see_link&amp;anchor=H12#H12\">",
"     \"Acute and chronic gastritis due to Helicobacter pylori\", section on 'Iron deficiency anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL METAPLASTIC ATROPHIC GASTRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental metaplastic atrophic gastritis (EMAG) is due to environmental factors, such as diet and H. pylori infection, on the gastric mucosa. Unlike AMAG, mucosal changes in patients with EMAG affect both the corpus and antrum in a multifocal distribution, but with heaviest involvement of the antrum. In addition, EMAG differs from AMAG in a number of other ways:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gastric acid production does not disappear entirely",
"     </li>",
"     <li>",
"      Serum gastrin is not elevated",
"     </li>",
"     <li>",
"      Parietal cell and intrinsic factor autoantibodies and pernicious anemia are absent",
"     </li>",
"     <li>",
"      There is an increased risk for gastric ulcer [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/53\">",
"       53",
"      </a>",
"      ] compared to AMAG, presumably due to the accompanying hypochlorhydria the latter disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with EMAG are at increased risk for gastric cancer, particularly the intestinal type [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pathologic features in EMAG are multiple, focally distributed areas of atrophy, metaplasia, and inflammation. As a general rule, these changes are most heavily concentrated in the antrum, but the location may vary depending upon the stage of the disease. Changes may be more evident along the lesser curvature at the junction of the body and antrum (ie, the transitional zone) in patients with mild or early disease. In severe or advanced disease, metaplastic epithelium can almost completely replace the normal antral mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The transition from early to advanced stages of EMAG is often reflected by proximal migration of the transitional zone, which can be demonstrated by endoscopy and in resection specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Oxyntic mucosa (ie, mucosa of the body and fundus) adjacent to the transitional zone is progressively replaced by intestinal and pseudopyloric metaplastic mucosa. In addition, the intact oxyntic mucosa may be thinned and have a reduced number of parietal cells, presumably due to decreased gastrin release resulting from the EMAG-associated reduction in the number of antral G cells. These changes need to be considered when making a pathologic distinction between EMAG and AMAG on gastric biopsy specimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have attempted to identify risk factors for EMAG based upon biopsy diagnosis. In epidemiologic studies, individuals with EMAG are usually identified indirectly by screening with serum pepsinogen concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification and diagnosis of gastritis and gastropathy\", section on 'Serum pepsinogen isoenzymes'",
"    </a>",
"    .) A shortcoming of this approach is that H. pylori infection, which is often common in the populations under study, increases serum pepsinogen values [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. As a result, the prevalence of EMAG is most likely to have been underestimated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/58\">",
"     58",
"    </a>",
"    ]. However, the correlation between serum pepsinogen values and histologic demonstration of EMAG is well documented, and pepsinogen determination is currently the best available tool for population studies of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    EMAG and intestinal-type gastric cancer are closely associated pathologically, clinically, and epidemiologically. Thus, similar contributing factors are proposed for the two conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous studies have investigated possible dietary causes of EMAG [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. The results have usually been inconclusive or inconsistent. Possible exceptions are nitroso compounds, which may be important in EMAG and in the development of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. Nitroso compounds, which are known carcinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/67,68\">",
"     67,68",
"    </a>",
"    ], are generated in the gastric lumen by bacterial metabolism of nitrates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although H. pylori gastritis is a risk factor for EMAG and gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], it is doubtful that longstanding H. pylori gastritis alone causes EMAG, but some authors feel these disorders are linked [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. It seems more likely that H. pylori gastritis is one of many possible factors that lead to metaplasia but is probably not causative alone [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/74\">",
"     74",
"    </a>",
"    ]. Supporting this conclusion is the observation that the prevalence of intestinal metaplasia and gastric cancer are surprisingly low in Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/75-77\">",
"     75-77",
"    </a>",
"    ], despite a high prevalence of H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/75\">",
"     75",
"    </a>",
"    ]. In one study, for example, intestinal metaplasia was found in only 4 percent of a group of Yemeni adults, despite a 93 percent prevalence of H. pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .) These differences may reflect the varying pathogenicity of H. pylori strains or differences in host factors that influence the rate of gastric cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One theory for the role of H. pylori in EMAG is that the epithelial cell injury and chronic inflammation associated with chronic infection increases the susceptibility of the mucosa to other mutagenic factors. This hypothesis is consistent with observations which suggest that diet or other aspects of the patient's environment, such as smoking, can also correlate closely with the presence of intestinal metaplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether eradication of H. pylori affects the natural history of gastric intestinal metaplasia and cancer risk is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=see_link\">",
"     \"Association between Helicobacter pylori infection and gastrointestinal malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PRACTICAL ASPECTS OF ENDOSCOPIC AND BIOPSY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate diagnosis of AMAG and EMAG depends upon good communication between the endoscopist and pathologist. To clearly distinguish between AMAG and EMAG from biopsy findings, two questions must be answered:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Where did the biopsy specimens come from?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe metaplastic atrophic gastritis can deprive the pathologist of the histologic clues needed to identify the origin of the biopsy. Thus, it is essential that biopsy specimens be taken from areas that the endoscopist believes are unequivocally within the body, fundus, or antrum, and indicate their origin clearly. As noted above, AMAG is confined to the gastric body and fundus whereas EMAG is usually most prominent in the antrum.",
"   </p>",
"   <p>",
"    Immunostaining for endocrine cells (ie, G cells, and ECL cells) is also helpful for showing that pseudopyloric metaplasia has replaced oxyntic mucosa. G cells are sparse or absent in pseudopyloric glands; in comparison, they are plentiful in biopsy specimens from the true antrum in AMAG and EMAG, except when there is marked antral intestinal metaplasia and atrophy. The presence of ECL cell hyperplasia in patients with AMAG can help confirm that a biopsy specimen is from the body or fundus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Is there sufficient intestinal metaplasia for a definite biopsy diagnosis of EMAG?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric biopsy specimens in patients without EMAG frequently show intestinal metaplasia in a single or a few nests of glands. Thus, we recommend that a diagnosis of EMAG should",
"    <strong>",
"     not",
"    </strong>",
"    be made from biopsy specimens unless at least 20 percent of the available antral or transitional mucosa is replaced by metaplastic glands, or there is unequivocal atrophy. The specimen is reported as showing \"focal intestinalization,\" and EMAG is considered only \"possible\" if a smaller proportion of the mucosa (&lt;20 percent) is intestinalized, and atrophy is lacking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intestinal metaplasia and gastric cancer risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intestinal type of gastric adenocarcinoma does not arise de novo. Gastritis is usually the first step in cancer induction regardless of the cause. A sequence of changes occurs, beginning with inflammation, passing through intestinal metaplasia, p53 alteration, and dysplasia to end in intestinal type cancer. This model of gastric carcinogenesis is known as Correa's cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although it is clear that intestinal metaplasia is an intermediate stage in the development of gastric cancer, there is no consensus as to the magnitude of risk in individual patients with IM. It is apparent that in high risk populations, IM has a significant rate of progression to neoplasia, warranting screening interventions, but this may not be appropriate in average risk populations. The key appears to be defining which patients fall within the high risk category for screening.",
"   </p>",
"   <p>",
"    High risk characteristics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of gastric cancer.",
"     </li>",
"     <li>",
"      Residence in or migration from a high risk location.",
"     </li>",
"     <li>",
"      Member of a high risk ethnic population.",
"     </li>",
"     <li>",
"      Dysplasia on biopsy.",
"     </li>",
"     <li>",
"      Extensive IM on biopsies. The extent of IM is probably more important than the metaplastic subtype [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of studies have examined molecular events in gastric carcinoma and IM in a search for biomarkers that may further characterize high risk populations. Such markers have included MSI, LOH, p53, and Sonic hedgehog (shh). No reliable markers of the propensity of IM to progress to gastric cancer have yet been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SURVEILLANCE ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic surveillance for patients found to have gastric intestinal metaplasia has not been as extensively studied as intestinal metaplasia in the esophagus.",
"   </p>",
"   <p>",
"    A diagnosis of intestinal metaplasia (IM) in gastric biopsies is frequent in populations at high gastric cancer risk, such as those of East Asia and the Andean regions of Latin America, but not in developed countries of North America and Western Europe. Immigrants from high risk countries also have high prevalence of IM. However, a diagnosis of IM of the \"complete\" type by itself is not an indication for endoscopic surveillance. On the other hand, a diagnosis of \"incomplete\" metaplasia, particularly Type III metaplasia with goblet cells containing acidic sulfomucin, should be followed by an in depth evaluation of its extent. The cancer risk is proportional to the extent of IM. The low incidence of gastric cancer in developed countries would likely make a surveillance program impractical [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/82\">",
"     82",
"    </a>",
"    ]. Furthermore, intestinal metaplasia is not as easy to recognize endoscopically in the stomach compared to the esophagus. On the other hand, a cohort study from the United Kingdom suggested that annual surveillance of patients with \"high risk\" endoscopic findings (which included dysplasia, intestinal metaplasia, atrophic gastritis, foveolar hyperplasia, regenerative changes, polyps, or gastric ulcers) may lead to the earlier detection of gastric cancer and possibly improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in endoscopic techniques, including confocal endomicroscopy may allow for a more precise identification and mapping of intestinal metaplasia in the future, permitting clinicians to better identify patients who would most benefit from surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=see_link\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A guideline issued by the American Society for Gastrointestinal Endoscopy (ASGE) suggests the following [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic surveillance for gastric intestinal metaplasia has not been extensively studied in the United States and therefore cannot be uniformly recommended.",
"     </li>",
"     <li>",
"      Patients at increased risk for gastric cancer due to either background or family history may benefit from surveillance.",
"     </li>",
"     <li>",
"      Endoscopic surveillance with gastric biopsies should incorporate a topographic mapping of the entire stomach histologically.",
"     </li>",
"     <li>",
"      Patients with confirmed high-grade dysplasia are at significant risk for progressing to cancer and should be considered for gastrectomy or local (eg, endoscopic) resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ASGE guideline has more specific recommendations for patients with pernicious anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/84\">",
"     84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single endoscopy should be performed to identify prevalent lesions (carcinoid tumors and gastric cancer) but there are insufficient data to support routine subsequent endoscopic surveillance for these patients.",
"     </li>",
"     <li>",
"      Surveillance of carcinoid tumors is controversial and should be individualized.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our approach is somewhat different; we suggest the following surveillance strategy for patients diagnosed with pernicious anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24185/abstract/46\">",
"     46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Upper endoscopy soon after diagnosis.",
"     </li>",
"     <li>",
"      Removal of gastric polyps if possible; most of these polyps will be benign.",
"     </li>",
"     <li>",
"      Frequent reinvestigation in patients whose polyps are not removed or who have severe mucosal dysplasia; in the remaining patients, follow-up endoscopies should be performed at approximately five-year intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"metaplastic atrophic gastritis\" specifies the presence of metaplastic epithelial changes. It recognizes two main subtypes, autoimmune and environmental (",
"      <a class=\"graphic graphic_table graphicRef73286 \" href=\"UTD.htm?38/54/39788\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      An accurate diagnosis of AMAG and EMAG depends upon good communication between the endoscopist and pathologist. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Practical aspects of endoscopic and biopsy diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific treatment for metaplastic gastritis. The offending agent should be eliminated wherever possible. It may be reasonable to treat empirically for H. pylori, even if it cannot be identified on pathology specimens since the density of H. pylori may be insufficient to yield a positive result by some testing methodologies such as urea-based tests or staining of pathology specimens. A serologic test may remain positive in such patients and thus may be an option if specific confirmation is desired. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=see_link\">",
"       \"Indications and diagnostic tests for Helicobacter pylori infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of gastric cancer in patients with gastric intestinal metaplasia is uncertain and probably does not warrant routine surveillance in low risk populations. Exceptions may be patients with a family history of gastric cancer or those in whom gastric biopsy specimens were concerning for dysplastic changes. In such cases, pathology specimens should be reviewed with an expert GI pathologist and a decision made about surveillance or specific treatment on an individual patient basis. As noted above, more specific recommendations have been issued in patients diagnosed with pernicious anemia. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Surveillance endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/1\">",
"      Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/2\">",
"      Carpenter HA, Talley NJ. Gastroscopy is incomplete without biopsy: clinical relevance of distinguishing gastropathy from gastritis. Gastroenterology 1995; 108:917.",
"     </a>",
"    </li>",
"    <li>",
"     Yardley JH, Hendrix TR. Gastritis, duodenitis, and associated ulcerative lesions. In: Textbook of gastroenterology, 2nd ed, Yamada T, Alpers DH, Owyang C, et al (Eds), Philadelphia 1995. p.1456.",
"    </li>",
"    <li>",
"     Yardley JH, Hendrix TR. Gastritis, duodenitis, and associated ulcerative lesions. In: Textbook of Gastroenterology, 3rd ed, Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE (Eds), Lippincott, Philadelphia 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/5\">",
"      Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973; 18:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/6\">",
"      Strickland RG, Bhathal PS, Korman MG, Hansky J. Serum gastrin and the antral mucosa in atrophic gastritis. Br Med J 1971; 4:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/7\">",
"      Correa P. The epidemiology and pathogenesis of chronic gastritis: three etiologic entites. Front Gastrointest Res 1980; 6:98.",
"     </a>",
"    </li>",
"    <li>",
"     Correa P. Chronic gastritis (non-specific). In: Gastrointestinal and oesophageal pathology, Whitehead R (Ed), Churchill Livingstone, Edinburgh 1989. p.402.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/9\">",
"      Doglioni C, Laurino L, Dei Tos AP, et al. Pancreatic (acinar) metaplasia of the gastric mucosa. Histology, ultrastructure, immunocytochemistry, and clinicopathologic correlations of 101 cases. Am J Surg Pathol 1993; 17:1134.",
"     </a>",
"    </li>",
"    <li>",
"     Fenoglio-Preiser CM. Metaplasias in gastritis. In: Gastrointestinal Pathology, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.190.",
"    </li>",
"    <li>",
"     Antonioli DA. Gastric carcinoma and its precursors. In: Gastrointestinal Pathology, Goldman H, Appelman HD, Kaufman N (Eds), United States and Canadian Academy of Pathology Monograph in Pathology No. 31, Williams &amp; Wilkins, Baltimore 1990. p.144.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/12\">",
"      Leung WK, Sung JJ. Review article: intestinal metaplasia and gastric carcinogenesis. Aliment Pharmacol Ther 2002; 16:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/13\">",
"      Filipe MI, Mu&ntilde;oz N, Matko I, et al. Intestinal metaplasia types and the risk of gastric cancer: a cohort study in Slovenia. Int J Cancer 1994; 57:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/14\">",
"      Cassaro M, Rugge M, Gutierrez O, et al. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol 2000; 95:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/15\">",
"      Triadafilopoulos G. Clinical and pathologic features of the nodular duodenum. Am J Gastroenterol 1993; 88:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/16\">",
"      Lessells AM, Martin DF. Heterotopic gastric mucosa in the duodenum. J Clin Pathol 1982; 35:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/17\">",
"      Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989; 96:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/18\">",
"      Kekki M, Siurala M, Varis K, et al. Classification principles and genetics of chronic gastritis. Scand J Gastroenterol Suppl 1987; 141:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/19\">",
"      Jones CM, Callaghan JM, Gleeson PA, et al. The parietal cell autoantigens recognized in neonatal thymectomy-induced murine gastritis are the alpha and beta subunits of the gastric proton pump [corrected]. Gastroenterology 1991; 101:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/20\">",
"      Varis K, Iham&auml;ki T, H&auml;rk&ouml;nen M, et al. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. Scand J Gastroenterol 1979; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/21\">",
"      Centanni M, Marignani M, Gargano L, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med 1999; 159:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/22\">",
"      Siurala M, Varis K, Kekki M. New aspects on epidemiology, genetics, and dynamics of chronic gastritis. Front Gastrointest Res 1980; 6:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/23\">",
"      Nilsson-Ehle H, Landahl S, Lindstedt G, et al. Low serum cobalamin levels in a population study of 70- and 75-year-old subjects. Gastrointestinal causes and hematological effects. Dig Dis Sci 1989; 34:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/24\">",
"      Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/25\">",
"      Kenney JA Jr. Vitiligo. Dermatol Clin 1988; 6:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/26\">",
"      Stolte M, Baumann K, Bethke B, et al. Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 1992; 30:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/27\">",
"      Ikeda T, Senoue I, Hara M, et al. Gastric pseudopolyposis: a new clinical manifestation of type A gastritis. Am J Gastroenterol 1985; 80:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/28\">",
"      Stemmermann GN, Hayashi T. Intestinal metaplasia of the gastric mucosa: a gross and microscopic study of its distribution in various disease states. J Natl Cancer Inst 1968; 41:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/29\">",
"      Stolte M, Bethke B, R&uuml;hl G, Ritter M. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 1992; 30:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/30\">",
"      Solcia E, Fiocca R, Rindi G, et al. The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 1993; 22:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/31\">",
"      Bordi C, Pilato F, Carfagna G, et al. Argyrophil cell hyperplasia of fundic mucosa in patients with chronic atrophic gastritis. Digestion 1986; 35 Suppl 1:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/32\">",
"      Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985; 88:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/33\">",
"      M&uuml;ller J, Kirchner T, M&uuml;ller-Hermelink HK. Gastric endocrine cell hyperplasia and carcinoid tumors in atrophic gastritis type A. Am J Surg Pathol 1987; 11:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/34\">",
"      Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991; 67:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/35\">",
"      Sculco D, Bilgrami S. Pernicious anemia and gastric carcinoid tumor: case report and review. Am J Gastroenterol 1997; 92:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/36\">",
"      Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/37\">",
"      Kern SE, Yardley JH, Lazenby AJ, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol 1990; 3:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/38\">",
"      Berendt RC, Jewell LD, Shnitka TK, et al. Multicentric gastric carcinoids complicating pernicious anemia. Origin from the metaplastic endocrine cell population. Arch Pathol Lab Med 1989; 113:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/39\">",
"      Stockbr&uuml;gger RW, Menon GG, Beilby JO, et al. Gastroscopic screening in 80 patients with pernicious anaemia. Gut 1983; 24:1141.",
"     </a>",
"    </li>",
"    <li>",
"     Fenoglio-Preiser CM. Autoimmune gastritis. In: Gastrointestinal Pathology, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 2008. p.188.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/41\">",
"      Kato I, Tominaga S, Ito Y, et al. Atrophic gastritis and stomach cancer risk: cross-sectional analyses. Jpn J Cancer Res 1992; 83:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/42\">",
"      Jedrychowski W, Popiela T, Boeing H, et al. A clinico-epidemiological study on gastritis in gastric carcinoma and in non-cancerous gastric pathology in Poland. Rev Environ Health 1997; 12:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/43\">",
"      Hsing AW, Hansson LE, McLaughlin JK, et al. Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer 1993; 71:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/44\">",
"      Tatsuta M, Iishi H, Nakaizumi A, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. Int J Cancer 1993; 53:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/45\">",
"      Kato I, Tominaga S, Ito Y, et al. A prospective study of atrophic gastritis and stomach cancer risk. Jpn J Cancer Res 1992; 83:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/46\">",
"      Armbrecht U, Stockbr&uuml;gger RW, Rode J, et al. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut 1990; 31:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/47\">",
"      Islami F, Sheikhattari P, Ren JS, Kamangar F. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma--a systematic review and meta-analysis. Ann Oncol 2011; 22:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/48\">",
"      Schafer LW, Larson DE, Melton LJ 3rd, et al. Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1985; 60:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/49\">",
"      Fong TL, Dooley CP, Dehesa M, et al. Helicobacter pylori infection in pernicious anemia: a prospective controlled study. Gastroenterology 1991; 100:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/50\">",
"      Siurala M, Sipponen P, Kekki M. Campylobacter pylori in a sample of Finnish population: relations to morphology and functions of the gastric mucosa. Gut 1988; 29:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/51\">",
"      Annibale B, Marignani M, Azzoni C, et al. Atrophic body gastritis: distinct features associated with Helicobacter pylori infection. Helicobacter 1997; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/52\">",
"      Hershko C, Ronson A, Souroujon M, et al. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 2006; 107:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/53\">",
"      Schrager J, Spink R, Mitra S. The antrum in patients with duodenal and gastric ulcers. Gut 1967; 8:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/54\">",
"      Kohli Y, Kato T, Suzuki K, et al. Incidence of atrophic gastritis with age in Japan and Canada. Jpn J Med 1987; 26:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/55\">",
"      Mossi S, Meyer-Wyss B, Renner EL, et al. Influence of Helicobacter pylori, sex, and age on serum gastrin and pepsinogen concentrations in subjects without symptoms and patients with duodenal ulcers. Gut 1993; 34:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/56\">",
"      Palli D, Decarli A, Cipriani F, et al. Helicobacter pylori antibodies in areas of Italy at varying gastric cancer risk. Cancer Epidemiol Biomarkers Prev 1993; 2:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/57\">",
"      Ricci C, Vakil N, Rugge M, et al. Serological markers for gastric atrophy in asymptomatic patients infected with Helicobacter pylori. Am J Gastroenterol 2004; 99:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/58\">",
"      Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology 1992; 102:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/59\">",
"      Stemmermann GN, Samloff IM, Nomura AM, Heilbrun LK. Serum pepsinogens I and II and stomach cancer. Clin Chim Acta 1987; 163:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/60\">",
"      Sitas F, Smallwood R, Jewell D, et al. Serum anti-Helicobacter pylori IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. Cancer Epidemiol Biomarkers Prev 1993; 2:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/61\">",
"      Graham DY, Nurgalieva ZZ, El-Zimaity HM, et al. Noninvasive versus histologic detection of gastric atrophy in a Hispanic population in North America. Clin Gastroenterol Hepatol 2006; 4:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/62\">",
"      Forman D. Are nitrates a significant risk factor in human cancer? Cancer Surv 1989; 8:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/63\">",
"      Friedman GD, Parsonnet J. Salt intake and stomach cancer: some contrary evidence. Cancer Epidemiol Biomarkers Prev 1992; 1:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/64\">",
"      Knight T, Pirastu R, Palli D, et al. Nitrate and N-nitrosoproline excretion in two Italian regions with contrasting rates of gastric cancer: the role of nitrate and other factors in endogenous nitrosation. Int J Cancer 1992; 50:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/65\">",
"      Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992; 52:6735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/66\">",
"      Stemmermann GN, Mower H. Gastritis, nitrosamines, and gastric cancer. J Clin Gastroenterol 1981; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/67\">",
"      Preston-Martin S, Correa P. Epidemiological evidence for the role of nitroso compounds in human cancer. Cancer Surv 1989; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/68\">",
"      Matsukura N, Kawachi T, Sasajima K, et al. Induction of intestinal metaplasia in the stomachs of rats by N-methyl-N'-nitro-N-nitrosoguanidine. J Natl Cancer Inst 1978; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/69\">",
"      Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/70\">",
"      An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 1993; 341:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/71\">",
"      Craanen ME, Dekker W, Blok P, et al. Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut 1992; 33:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/72\">",
"      Kuipers EJ, Uyterlinde AM, Pe&ntilde;a AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/73\">",
"      Stolte M. A critical look at the Sydney classification of gastritis. Endoscopy 1991; 23:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/74\">",
"      Craanen ME, Blok P, Dekker W, Tytgat GN. Helicobacter pylori and early gastric cancer. Gut 1994; 35:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/75\">",
"      Holcombe C. Helicobacter pylori: the African enigma. Gut 1992; 33:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/76\">",
"      M&eacute;graud F, Brassens-Rabb&eacute; MP, Denis F, et al. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989; 27:1870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/77\">",
"      el-Guneid A, el-Sherif AM, Murray-Lyon IM, et al. Effect of chewing Qat on mucosal histology and prevalence of Helicobacter pylori in the oesophagus, stomach and duodenum of Yemeni patients. Histopathology 1991; 19:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/78\">",
"      Peek RM Jr, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002; 2:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/79\">",
"      Stemmermann GN, Nomura AM, Chyou PH, Hankin J. Impact of diet and smoking on risk of developing intestinal metaplasia of the stomach. Dig Dis Sci 1990; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/80\">",
"      Akiyama J, Uemura N. Intestinal metaplasia subtype and gastric cancer risk. J Gastroenterol Hepatol 2009; 24:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/81\">",
"      Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis. J Gastroenterol Hepatol 2009; 24:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/82\">",
"      Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology 2003; 125:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/83\">",
"      Whiting JL, Sigurdsson A, Rowlands DC, et al. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002; 50:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24185/abstract/84\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 30 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-8F673A88A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24185=[""].join("\n");
var outline_f23_39_24185=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      METAPLASTIC ATROPHIC GASTRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pseudopyloric metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intestinal metaplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Heterotopic gastric mucosa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AUTOIMMUNE METAPLASTIC ATROPHIC GASTRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperplastic and neoplastic lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Gastric adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H122606258\">",
"      - Esophageal squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ENVIRONMENTAL METAPLASTIC ATROPHIC GASTRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PRACTICAL ASPECTS OF ENDOSCOPIC AND BIOPSY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Where did the biopsy specimens come from?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Is there sufficient intestinal metaplasia for a definite biopsy diagnosis of EMAG?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intestinal metaplasia and gastric cancer risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SURVEILLANCE ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/30\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/30|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/24/17802\" title=\"picture 1\">",
"      Gastritis intestinal metaplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/30|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/54/39788\" title=\"table 1\">",
"      Classification of gastritis and gastropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30055?source=related_link\">",
"      Acute and chronic gastritis due to Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2634?source=related_link\">",
"      Association between Helicobacter pylori infection and gastrointestinal malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31205?source=related_link\">",
"      Classification and diagnosis of gastritis and gastropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37817?source=related_link\">",
"      Indications and diagnostic tests for Helicobacter pylori infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/53/42840?source=related_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_39_24186="Factors affecting HIV progression";
var content_f23_39_24186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Factors affecting HIV progression",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24186/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24186/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24186/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24186/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/39/24186/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/39/24186/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/39/24186/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As of 2009, the World Health Organization (WHO) estimated that approximately 33 million people are living with",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/1\">",
"     1",
"    </a>",
"    ]. From early in the HIV epidemic, it was clear that some patients rapidly progressed to AIDS, while others experienced relative immunologic stability.",
"   </p>",
"   <p>",
"    Laboratory measurements, such as numbers of CD4 cells and levels of plasma HIV RNA, are helpful in determining the stage of infection and may serve as prognostic markers. Other factors may also influence outcome. This topic covers the demographic, viral, and host factors that may play a role in disease progression as well as describing the important impact antiretroviral therapy has had over the past decade.",
"   </p>",
"   <p>",
"    The relative stages of HIV infection are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LABORATORY MARKERS OF PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two important laboratory determinants of the rate of progression are the CD4 cell count and the plasma viral load [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=see_link\">",
"     \"Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     CD4 counts and levels of HIV RNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average rate of decline of CD4 cells (\"CD4 slope\") is about",
"    <span class=\"nowrap\">",
"     50/mm3",
"    </span>",
"    per year and the average viral burden (without therapy) is 30,000 to 50,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    The CD4 cell count and the viral load are independent predictors of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This is illustrated by the following natural history studies prior to the era of HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five-year risk of progressing to AIDS in 522 injection drug users ranged from zero percent in those with a baseline viral load &lt;500",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and a CD4 cell count",
"      <span class=\"nowrap\">",
"       &ge;500/mm3",
"      </span>",
"      to 81 percent in those with a baseline viral load &ge;10,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and a CD4 cell count",
"      <span class=\"nowrap\">",
"       &lt;200/mm3",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Multicenter AIDS Cohort Study (MACS) is a database of men who have sex with men (MSM) that was initiated prior to the availability of HAART [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/5\">",
"       5",
"      </a>",
"      ]. After nine years of follow-up, 100 percent of patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &lt;200/mm3",
"      </span>",
"      and a viral load &gt;55,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      by RT-PCR had an AIDS-defining condition compared to 12.7 percent of patients with CD4 cell counts",
"      <span class=\"nowrap\">",
"       &gt;350/mm3",
"      </span>",
"      and a viral load &le;1500 by RT-PCR.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, a group of individuals with similar levels of viremia tend to lose CD4 cells at a faster rate than another group with lower levels of viremia. However, one study of more than 2700 antiretroviral-naive, chronically infected persons, demonstrated that presenting HIV RNA levels only minimally predicted the degree of CD4+ T-cell count decline for the individual patient [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/6\">",
"     6",
"    </a>",
"    ]. These data suggest that there are other unmeasured factors that contribute to CD4 T-cell loss. One potential variable is immune activation, which can be indirectly measured through flow cytometry (eg, CD38 and HLA-DR markers) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/7\">",
"     7",
"    </a>",
"    ]. Proposed mechanisms of immune activation-mediated CD4 cell destruction include programmed cell death, bystander cell killing, and accelerated cellular senescence.",
"   </p>",
"   <p>",
"    The risk of opportunistic infections increases as CD4 cell counts decline. Thresholds of various CD4 T-cell cut-offs are used to determine when prophylaxis for various opportunistic infections, such PCP, toxoplasmosis, MAC infection should be initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .) In the era of HAART, the three-year probability of developing AIDS has changed dramatically, even in high-risk groups [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/8\">",
"     8",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef62317 \" href=\"UTD.htm?30/38/31329\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CD4 counts versus CD4 percentages",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been debate about the relative merits of the CD4 count versus CD4 percent as a predictor of progression to an AIDS defining-complication [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. It appears that the CD4 count may be preferred with counts &lt;350",
"    <span class=\"nowrap\">",
"     cells/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/9\">",
"     9",
"    </a>",
"    ]. However, the CD4 T cell percentages may be a more accurate marker of disease progression in patients with CD4 cell counts &gt;350",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/13\">",
"     13",
"    </a>",
"    ]. In a study of 788 patients who took their first HAART regimen, subjects were stratified by their baseline absolute CD4 cell count and CD4 lymphocyte percentage as derived from the Centers for Disease Control and Prevention recommendations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/14\">",
"     14",
"    </a>",
"    ]. The median CD4 lymphocyte percentage of 17 percent was used to compare disease progression within the absolute CD4 lymphocyte count strata. The study was significant for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty-six patients had discordant CD4 cell counts and percentages.",
"     </li>",
"     <li>",
"      Among subjects with an absolute CD4 cell count &gt;350",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      those with a CD4 lymphocyte percentage &lt;17 percent had faster progression to an AIDS defining illness or death than did subjects with a CD4 cell percentage of &gt;17 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Since the number of patients with discordant results was small, a subsequent study was undertaken in a large cohort of 1891 patients, and demonstrated that the CD4 cell percentage at the initiation of ART predicted disease progression, independent of absolute CD4 cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/12\">",
"     12",
"    </a>",
"    ]. For example, their model predicted that for a person with an absolute CD4 count of 240",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and a CD4 cell percentage of 9, the hazard of an AIDS-defining event or death was 65 percent greater than that for a person with the same absolute CD4 cell count and a CD4 cell percentage of 24.",
"   </p>",
"   <p>",
"    The study involved mainly white men who acquired HIV infection through sex with men, and gives increasing support for the use of both markers to guide clinical-decision making. In a study of 60 HIV-seronegative patients with cirrhosis, the absolute CD4 cell count was found to be low in 65 percent, most of whom had a normal CD4 cell percentage [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/15\">",
"     15",
"    </a>",
"    ]. This study suggests that in HIV-infected patients with liver disease, the CD4 cell percentage may also be more informative than the CD4 cell count alone in assessing a patient's immune status [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RATE OF PROGRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average life expectancy for a HIV-infected patient in the absence of treatment is approximately ten years. In the San Francisco City Clinical Cohort of 341 men infected from 1977 to 1980, 11-year follow-up revealed that 54 percent progressed to AIDS and 19 percent remained asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/17\">",
"     17",
"    </a>",
"    ]. The percentage of patients developing AIDS (according to the 1987 definition) following seroconversion was zero at one year, 3 percent at three years, 12 percent at five years, 36 percent at eight years, 53 percent at ten years, and 68 percent at 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/18\">",
"     18",
"    </a>",
"    ]. Analysis of this same cohort showed that the mean survival time following a CD4 count of 200 was 38 to 40 months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/19\">",
"     19",
"    </a>",
"    ]. The most rapid progression from viral transmission to death from AIDS was 28 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple factors may influence the rate of progression of HIV infection as discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Demographic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have demonstrated that increasing age at the time of HIV infection is associated with more rapid progression to AIDS in the absence of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. In one series, for example, the median time from seroconversion to AIDS without therapy was 15 years for patients aged 16 to 24 years at seroconversion, compared to 6 years for those 35 years or older at seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of progression appear similar by sex, race, and risk category if adjusted for the quality of care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/21-23,25-30\">",
"     21-23,25-30",
"    </a>",
"    ]. Multiple studies have documented modest differences in viral load between men and women, but the average time from infection to AIDS or death does not differ. An observational cohort study of 759 women on ART suggested that those patients with a history of pregnancy had a lower risk of HIV disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Calendar year of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An analysis was performed of 22 cohorts of patients with HIV infection from Europe, Australia, and Canada to study temporal trends in CD4 cell counts and HIV RNA levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/32\">",
"     32",
"    </a>",
"    ]. The probability of progressing to a CD4 cell count of &lt;500",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    by 24 months after seroconversion increased from 0.66 in patients infected from 1999 to 2002 to 0.80 in those who were infected before 1991. Hypotheses to explain this include emerging changes in the phenotype of circulating virus, leading to increased pathogenicity (eg, varying subtype distribution or emergence of a CXCR4 phenotype). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'HIV subtype'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12\">",
"     'Coreceptor usage'",
"    </a>",
"    below.) However, others have suggested that HIV-1 may actually be evolving to a less virulent form in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Symptoms during primary HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic primary HIV infection tend to progress more rapidly than those with asymptomatic seroconversion (see above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Viral attenuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics of the virus itself may also influence the rate of progression. A cohort of patients from Australia (one blood donor and eight recipients), infected with an HIV-1 strain with a deletion in the region where new and the long terminal repeat overlap, have been followed for 14 to 18 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/34\">",
"     34",
"    </a>",
"    ]. This HIV strain appears to be attenuated since three of the recipients have an undetectable viral load and normal CD4 cell counts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Viral fitness and replication capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral fitness as measured by replication capacity (the ratio of replication of a mutated viral strain to a wild-type reference strain) may influence disease progression. As an example, in 191 patients recently infected with HIV, patients with a replication capacity below 43 percent had significantly higher CD4 cell counts; only 6 percent of the variance in replication capacity was explained by drug resistance mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 128 hemophiliacs with chronic HIV infection, the utility of measuring pol replication capacity for predicting immunologic decline and disease progression was assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/36\">",
"     36",
"    </a>",
"    ]. Pol replication capacity was correlated with baseline HIV RNA and CD4 cell counts and independently predicted CD4 cell decline and progression to AIDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HIV subtype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spread of HIV-1 has been facilitated by rapid genetic diversification as the virus has adapted to the human host. Evidence suggests that cross-species transmission of simian immunodeficiency virus (SIV) from chimpanzees to humans has occurred more than once, giving rise to three distinct groups of HIV-1 called M, N, and O, although only group M has spread globally [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some data suggest that the various subtypes (clades A to J) within group M may vary in immunogenicity, replication kinetics, patterns of transmission, and pathogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/38\">",
"     38",
"    </a>",
"    ]. A small, but growing body of evidence suggests that HIV-1 subtype D may be more virulent than other subtypes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study in 428 pregnant women in Tanzania found that patients with subtype D experienced more rapid disease progression and risk of death compared to patients with other HIV group M subtypes [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of 218 commercial sex workers in Kenya who were followed from the onset of HIV seroconversion for a median of 5.4 years, subtype D was associated with a greater than twofold increased risk of death compared to subtype A [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study of 350 HIV seroconverters in Uganda, the median time to AIDS was significantly shorter for persons with subtype D (6.5 years) than subtype A (8 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Coreceptor usage",
"    </span>",
"    &nbsp;&mdash;&nbsp;CCR5 and CXCR4 are the major chemokine coreceptors used by HIV to enter into human lymphocytes. Based on this coreceptor usage, HIV isolates are classified as CCR5-tropic (R5), CXCR4-tropic (X4), or dual tropic",
"    <span class=\"nowrap\">",
"     (R5/X4)",
"    </span>",
"    strains.",
"   </p>",
"   <p>",
"    CCR5-tropic viruses (R5) are generally non-syncytium (NSI) inducing isolates that predominate in primary infection. R5 viruses are usually associated with a less virulent phenotype; these strains replicate in monocytes and macrophages and are also sometimes referred to as \"M-tropic\" viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/42\">",
"     42",
"    </a>",
"    ]. R5 viruses can also infect CCR5-expressing dendritic cells, which are responsible for trafficking of HIV particles to lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CXCR4-tropic viruses (X4) generally are syncytium-inducing and often emerge later in infection. These viral strains frequently appear more virulent and are able to replicate more efficiently in T-lymphocytes (\"T-tropic\" viruses). The emergence of X4 virus has been associated with the development of an AIDS-defining illness or a CD4 cell count &lt;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    compared with those with R5 persistence and slowly progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies suggest that treatment-experienced patients with ongoing detectable viremia have a greater risk of having",
"    <span class=\"nowrap\">",
"     dual/mixed",
"    </span>",
"    X4 tropism despite treatment-mediated gains in CD4+ T cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/46-48\">",
"     46-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Viral phenotype'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The reason R5 viruses predominate early on is unclear since CCR5 is expressed on fewer T cells than is CXCR4. R5 viruses produce five to ten times more infectious virus per CCR5+ target cell than X4 variants [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/49\">",
"     49",
"    </a>",
"    ] and also appear to be more efficiently transmitted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/43\">",
"     43",
"    </a>",
"    ]. These advantages may contribute to the predominance of R5 in early infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pathogenicity of X4 viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenicity of X4 HIV strains may be due to the ability of these isolates to infect thymocytes, the precursors of mature CD4 T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/50\">",
"     50",
"    </a>",
"    ]. HIV progression and viral replication has also been linked to the density of coreceptors on the surface of potential cellular targets [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/51\">",
"     51",
"    </a>",
"    ]. Since X4 variants have greater cytopathicity, this phenotypic change is usually accompanied by declines in CD4 counts and clinical progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 402 treatment-naive patients, 76 of whom harbored X4- or",
"      <span class=\"nowrap\">",
"       D/M-tropic",
"      </span>",
"      virus, the times to viral suppression and CD4 cell increases were similar despite baseline differences in tropism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/55\">",
"       55",
"      </a>",
"      ]. However, a multivariate analysis demonstrated that clinical events were more common in patients with X4- or",
"      <span class=\"nowrap\">",
"       D/M-tropic",
"      </span>",
"      virus (RR 2.56, 95% CI 1.37-4.76).",
"     </li>",
"     <li>",
"      In a cohort of 126 children and adolescents with hemophilia, detection of CXCR4-using virus at baseline predicted a greater decline in CD4+ T cell counts over time and was associated with a 3.8-fold increased risk of progression to clinical AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Effect of CCR5 delta32 genetic background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different genetic backgrounds may explain why some patients have an altered natural history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    susceptibility to HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. CCR5 (delta) 32 is an allele that contains a 32-base pair deletion and codes for a nonfunctional co-receptor. The presence of the 32-base pair deletion influences susceptibility to infection and progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. CCR5 (delta) 32 homozygotes (people who inherited the allele from both parents) are highly resistant to HIV infection. CCR5 delta 32 heterozygotes (people who inherited the CCR5 delta 32 allele from one parent and a functional CCR5 allele from the other parent) are susceptible to HIV infection. However, in a large meta-analysis of 19 prospective cohort and case-control studies, CCR5-delta 32 heterozygosity was associated with a decreased risk for progression to AIDS and death and was associated with lower HIV RNA levels after seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The critical role of CCR5 was well illustrated in an HIV-infected patient with acute myeloid leukemia who received two stem cell transplants from an HLA-matched donor who was homozygous for the CCR5 delta32 mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/62\">",
"     62",
"    </a>",
"    ]. The second procedure led to complete remission of the patient's acute leukemia. In addition, 20 months after ART was discontinued, no active replicating HIV could be detected in the peripheral blood, bone marrow, or rectal mucosa, as assessed by RNA and proviral DNA assays. This case report highlights the important role of the CCR5 receptor in HIV infection and disease progression.",
"   </p>",
"   <p>",
"    The CCR5 delta 32 allele is common in whites, but is almost never seen in Asians or Africans. The high penetrance of this mutation in certain populations suggests that, at some time point, this allele conferred a survival advantage. Candidates for this selection pressure include Yersinia pestis (agent of plague) or variola virus (agent of smallpox) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Viral phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the course of HIV infection, syncytium-inducing (SI) viruses, strains that use the CXCR4 coreceptor, will develop in approximately one-half of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/64\">",
"     64",
"    </a>",
"    ]. The detection of SI HIV viral variants (also known as X4 variants, due to their usage of the CXCR4 coreceptor) is associated with more rapid disease progression than with nonsyncytium-inducing HIV strains. In a study of 225 HIV-infected MSM, 71 percent of those with SI variants progressed to AIDS over 30 months compared with only 16 percent of men without SI variants at baseline [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not well understood why SI variants emerge in some individuals and not in others. One cohort study of 207 HIV-infected patients with hemophilia found that subjects heterozygous or homozygous for stromal cell-derived factor-1 (SDF-1) were at increased risk for AIDS progression and death [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/66\">",
"     66",
"    </a>",
"    ]. They were also more likely to have X4 tropic viruses, suggesting that the observed adverse effect of this allele is linked to an increased risk of a more pathogenic viral phenotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Immune escape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loss of CD8 cell responses against specific HIV epitopes is associated with clinical progression. This concept was well illustrated in a case report of a long-term nonprogressor who developed symptomatic HIV disease with a decline in CD4 T-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/67\">",
"     67",
"    </a>",
"    ]. This change in clinical status was associated with acquisition of viral mutations conferring escape from previously documented CD8 T-cell responses against certain HIV epitopes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Toll-like receptor polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toll-like receptor genes encode a family of transmembrane proteins that are important for immune responses to pathogens. TLR activation leads to production of inflammatory cytokines, which can enhance viral replication. Common polymorphisms in TLR genes have been associated with an increased susceptibility to certain infectious diseases. In one study of 428 HIV-infected patients who were antiretroviral therapy-naive, those with a rapid progressor phenotype had two single-nucleotide polymorphisms (SNPs) in TLR9 that were in linkage disequilibrium [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/68\">",
"     68",
"    </a>",
"    ]. These data suggest that TLR polymorphisms may be associated with varying rates of HIV disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     APOBEC3B deletions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The human APOBEC3 family of cytidine deaminases provides intrinsic immunity to retroviral infection. A naturally occurring deletion removes the entire APOBEC3B gene. One study suggested that the homozygous deletion was significantly associated with unfavorable outcomes for HIV acquisition, progression to AIDS, and viral set point, although the frequency of these deletions was very low in the five cohorts that were examined [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/69\">",
"     69",
"    </a>",
"    ]. Future studies will need to evaluate the impact of this deletion in other patient populations where the frequency of the APOBEC3 gene deletion is much more common, such as Eastern Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dual HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with more than one HIV strain may lead to more rapid disease progression. The dual infection could occur at the time of the primary infection, or it could represent superinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link&amp;anchor=H30#H30\">",
"     \"Immunology of HIV-1 infection\", section on 'HIV superinfection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Genetic background",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rates of disease progression in untreated patients can vary markedly, which may be related to genetic background [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/52\">",
"     52",
"    </a>",
"    ]. Numerous reports have identified a role for HLA genotype in AIDS outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/71\">",
"     71",
"    </a>",
"    ]. Rapid progression to AIDS has been associated with HLA alleles A24, B35, B37, B56, B58S and A1-B8-DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/72\">",
"     72",
"    </a>",
"    ]. In contrast, alleles B57, B27, B14 and C8 have been associated with long-term nonprogression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genomewide association studies have offered new insights into genetic risk factors associated with varying rates of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. One genomewide association study of a nonprogressor cohort of 275 HIV-infected patients identified the presence of the single-nucleotide polymorphism (SNP), HCP5, as a genetic marker strongly associated with long-term non-progressor status, when compared to a control group of 1352 HIV-seronegative individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some have proposed that genetic markers can assist in predicting whether or not an individual will be a long-term nonprogressor [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/76\">",
"     76",
"    </a>",
"    ]. By a multivariate logistic regression model, patients heterozygous for",
"    <span class=\"nowrap\">",
"     CCR5-&Delta;32,",
"    </span>",
"    homozygous for SDF1, and positive for HLA-B27 without HLA-DR6 but with at least three other HLA alleles (-A3, -B14,-B17, or -DR7) were correctly classified as long-term nonprogressors (70 percent) or progressors (81 percent). In a whole-genome association study, polymorphisms were identified, including HLA-B5701, which explained nearly 15 percent of the variation in viral loads seen among individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/77\">",
"     77",
"    </a>",
"    ]. Another study demonstrated that among patients expressing B57 alleles, a non-progressive clinical course was associated with preserved CD8 T-cell responses to nef antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Coreceptor usage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A subsequent meta-analysis of patients of European or African descent found that patients with the",
"    <span class=\"nowrap\">",
"     CCR5-&Delta;32",
"    </span>",
"    and CCR2-64I alleles had a reduced risk for progression to AIDS or death and had lower viral load following seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/79\">",
"     79",
"    </a>",
"    ]. Neither of these alleles appeared protective once progression to AIDS had occurred. In this analysis, homozygosity for SDF1 did not have an effect upon any of the parameters studied.",
"   </p>",
"   <p>",
"    Research into other possible genetic markers of susceptibility to progression include: RANTES and MIP-1a for chemokine and cytokine susceptibility and class I HLA alleles B5701, B35, and Cw04 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/80\">",
"     80",
"    </a>",
"    ]. RANTES is the main natural ligand that binds to CCR5. Polymorphisms of the RANTES chemokine gene promoter were not associated with long-term nonprogressor (LTNP) status in 167 HIV-infected injection drug users, 58 of whom were LTNPs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/81\">",
"     81",
"    </a>",
"    ]. Another study that examined the role of RANTES in protection against HIV infection found that no particular RANTES genotype or haplotype was more common in repeatedly exposed but uninfected subjects compared to HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although an IL28B haplotype strongly affects the immune response in hepatitis C virus-infected patients, there is no evidence that it influences disease progression in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Coinfection with other pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with other pathogens may influence the rate of progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/84-87\">",
"     84-87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are conflicting results as to whether CMV infection is associated with HIV disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/79,88-90\">",
"       79,88-90",
"      </a>",
"      ]. One study of patients taking HAART found that CMV viremia was associated with disease progression after controlling for CD4 count and viral load [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/91\">",
"       91",
"      </a>",
"      ]. It is unclear, however, whether CMV viremia is acting as a cofactor promoting progression or is simply a marker of worse immune status.",
"     </li>",
"     <li>",
"      Coinfection with GB virus (GBV-C), a relative of hepatitis C virus, may slow the progression of HIV, although data are conflicting [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/84,92,93\">",
"       84,92,93",
"      </a>",
"      ]. The favorable effect of GBV-C virus infection on patients with HIV may be mediated through lower T cell activation, which has been recognized as an important factor in disease progression [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/94\">",
"       94",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=see_link&amp;anchor=H4#H4\">",
"       \"GB virus C (hepatitis G) infection\", section on 'HIV infection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Studies of HIV infection and coinfection with either human T-lymphotropic virus type-I (HTLV-I) or human T-lymphotropic virus type-II (HTLV-II) have raised the possibility that patients with coinfection may experience slower progression of their HIV [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. One study followed 96",
"      <span class=\"nowrap\">",
"       HIV/HTLV-II",
"      </span>",
"      coinfected IDUs and 437 HIV monoinfected IDUs. On entry, participants were matched for baseline CD4 cell counts and followed every six months for an average of 13 years [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/97\">",
"       97",
"      </a>",
"      ].",
"      <span class=\"nowrap\">",
"       HIV/HTLV",
"      </span>",
"      coinfection was associated with older age and higher CD4 and CD8 cell counts compared with patients with HIV alone; no difference was seen in HIV viral RNA levels.",
"     </li>",
"     <li>",
"      Herpes simplex virus (HSV) coinfection may increase HIV viral load based on the observation that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"       acyclovir",
"      </a>",
"      , a drug with no intrinsic activity versus HIV, has been associated with a modest but significant reduction in HIV viral load when given to HSV co-infected patients [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coinfection with tuberculosis accelerates HIV-associated immunodeficiency and increases levels of viremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are conflicting data as to whether HCV coinfection may influence the rate of HIV progression. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infection with syphilis can also have a significant impact on HIV disease status. In a retrospective study of 52 HIV-infected men with primary or secondary syphilis, HIV RNA levels increased and CD4 counts declined with the acquisition of syphilis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/86\">",
"       86",
"      </a>",
"      ]. These trends reversed with effective treponemal therapy. The effect of syphilis infection on viremia and immunologic status was most marked in those HIV-infected patients who were not on highly active antiretroviral therapy.",
"     </li>",
"     <li>",
"      Fungal infection (eg, oropharyngeal candidiasis, cryptococcosis, histoplasmosis) was found to be a risk factor for HIV disease progression in the EuroSIDA cohort in the era of combination ART [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Three randomized controlled trials in Africa have demonstrated that deworming HIV-infected patients with helminthic infections is associated with declines in HIV viremia and improvements in CD4 cell counts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/98-101\">",
"       98-101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HIV-associated complications &mdash; Nearly all HIV-associated complications can be successfully managed with treatment directed at both HIV and the complication, but there are some exceptions. Complications that are often fatal despite HAART include CNS lymphoma (EBV), PML, Castleman&rsquo;s Syndrome (HHV-8) and Kaposi sarcoma (HHV-8) with lung involvement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is associated with progression of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/102\">",
"     102",
"    </a>",
"    ], however it is unclear whether weight loss is a cause of progression or a marker for disease severity.",
"   </p>",
"   <p>",
"    Micronutrient supplements may be of benefit in some patients with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of vitamin supplements in 1078 pregnant women in Tanzania found that women who received a multivitamin supplement (vitamins B, C, and E dosed at the recommended dietary allowance [RDA] level) had delayed progression of HIV disease compared with women receiving placebo; vitamin A supplementation was not beneficial [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Forty HIV-infected patients taking ART were randomly assigned to receive a micronutrient supplement (with 33 ingredients) or placebo twice daily for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/105\">",
"       105",
"      </a>",
"      ]. The absolute CD4 count increased by an average of 24 percent in the micronutrient group versus no change in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, despite the observation that vitamin deficiencies persist in HIV-infected patients consuming micronutrients at the RDA level [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/106\">",
"     106",
"    </a>",
"    ], administration of vitamins beyond standard dosing does not appear to offer incremental benefit in the setting of ART and may have greater adverse effects. In a trial of 3418 HIV-infected patients initiating ART in Tanzania, there was no difference in HIV disease progression or death from any cause between those randomly assigned to standard (at the RDA) versus high (2 to 21 times the RDA) dose vitamin B complex, E, and C supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/107\">",
"     107",
"    </a>",
"    ]. The study was halted prematurely due to a higher rate of abnormally elevated ALT levels among those taking high-dose vitamins.",
"   </p>",
"   <p>",
"    Further trials are needed to confirm these effects of standard-dose vitamin administration and to extend them to other populations before multivitamin supplementation can be recommended as routine therapy for the purpose of delaying HIV progression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are theoretical concerns that injection drug use could affect HIV disease progression. Drugs, such as opioids, may increase HIV replication in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. Furthermore, drug use may negatively impact on medication adherence and access to care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are conflicting clinical data as to whether injection drug use affects the progression of HIV disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective observational cohort of 3116 treatment-naive patients in Canada who were followed for a median duration of 5.3 years, all-cause mortality rates were similar between injection drug users (IDUs) and non-IDUs [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Life expectancy in IDUs was lower than in other risk groups in a multinational collaboration of HIV cohort studies in Europe and North America [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In an observational cohort of 1851 participants who were followed longitudinally from 1998 to 2003, subjects were categorized as non-users of illicit drugs (56 percent), intermittent users (32 percent) and persistent users (13 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/113\">",
"       113",
"      </a>",
"      ]. Persistent drug use, compared with nonuse, was associated with a two-fold risk of developing new opportunistic infections. Intermittent drug users had a risk of HIV disease progression similar to nonusers during periods of abstinence, but similar to persistent users during periods of relapse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Alcohol use",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol has been demonstrated to depress levels of CD4 counts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. One prospective study evaluated the effect of alcohol use on CD4 T-cell counts in 595 HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/114\">",
"     114",
"    </a>",
"    ]. In patients not on ART, heavy alcohol consumption was associated with a lower CD4 cell count compared to patients who had a history of abstinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     IMPACT OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The data summarized above are based upon studies of patients who received no antiretroviral therapy or nucleoside analogues only. There are now four treatment strategies that are known to prolong survival:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antiretroviral therapy (see below)",
"     </li>",
"     <li>",
"      P. carinii prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/116\">",
"       116",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      M. avium prophylaxis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/117\">",
"       117",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Care by a physician with HIV-care experience [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/118-121\">",
"       118-121",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=see_link\">",
"     \"Primary prevention of opportunistic infections in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protease inhibitors were introduced in late 1995 and early 1996, and ART became a widely embraced therapeutic concept in late 1996. The benefits of combination ART became apparent almost immediately and have become more profound over time [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/122-128\">",
"     122-128",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of AIDS deaths fell by 12 percent in the United States in 1996 and by 47 percent in 1997.",
"     </li>",
"     <li>",
"      During the period 1996 to 2000, multiples studies showed a 60 to 80 percent decrease in AIDS-related deaths, opportunistic infections (OI), and hospitalizations. These results were achieved in all countries with access to antiretroviral agents [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/129,130\">",
"       129,130",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Continued improvement in survival was demonstrated in one study of 2238 patients in Vancouver who were ART-naive; life expectancy steadily increased in four different time periods spanning 1993 to 2004 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/131\">",
"       131",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study based in Denmark found that mortality rates continue to decline from 38 per 1000 person-years in the early HAART period (1997 to 1999) to 25 per 1000 person-years in the more recent HAART period (2000 to 2005) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/132\">",
"       132",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When examining the risk of death in HIV seroconverters, excess mortality compared to the general population has continued to narrow in every calendar year from 1981 to 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is speculated that further progress in therapeutics with new drugs may add substantially to this impressive record. However, as these dramatic improvements are observed, the importance of non-HIV-related causes of death (such as cardiovascular disease), non-AIDS-defining cancer, premature aging, and substance abuse, is rising as patients with HIV live longer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Antibiotic prophylaxis and ART",
"    </span>",
"    &nbsp;&mdash;&nbsp;The profound effect of antibiotic prophylaxis and HAART on survival was illustrated in a collaborative study of HIV treatment from 1989 to 2003. Seven life-prolonging inventions were assessed by year of introduction including PCP prophylaxis (1989), MAC prophylaxis (1993) and four sequential HAART regimens (1996 to 2003). The study demonstrated that the average gain in survival expectation was an additional 15 years when initial treatment was started at a CD4 count of 87",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/135\">",
"     135",
"    </a>",
"    ] and longevity was estimated at 24 years when treatment was started at a CD4 count of 310",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/136\">",
"     136",
"    </a>",
"    ]. These estimates were based on data for treatments available through 2003.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Risk group and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies have demonstrated that persons who acquired their HIV infection through injection drug use have higher rates of death compared to those who acquired their infection through sex [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/133,137\">",
"     133,137",
"    </a>",
"    ]. One study examined whether the incidence of AIDS events in treatment-naive individuals initiating HAART varied among patient subgroups according to specific demographic and clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/137\">",
"     137",
"    </a>",
"    ]. From a database of more than 22,000 patients from Europe and North America, it was demonstrated that AIDS event rates declined more precipitously in MSM than in injection drug users (77 versus 56 percent) and in those with CD4 counts less than 350 cells compared to more than 350 cells. The most common AIDS events were tuberculosis, Kaposi's sarcoma, mycobacterium avium complex, cytomegalovirus, esophageal candidiasis, and Pneumocystis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Resource-poor settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality rates of HIV-infected patients from resource-poor settings in Africa, South America, and Asia have fallen substantially as well. However, in a systematic comparison of HAART outcomes between low-income and high-income countries in treatment naive patients, all cause mortality was higher in resource poor settings than in industrialized nations [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/138\">",
"     138",
"    </a>",
"    ]. Compared with high-income countries, patients starting HAART in low-income settings had lower CD4 cell counts (median 108",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    versus 232",
"    <span class=\"nowrap\">",
"     cells/microL);",
"    </span>",
"    however, this factor only partly explained these results. Concomitant tuberculosis and invasive bacterial and fungal infections may contribute to these results, due to limited access to prophylaxis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Immunologic recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation of ART is associated with improvements in CD4 cell counts and function. The initial rise in T-cells in response to treatment is related to an increase in memory CD4+ cells, caused by redistribution from lymphoid tissues, rather than by new T-cell production [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/139\">",
"     139",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study evaluated CD4 cell count increases in 1835 treatment-naive patients who attained viral suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/140\">",
"     140",
"    </a>",
"    ]. The greatest increase in CD4 count (100",
"    <span class=\"nowrap\">",
"     cells/microL)",
"    </span>",
"    was seen in the first year after starting ART, but substantial annual increases were still observed five years into therapy. All patients starting ART with more than 350 CD4+ T",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    at baseline achieved normalization of their CD4 counts over the period of observation.",
"   </p>",
"   <p>",
"    The extent of the immunologic recovery may be affected by several factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline characteristics that may contribute to immunologic recovery were assessed in the ACTG 384 treatment trial, which randomly assigned 980 patients to either",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"        stavudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"        didanosine",
"       </a>",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"        zidovudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"        lamivudine",
"       </a>",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"       nelfinavir",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"       efavirenz",
"      </a>",
"      , or both [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/141\">",
"       141",
"      </a>",
"      ]. Greater CD4+ T-cell recovery was associated with age of 40 years or younger, female sex, higher baseline",
"      <span class=\"nowrap\">",
"       naive/memory",
"      </span>",
"      CD4 cell ratio, higher baseline virus load and viral suppression. Persistent T-cell activation was associated with lower CD4 cell recovery, even in subjects who achieved viral suppression.",
"     </li>",
"     <li>",
"      In a longitudinal study of 655 patients who were observed on ART, only patients with baseline CD4 cell counts &gt;350",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      returned to nearly normal levels after six years of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/142\">",
"       142",
"      </a>",
"      ]. There was no difference in CD4 cell gain in terms of HCV serostatus or specific ART regimen employed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Provider expertise",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAART brought new complexities to HIV care that have led to the emergence of provider expertise as another important variable in HIV outcome. Several reports have documented a correlation between HIV patient panel size and patient survival and optimal use of antiretroviral medications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/118-121\">",
"     118-121",
"    </a>",
"    ]. This is one of the few diseases in medicine where physician expertise has a documented impact on outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Persisting viral reservoirs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who respond to aggressive antiretroviral therapy may have prolonged suppression of plasma viremia as indicated by failure to detect plasma HIV RNA. However, the designation of \"no detectable virus\" depends upon the assay used, which usually has a threshold of detection of 50",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p>",
"    In",
"    most patients with \"no detectable virus\", there is viral persistence and there may be ongoing viral replication at lower levels in persistent viral reservoirs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/143\">",
"     143",
"    </a>",
"    ]. The main reservoir is the latently infected CD4 cell. In one study of patients with undetectable viremia for up to seven years, the decay of resting memory CD4 cells was found to be so slow that eradication would take an average of 73 years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/144\">",
"     144",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other HIV reservoirs include lymph tissue, genital tract, and central nervous system, all representing sequestered havens of replication competent HIV. Due to the different compartments with the potential for variations in drug exposure, HIV strains can evolve independently in the face of antiretroviral therapy.",
"   </p>",
"   <p>",
"    There appears to be little or no evolution of resistance mutations when the plasma viral load is &lt;50",
"    <span class=\"nowrap\">",
"     c/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/145\">",
"     145",
"    </a>",
"    ]. However, latently infected CD4 cells may harbor archived strains with previously established resistance mutations that are replication competent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/146-148\">",
"     146-148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This reservoir of nonevolving latent virus should be considered when decisions are made about possible termination of antiretroviral therapy. Prior experience shows that viral rebound with high viral loads is noted in patients at two to four weeks, even among those with sustained viral suppression to &lt;5",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    for prolonged periods prior to treatment interruption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. In the absence of therapy there may be reversion to wild-type virus, but resistant strains persist in the latent reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/151\">",
"     151",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Researchers are actively investigating ways in which to purge virus from this latent reservoir, although no effective therapy exists at present [",
"    <a class=\"abstract\" href=\"UTD.htm?23/39/24186/abstract/152,153\">",
"     152,153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of progression of HIV infections shows enormous individual patient variation in the absence of antiretroviral therapy. Some patients progress to late-stage AIDS within two years of infection. Others maintain low viral loads and normal CD4 counts for &gt;10 years without treatment (ie, \"long-term nonprogressors\") and others have no detectable viremia without any treatment (ie, \"elite suppressors\"). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Rate of progression'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two most important factors in the rate of disease progression appear to be the genetic regulation of immunologic control of HIV and medication adherence. Other factors that negatively impact the rate of progression are older age, viral variants, substance abuse, nutritional status of the host, active tuberculosis, and possibly other forms of chronic immune activation.",
"     </li>",
"     <li>",
"      The impact of HAART has dramatically altered the natural history of disease; however, viral reservoirs persist despite availability of potent medications so the need for treatment may be life-long once initiated. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Persisting viral reservoirs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.unaids.org/en/aboutunaids/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/2\">",
"      Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/3\">",
"      Mellors JW, Mu&ntilde;oz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/4\">",
"      Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998; 279:35.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. www.aidsinfo.nih.gov/guidelines/adult/AA_040705.pdf (Accessed on April 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/6\">",
"      Rodr&iacute;guez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/7\">",
"      Giorgi JV, Liu Z, Hultin LE, et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993; 6:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/8\">",
"      Egger M, May M, Ch&ecirc;ne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/9\">",
"      Gebo KA, Gallant JE, Keruly JC, Moore RD. Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic illness in HIV infection. J Acquir Immune Defic Syndr 2004; 36:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/10\">",
"      Goicoechea M, Haubrich R. CD4 lymphocyte percentage versus absolute CD4 lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect Dis 2005; 192:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/11\">",
"      Moore DM, Hogg RS, Yip B, et al. CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL. HIV Med 2006; 7:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/12\">",
"      Hulgan T, Shepherd BE, Raffanti SP, et al. Absolute count and percentage of CD4+ lymphocytes are independent predictors of disease progression in HIV-infected persons initiating highly active antiretroviral therapy. J Infect Dis 2007; 195:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/13\">",
"      Hulgan T, Raffanti S, Kheshti A, et al. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts &gt;350 lymphocytes/mm3. J Infect Dis 2005; 192:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/14\">",
"      1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/15\">",
"      McGovern BH, Golan Y, Lopez M, et al. The impact of cirrhosis on CD4+ T cell counts in HIV-seronegative patients. Clin Infect Dis 2007; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/16\">",
"      Gandhi RT. Cirrhosis is associated with low CD4+ T cell counts: implications for HIV-infected patients with liver disease. Clin Infect Dis 2007; 44:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/17\">",
"      Rutherford GW, Lifson AR, Hessol NA, et al. Course of HIV-I infection in a cohort of homosexual and bisexual men: an 11 year follow up study. BMJ 1990; 301:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/18\">",
"      Centers for Disease Control (CDC). Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36 Suppl 1:1S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/19\">",
"      Osmond D, Charlebois E, Lang W, et al. Changes in AIDS survival time in two San Francisco cohorts of homosexual men, 1983 to 1993. JAMA 1994; 271:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/20\">",
"      Walsh MB, Calabrese LH. Rapid progression of HIV-1 infection to AIDS. Cleve Clin J Med 1992; 59:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/21\">",
"      Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe. Lancet 2000; 355:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/22\">",
"      Altisent C, Montoro JB, Ruiz I, Lorenzo JI. Long-term survivors and progression of human immunodeficiency virus infection. N Engl J Med 1996; 334:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/23\">",
"      Darby SC, Ewart DW, Giangrande PL, et al. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation. Lancet 1996; 347:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/24\">",
"      Mariotto AB, Mariotti S, Pezzotti P, et al. Estimation of the acquired immunodeficiency syndrome incubation period in intravenous drug users: a comparison with male homosexuals. Am J Epidemiol 1992; 135:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/25\">",
"      Galai N, Vlahov D, Margolick JB, et al. Changes in markers of disease progression in HIV-1 seroconverters: a comparison between cohorts of injecting drug users and homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/26\">",
"      Margolick JB, Mu&ntilde;oz A, Vlahov D, et al. Direct comparison of the relationship between clinical outcome and change in CD4+ lymphocytes in human immunodeficiency virus-positive homosexual men and injecting drug users. Arch Intern Med 1994; 154:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/27\">",
"      Melnick SL, Sherer R, Louis TA, et al. Survival and disease progression according to gender of patients with HIV infection. The Terry Beirn Community Programs for Clinical Research on AIDS. JAMA 1994; 272:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/28\">",
"      Vella S, Giuliano M, Floridia M, et al. Effect of sex, age and transmission category on the progression to AIDS and survival of zidovudine-treated symptomatic patients. AIDS 1995; 9:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/29\">",
"      Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995; 333:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/30\">",
"      Alcabes P, Mu&ntilde;oz A, Vlahov D, Friedland GH. Incubation period of human immunodeficiency virus. Epidemiol Rev 1993; 15:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/31\">",
"      Tai JH, Udoji MA, Barkanic G, et al. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. J Infect Dis 2007; 196:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/32\">",
"      Dorrucci M, Rezza G, Porter K, et al. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. J Infect Dis 2007; 195:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/33\">",
"      Ari&euml;n KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nat Rev Microbiol 2007; 5:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/34\">",
"      Learmont JC, Geczy AF, Mills J, et al. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 1999; 340:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/35\">",
"      Barbour JD, Hecht FM, Wrin T, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis 2004; 190:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/36\">",
"      Daar ES, Kesler KL, Wrin T, et al. HIV-1 pol replication capacity predicts disease progression. AIDS 2005; 19:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/37\">",
"      Simon F, Maucl&egrave;re P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/38\">",
"      Kanki PJ, Hamel DJ, Sankal&eacute; JL, et al. Human immunodeficiency virus type 1 subtypes differ in disease progression. J Infect Dis 1999; 179:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/39\">",
"      Vasan A, Renjifo B, Hertzmark E, et al. Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype. Clin Infect Dis 2006; 42:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/40\">",
"      Baeten JM, Chohan B, Lavreys L, et al. HIV-1 subtype D infection is associated with faster disease progression than subtype A in spite of similar plasma HIV-1 loads. J Infect Dis 2007; 195:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/41\">",
"      Kiwanuka N, Laeyendecker O, Robb M, et al. Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J Infect Dis 2008; 197:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/42\">",
"      Poveda E, Briz V, Qui&ntilde;ones-Mateu M, Soriano V. HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. AIDS 2006; 20:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/43\">",
"      Pope M, Haase AT. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 2003; 9:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/44\">",
"      Shepherd JC, Jacobson LP, Qiao W, et al. Emergence and persistence of CXCR4-tropic HIV-1 in a population of men from the multicenter AIDS cohort study. J Infect Dis 2008; 198:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/45\">",
"      Goetz MB, Leduc R, Kostman JR, et al. Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection. J Acquir Immune Defic Syndr 2009; 50:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/46\">",
"      Hunt PW, Harrigan PR, Huang W, et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194:926.",
"     </a>",
"    </li>",
"    <li>",
"     Wilkin T, Su Z, Kuritzkes D, et al. Presented at the 13th annual Conference on Retroviruses and Opportunistic Infections, Denver, CO, February 5-8th, 2006; abstract #283.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/48\">",
"      Wilkin TJ, Su Z, Kuritzkes DR, et al. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis 2007; 44:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/49\">",
"      Roy AM, Schweighardt B, Eckstein LA, et al. Enhanced replication of R5 HIV-1 over X4 HIV-1 in CD4(+)CCR5(+)CXCR4(+) T cells. J Acquir Immune Defic Syndr 2005; 40:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/50\">",
"      Zaitseva MB, Lee S, Rabin RL, et al. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol 1998; 161:3103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/51\">",
"      Lin YL, Mettling C, Portal&egrave;s P, et al. The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling. AIDS 2006; 20:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/52\">",
"      Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005; 365:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/53\">",
"      Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis 1994; 169:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/54\">",
"      Weiser B, Philpott S, Klimkait T, et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/55\">",
"      Waters L, Mandalia S, Randell P, et al. The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen. Clin Infect Dis 2008; 46:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/56\">",
"      Daar ES, Kesler KL, Petropoulos CJ, et al. Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 2007; 45:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/57\">",
"      Vasilescu A, Terashima Y, Enomoto M, et al. A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients. Proc Natl Acad Sci U S A 2007; 104:3354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/58\">",
"      Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/59\">",
"      Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/60\">",
"      McDermott DH, Zimmerman PA, Guignard F, et al. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). Lancet 1998; 352:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/61\">",
"      Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/62\">",
"      H&uuml;tter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009; 360:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/63\">",
"      Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 2006; 296:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/64\">",
"      Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992; 66:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/65\">",
"      Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med 1993; 118:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/66\">",
"      Daar ES, Lynn HS, Donfield SM, et al. Stromal cell-derived factor-1 genotype, coreceptor tropism, and HIV type 1 disease progression. J Infect Dis 2005; 192:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/67\">",
"      Kemal KS, Beattie T, Dong T, et al. Transition from long-term nonprogression to HIV-1 disease associated with escape from cellular immune control. J Acquir Immune Defic Syndr 2008; 48:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/68\">",
"      Bochud PY, Hersberger M, Taff&eacute; P, et al. Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/69\">",
"      An P, Johnson R, Phair J, et al. APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis 2009; 200:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/70\">",
"      Kidd JM, Newman TL, Tuzun E, et al. Population stratification of a common APOBEC gene deletion polymorphism. PLoS Genet 2007; 3:e63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/71\">",
"      Brumme ZL, Brumme CJ, Chui C, et al. Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy. J Infect Dis 2007; 195:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/72\">",
"      Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/73\">",
"      Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/74\">",
"      Limou S, Le Clerc S, Coulonges C, et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J Infect Dis 2009; 199:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/75\">",
"      Le Clerc S, Limou S, Coulonges C, et al. Genomewide association study of a rapid progression cohort identifies new susceptibility alleles for AIDS (ANRS Genomewide Association Study 03). J Infect Dis 2009; 200:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/76\">",
"      Magierowska M, Theodorou I, Debr&eacute; P, et al. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 1999; 93:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/77\">",
"      Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/78\">",
"      Navis M, Schellens IM, van Swieten P, et al. A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef. J Infect Dis 2008; 197:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/79\">",
"      Jackson JB, Erice A, Englund JA, et al. Prevalence of cytomegalovirus antibody in hemophiliacs and homosexuals infected with human immunodeficiency virus type 1. Transfusion 1988; 28:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/80\">",
"      Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/81\">",
"      Vidal F, Peraire J, Domingo P, et al. Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years. J Acquir Immune Defic Syndr 2006; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/82\">",
"      Liu H, Hwangbo Y, Holte S, et al. Analysis of genetic polymorphisms in CCR5, CCR2, stromal cell-derived factor-1, RANTES, and dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin in seronegative individuals repeatedly exposed to HIV-1. J Infect Dis 2004; 190:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/83\">",
"      Martin MP, Qi Y, Goedert JJ, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010; 202:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/84\">",
"      Schwarze-Zander C, Blackard JT, Zheng H, et al. GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis 2006; 194:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/85\">",
"      Schacker T, Zeh J, Hu H, et al. Changes in plasma human immunodeficiency virus type 1 RNA associated with herpes simplex virus reactivation and suppression. J Infect Dis 2002; 186:1718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/86\">",
"      Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004; 18:2075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/87\">",
"      Podlekareva D, Mocroft A, Kirk O, et al. Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. Scand J Infect Dis 2008; 40:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/88\">",
"      Webster A, Lee CA, Cook DG, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet 1989; 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/89\">",
"      Rugman FP, Mannion PT, Hay CR, et al. Cytomegalovirus, serum beta 2 microglobulin, and progression to AIDS in HIV-seropositive haemophiliacs. Lancet 1989; 2:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/90\">",
"      Becherer PR, Smiley ML, Matthews TJ, et al. Human immunodeficiency virus-1 disease progression in hemophiliacs. Am J Hematol 1990; 34:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/91\">",
"      Deayton JR, Prof Sabin CA, Johnson MA, et al. Importance of cytomegalovirus viraemia in risk of disease progression and death in HIV-infected patients receiving highly active antiretroviral therapy. Lancet 2004; 363:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/92\">",
"      Sheng WH, Hung CC, Wu RJ, et al. Clinical impact of GB virus C viremia on patients with HIV type 1 infection in the era of highly active antiretroviral therapy. Clin Infect Dis 2007; 44:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/93\">",
"      Vahidnia F, Petersen M, Stapleton JT, et al. Acquisition of GB virus type C and lower mortality in patients with advanced HIV disease. Clin Infect Dis 2012; 55:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/94\">",
"      Maidana-Giret MT, Silva TM, Sauer MM, et al. GB virus type C infection modulates T-cell activation independently of HIV-1 viral load. AIDS 2009; 23:2277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/95\">",
"      Beilke MA, Theall KP, O'Brien M, et al. Clinical outcomes and disease progression among patients coinfected with HIV and human T lymphotropic virus types 1 and 2. Clin Infect Dis 2004; 39:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/96\">",
"      Bassani S, L&oacute;pez M, Toro C, et al. Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. Clin Infect Dis 2007; 44:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/97\">",
"      Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr 2006; 41:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/98\">",
"      Walson JL, Herrin BR, John-Stewart G. Deworming helminth co-infected individuals for delaying HIV disease progression. Cochrane Database Syst Rev 2009; :CD006419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/99\">",
"      Kallestrup P, Zinyama R, Gomo E, et al. Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis 2005; 192:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/100\">",
"      Nielsen NO, Simonsen PE, Dalgaard P, et al. Effect of diethylcarbamazine on HIV load, CD4%, and CD4/CD8 ratio in HIV-infected adult Tanzanians with or without lymphatic filariasis: randomized double-blind and placebo-controlled cross-over trial. Am J Trop Med Hyg 2007; 77:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/101\">",
"      Walson JL, Otieno PA, Mbuchi M, et al. Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS 2008; 22:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/102\">",
"      Wheeler DA. Weight loss and disease progression in HIV infection. AIDS Read 1999; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/103\">",
"      Fawzi WW, Msamanga GI, Spiegelman D, et al. A randomized trial of multivitamin supplements and HIV disease progression and mortality. N Engl J Med 2004; 351:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/104\">",
"      Marston B, De Cock KM. Multivitamins, nutrition, and antiretroviral therapy for HIV disease in Africa. N Engl J Med 2004; 351:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/105\">",
"      Kaiser JD, Campa AM, Ondercin JP, et al. Micronutrient supplementation increases CD4 count in HIV-infected individuals on highly active antiretroviral therapy: a prospective, double-blinded, placebo-controlled trial. J Acquir Immune Defic Syndr 2006; 42:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/106\">",
"      Baum MK, Shor-Posner G, Bonvehi P, et al. Influence of HIV infection on vitamin status and requirements. Ann N Y Acad Sci 1992; 669:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/107\">",
"      Isanaka S, Mugusi F, Hawkins C, et al. Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial. JAMA 2012; 308:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/108\">",
"      Peterson PK, Sharp BM, Gekker G, et al. Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 1990; 4:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/109\">",
"      Mientjes GH, Miedema F, van Ameijden EJ, et al. Frequent injecting impairs lymphocyte reactivity in HIV-positive and HIV-negative drug users. AIDS 1991; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/110\">",
"      Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS 2001; 15:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/111\">",
"      Wood E, Hogg RS, Lima VD, et al. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA 2008; 300:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/112\">",
"      Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/113\">",
"      Lucas GM, Griswold M, Gebo KA, et al. Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol 2006; 163:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/114\">",
"      Samet JH, Cheng DM, Libman H, et al. Alcohol consumption and HIV disease progression. J Acquir Immune Defic Syndr 2007; 46:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/115\">",
"      Pol S, Artru P, Th&eacute;pot V, et al. Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients. AIDS 1996; 10:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/116\">",
"      Fischl MA, Dickinson GM, La Voie L. Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS. JAMA 1988; 259:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/117\">",
"      Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/118\">",
"      Kitahata MM, Koepsell TD, Deyo RA, et al. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996; 334:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/119\">",
"      Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 24:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/120\">",
"      Brosgart CL, Mitchell TF, Coleman RL, et al. Clinical experience and choice of drug therapy for human immunodeficiency virus disease. Clin Infect Dis 1999; 28:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/121\">",
"      Cunningham WE, Tisnado DM, Lui HH, et al. The effect of hospital experience on mortality among patients hospitalized with acquired immunodeficiency syndrome in California. Am J Med 1999; 107:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/122\">",
"      Detels R, Tarwater P, Phair JP, et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 2001; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/123\">",
"      Jaggy C, von Overbeck J, Ledergerber B, et al. Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population. Lancet 2003; 362:877.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV-AIDS Surveillance Report 1985-2002, United States. www.cdc.gov/hiv/dhap.htm (Accessed on March 09, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/125\">",
"      Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002; 324:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/126\">",
"      Tassie JM, Grabar S, Lancar R, et al. Time to AIDS from 1992 to 1999 in HIV-1-infected subjects with known date of infection. J Acquir Immune Defic Syndr 2002; 30:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/127\">",
"      Lee LM, Karon JM, Selik R, et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA 2001; 285:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/128\">",
"      Mocroft A, Katlama C, Johnson AM, et al. AIDS across Europe, 1994-98: the EuroSIDA study. Lancet 2000; 356:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/129\">",
"      Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 2005; 353:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/130\">",
"      Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 2006; 367:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/131\">",
"      Lima VD, Hogg RS, Harrigan PR, et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/132\">",
"      Lohse N, Hansen AB, Pedersen G, et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007; 146:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/133\">",
"      Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/134\">",
"      Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/135\">",
"      Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/136\">",
"      Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/137\">",
"      Sabine C, Antiretroviral Therapy (ART) Cohort Collaboration. AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others? AIDS 2005; 19:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/138\">",
"      Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/139\">",
"      Pakker NG, Notermans DW, de Boer RJ, et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998; 4:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/140\">",
"      Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/141\">",
"      Gandhi RT, Spritzler J, Chan E, et al. Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr 2006; 42:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/142\">",
"      Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/143\">",
"      Poles MA, Boscardin WJ, Elliott J, et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006; 43:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/144\">",
"      Siliciano JD, Kajdas J, Finzi D, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003; 9:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/145\">",
"      Kieffer TL, Finucane MM, Nettles RE, et al. Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis 2004; 189:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/146\">",
"      Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/147\">",
"      Wong JK, Hezareh M, G&uuml;nthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/148\">",
"      Persaud D, Pierson T, Ruff C, et al. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000; 105:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/149\">",
"      Garc&iacute;a F, Plana M, Vidal C, et al. Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy. AIDS 1999; 13:F79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/150\">",
"      Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/151\">",
"      Wirden M, Delaugerre C, Marcelin AG, et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/152\">",
"      Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005; 366:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/39/24186/abstract/153\">",
"      Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007; 195:833.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3715 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24186=[""].join("\n");
var outline_f23_39_24186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LABORATORY MARKERS OF PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CD4 counts and levels of HIV RNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CD4 counts versus CD4 percentages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RATE OF PROGRESSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Demographic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Calendar year of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Symptoms during primary HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Viral attenuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Viral fitness and replication capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HIV subtype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Coreceptor usage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pathogenicity of X4 viruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Effect of CCR5 delta32 genetic background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Viral phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Immune escape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Toll-like receptor polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      APOBEC3B deletions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dual HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Genetic background",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Coinfection with other pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Alcohol use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      IMPACT OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Antibiotic prophylaxis and ART",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Risk group and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Resource-poor settings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Immunologic recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Provider expertise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Persisting viral reservoirs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3715\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3715|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/38/31329\" title=\"figure 1\">",
"      Prognosis of HIV according to CD4 cell count and HIV viral load",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1194?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of tuberculosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/24/7557?source=related_link\">",
"      GB virus C (hepatitis G) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33450?source=related_link\">",
"      Primary prevention of opportunistic infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/52/21320?source=related_link\">",
"      Techniques and interpretation of measurement of the CD4 cell count in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_39_24187="Major gastroenteritis viruses";
var content_f23_39_24187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F80577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F80577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Medically important agents of viral gastroenteritis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Virus name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Viral family",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical virologic features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prominent epidemiologic features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rotavirus",
"       </td>",
"       <td>",
"        Reoviridae",
"       </td>",
"       <td>",
"        Group A strains cause most illness",
"       </td>",
"       <td>",
"        Most common severe childhood diarrhea, endemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norovirus",
"       </td>",
"       <td>",
"        Caliciviridae",
"       </td>",
"       <td>",
"        Also called Norwalk-like virus or calicivirus",
"       </td>",
"       <td>",
"        Causes most outbreaks of nonbacterial gastroenteritis, epidemic in all age groups",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric Adenovirus",
"       </td>",
"       <td>",
"        Adenoviridae",
"       </td>",
"       <td>",
"        Also called Adenovirus types 40 and 41 or fastidious adenovirus",
"       </td>",
"       <td>",
"        Rotavirus-like childhood diarrhea, endemic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Astrovirus",
"       </td>",
"       <td>",
"        Astroviridae",
"       </td>",
"       <td>",
"        Small virus, distinct morphology unlike norovirus",
"       </td>",
"       <td>",
"        Endemic diarrhea in young children, some outbreaks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24187=[""].join("\n");
var outline_f23_39_24187=null;
var title_f23_39_24188="Organic causes chronic abdominal pain";
var content_f23_39_24188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical clues for probable organic cause of chronic abdominal pain in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical clues",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Quadrant pain",
"       </td>",
"       <td>",
"        The further the pain from the umbilicus, the greater the likelihood of organic disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early morning pain, pain awakens at night",
"       </td>",
"       <td>",
"        Peptic origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Early satiety, nausea, sour breath, belching",
"       </td>",
"       <td>",
"        Peptic origin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crampy pain and/or bloating and/or intestinal gas related to meals, dairy products and foods containing dairy products",
"       </td>",
"       <td>",
"        Lactose intolerance, giardiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory symptoms, such a chronic cough, wheezing, laryngitis",
"       </td>",
"       <td>",
"        Gastroesophageal reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infrequent stooling, incomplete evacuation, encopresis, mass in the left lower abdominal quadrant and hard stool in rectal vault, diet low in fiber and high in starches, abdominal distension",
"       </td>",
"       <td>",
"        Constipation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood in stool",
"       </td>",
"       <td>",
"        Peptic origin or inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever, weight loss, no increase in height, joint complaints and rash",
"       </td>",
"       <td>",
"        Inflammation or an infectious disease process",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Self-induced purging behavior with or without weight loss",
"       </td>",
"       <td>",
"        Gastroesophageal reflux from an eating disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss, restrictive eating behavior, and fecal mass in left lower abdominal quadrant",
"       </td>",
"       <td>",
"        Constipation from an eating disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications such as antibiotics for acne",
"       </td>",
"       <td>",
"        Esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pain with specific physical activity and primarily muscle tenderness on examination",
"       </td>",
"       <td>",
"        Muscle strain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cervical motion tenderness, adnexal tenderness, or adnexal mass on pelvic examination",
"       </td>",
"       <td>",
"        Pelvic inflammatory disease, ovarian cyst, ectopic pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Episodic swelling of the throat or skin (extremities, face, or genitalia)",
"       </td>",
"       <td>",
"        Hereditary angioedema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Lake AM. AM Fam Physician 1999; 59:1823.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24188=[""].join("\n");
var outline_f23_39_24188=null;
var title_f23_39_24189="HBV immunoprophylaxis";
var content_f23_39_24189=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended schedule of hepatitis B immunoprophylaxis for term infants and infants with birth weight &gt;2000 gm",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Maternal HBsAg status",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Single-antigen vaccine",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Single antigen + combination vaccine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Positive",
"       </td>",
"       <td>",
"        1*",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"       <td>",
"        1*",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBIG",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"       <td>",
"        HBIG",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1-2 months",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months (Pediarix) or 12-15 months (Comvax)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Unknown",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1*",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"       <td>",
"        1*",
"       </td>",
"       <td>",
"        Birth (&le;12 hours)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1-2 months",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months (Pediarix) or 12-15 months (Comvax)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Negative",
"       </td>",
"       <td>",
"        1*",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Birth (before discharge)",
"       </td>",
"       <td>",
"        1*",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        Birth (before discharge)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        1-2 months",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6-18 months",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        4 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        4",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months (Pediarix) or 12-15 months (Comvax)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HBsAg: hepatitis B surface antigen; HBIG: hepatis B immune globulin; anti-HBs: antibody to HBsAg.",
"     <br/>",
"     * Rocombivax HB or Engerix-B should be used for the birth dose. Comvax and Pediarix cannot be administered at birth or before age six weeks.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Hepatitis B immune globulin (0.5mL) administered intramuscularly in a separate site from vaccine.",
"     <br/>",
"     &Delta; The final dose in the vaccine series should not be administered before age 24 weeks (164 days).",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     These infants should be tested for antibody to HBsAg (anti-HBs) and HBsAg at age 9 to 18 months - approximately three months after the last dose.",
"     <br/>",
"     &sect; Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery; if the mother is found to be HBsAf positive, the infant should receive HBIG as soon as possible but no later than age seven days.",
"     <br/>",
"     &yen; On a case-by-case basis and only in rare circumstances, the first dose may be delayed until after hospital discharge for an infant who weighs &ge;2000 g and whose mother is HBsAg negative, but only if a physician's order to withhold the birth dose and a copy of the mother's original HBsAg-negative laborator report are documented in the infant's medical record.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24189=[""].join("\n");
var outline_f23_39_24189=null;
var title_f23_39_24190="Pericardial effusion without tamponade subcostal view";
var content_f23_39_24190=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/51184/subpref1_conv.mp4?title=Pericardial+effusion+without+tamponade+subcostal+view\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pericardial effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 320px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAUADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5iooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoooxxmgAoo7Z7dfoKOMqMgFunvQAUUdyPQ4ooAKKKTuPegBaKt6fpt5qLulhbSXDoMsqDJA9av/APCK68AM6VdDd935etAGLRVzUdLvtNZRqFpLblvu+YMZqnQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFPgieeVIolLu5AVV6k+lABDFJNKkUSlpJDtVR3Ne4/D34QTz6DNN4lW5tZr+LdZQIoJJAO1mz2O5cda6n9nf4MrcRjxF4qiUhWVrGAOwdCOSz4x/s45PevozULG3BslktJJFtuY2U8JjGO/tQB8ky/DzRPC2kLL4sgGbiS6jF08jKImUgQ4AIBPJyCMcVlaJ4R8Irb6t9o1OyvN9lPPG6zOJIXCExgKMAlie/pXsnxcsLHxHcalp11ol/GzIotbqT5UjlOfnOG+5nBPB4HAr5h8Z+EtS8K3ccV60M0EgIS4hYmNh7EgHjPpQBgXSLHcyJHkorFVJ6kCoqOnHpxRQAUqkgjGDznaf4vakoycEdj1oA9d+Afia38JPrOrah9p+xQy25aK2jV3Ykv8vzEemOte93H7QXhSDRrfV207WvIuHkjRRbx7kKY3Z+fvkV8e6F4h1PQknTSrnyFnwJBsVt2M46g+prUk+IPiaSxSzfUgbdGZ1TyI+CevO3PagD0D9pDxTp/i4eHdS0mK5igkjkci4RVJ3BCOhNeK1s+IPE+r+IIbSLV7rz47RSsI8tU2A49AM9B1rGoAKKKKACiiigAooooAKKK+uPgn8IfA/ib4eafqetaL9pvpSd8n2mVc9OysBQB8j0V9H/ALS/w28KeDPD2n3HhvShZ3E0jKzefI+QNvZmPqa+b/qaAFooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKdFG8siRxqWdyFVR3J6CgBteqfCPwtbm5XVdYf7OVKtasxICH++3sOD3rjLLw/dW90DqNsUAj8wK5x1GR+ddzpHib+yNJSK1k2BX+dSASnr17en0oA+i/C2r6moe2ttW0w20KFmmhJZTkfKeV68cjpV59f1nTYzLNr1ldGZ9kcWwAJuPysSEzj1r5euvFl7B9ouILhg1yQVfy1wAM/407RfHmpJdx+ddRyyoj4G0DK/l1oA+lddkl1jSnbXrjSLuaAeZAkc0ikHqTwoyeBXmmtf2H4m0Sfw81mLu8jWaZWSRgsLAZPOQSQex9K88vvHOqzzeZHIEMXzIoUEjPrx7VzK+KNViv57r7V+8O+QbY14zyc8dKAMLxDoN9o15LHc28iQq2EcjgrnisccgkdAcV0mq6zqevQGK9nMqZ3oAihQfqBmsK8gMEiK0sUhKBsIT8v6UAQUY4z2oycZBBHejuSO9ABRRRQAUUUUAFFFFABRRRQAUUUUAIelfen7NRDfCTSuf4m/pXwWeQa+8f2Zhj4SaX/vP/SgDhv2zpFXQNCVlJ3SSnj/AIBXyQPu8cc9D6V9Uftqyn7J4aizwxnP/ouvlbOfyFAC0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU6NGkkVI1LOxAVQOSfSgBEVndUQFmY4AHc133gnwxMl2s97LHZXa7XgWfIGeoY4B9q0/APg97MrfanEPt7Ddb2TkhyOzHHrxjmvfPDNj4fuNEkn8T6c0k8KDhJGUoMH5eCOeMCgDzLWNHu9SeM6jZqZYYNyyqx2yYHDj27ivMtfjjiuZgIXjnXKuH43jsV5+tex+JfFR8ManHdRuJtKZiLK1jALQqOokJ56Fe56GvMtQ8W6Jq+uzz6pYOscsjMxVjwSeo5oA5G6vC0aBGLbAAEIAPFMW7hIQGEpcg79ynPPbOfStrXdM0+7cS6TdwzxD50hVjvTPIz/wDrrCWza3MvmGNGyMEEk5oAvpqJ8ogsqyv8sjHqwPbHbvVOcvCJJEk/1i+WdoyNvpzWppNtbWrtcagZz8mECKPmyOO9Mngkvt+xmhh3/JHIACfyoAwYfNXLxkbfukD096mtDbtOGvFkkiQsSEHP4Vca3uLMujhAjg9CfmxT9MtVaO5kkBVlUlX7DrxQBiXQTz5pIlKQsx2BuuOxNQgYUDIPuOla87Otu8dsRtkxv7gkdTnr3rNmh2KknmI5bgqDyuPWgCKiiigBCcfXtXSap4dj0zw1p2p3E8jTXwdkjjAKqFC53E8/xCucHPHJB4IHWvUJr7wtqHgrRbfWL/c1tHInkQHM8TYUA7TgEcdz2oA8vGDgAjmggg4II9M966NtA0+YTSWfiDSooBzGt1I6y47BgqkZ/GmWnhu2mZyfEehQ7VJ+eWT5/YfJ1oA5/GOpAPvVzSoba4u0ju3nWNiFBgUMcnp1xxWjDoNuZUX+3tHGWI3GR/8A4mtOx8OaZFdRyXfirSCqPuAhdyQQe+UFAGf4x8Pr4dvreFZzOk1tHcgkYZQ65UH3rn67b4q31he65Ytpd7DeQRafbwNLCSQXVMEcgc5riT75oAQ9u3PevvT9mvj4SaZgg4Z/6V8GA47fnX2/+znqSwfCjTFZlUl5Ov4UAeeftqPm68Lrnotwcf8AfuvmPHGa+kP2x5hPf+GHDBgUn5H/AGzr5vLZ4oAKKKKACiiigAooooAKKKKACiiigAooooAK7LwDpqsJdV89Y57ORJIg3Q7SSR9eBisHTNPVgs918sY+ZVb+IV1FkgNtceQRvkUAEf3SDkUAd+/jt57f7Rq6D7bBgwPgDzFXoABxxx+dU/FXxFm1KxQSAKjwBWAA4wOD9a4xJUFv5d/AZI4QwCg4x7/pWNrN7FMkZgiYIvypu6rigClq1+buYGGRmH+0BWXLnc27gdTViSdn6np7VXkG4Pt6kGgDorvwzrulmCR7VAfNihwkySFJJF3Rq4UkqWHIzjvVyQ/2RetZeI4IGkV23C3uUkZGBwynY2Ac9jWlq3iWfX/EtsbKAw6UJ7S5dEiVJJWiRVzIRyxHz7ecDdXZ6b8Px8RPGd1dQysbF5ZJpRLaJahFLlgD5ZO44J+Y80Aeew21tqUVy1lcpHGudsDf6zBzg/QfWiLRtVaxMsUDyWls2fNIG0fj+FeifEPwr4Z8GSW1raRxyPIPnHnORlcZzzxnPFc4nj42WkT6Pa20SWDjBRGLfqeaAOWmummaJJVSSUhk2gngcVXhntEuJEmDpGFwwHYitCw1y0huHM8T/wAW0r2z2PNNvpNMvFYwxEsw3EliDu/OgDBu3J3eWwNtuJX1qkEUyfNvWPPLKMkelbljp1zeJcrDAWVBwR0HWkudImtbQXMxUyfdCKfu/WgDCnVA4EYbaejMME1GetWSVRZRLCHZv4mJBX6YqJoJFgSbYfJclVb6dfyzQBHRQORkdOx9aOhweB60AFFFFABRRRQAUUUUAFfVvwb1G2j+HOmxPncpf9cV8pZwc4zXuvw71OeHwnbRIq9TjP4UAJ+09cRzSeGzGc7Y5v5JXheDhmHevUfjfcy3DaKZQMhJBx7hK8uA4+nFABRRRQAUUUUAFFFFABRRRQAUUUUAFWbOFJS/mDgKSM8D2plqitKvmfd9PWtQxr8658kFQeejelAF23uh/ZkVvKhEkZO1h93af/1VKLqOBAwbcADkCsuOSWJWAX95jG5eQVrW0/RJr2CWZCDlFIU8ZODQA97yzmgxuZC0fQ+uK565KxswjbcpzVnUQLSZobmPa6jAwelZjNk7s5UdvagAYfJn1qxpVhJf3S28TokjnALdKrnfIPlX5R0NbXh+4itH3TRrI3GBkigDrbXQfsMcIuCh2hQ7KxrWbxbcaBZ3dno/2mOK4iCSAxowY4IJycnnNY8XimxhkWLULEPE+MYcjH61ha/rtuLhhpTNFG5yVwG/nmgDL1XU2u7iRrrcGY5K+p9ao6fB9q1S2t4n2C4mSLcRnbuYDP6027unmcsW5bgkgU2yuJLK9t7uNcyQyLKNw+UlSCM+3FAHc6l4EXTvEOmabLqUkX9o3k9ihu7XyXV0YKr7dxzE7MAHz2bjiudm0qbTNNsry6bybi7nmjFsy/MqRkKzk/7+5QP9hqn1TWtQ8SxBryS1jlt7ia5inO4OgkbeYgefkDZZR1BY881F4t16/wDFWuvf36W/neWsRW1XbGAOpAPQsxZj6liaAF0vXm01Z4kfJdvQdKm1jVl1OCFIxhgfnPrmuclRo+CPl9T/AA062jZh+6LHn5Se9AGjd2yBYtqljjmqk9tt3EOoUhSR6CrIjlhZPtIHzD7w7VNKYY7Yhd5lbOcjgjtQBVuI7GGwSOMG5u3+bfGTtjX09z65HGOKzOMbTnGfyrofD+rx6c92l1aLO8sZSNyxGzII7fWsi8ilka4ufKKwljz2yelAFY5GM0UgB2jAHTsaUHPtQAUUUUAFFFFAB9K9H8L3vkaJarvxye30rzgda6vSLtYrCNQv3elAFr4j3huhpo3Z2K/P/fNcX/D9a3/FlyLlrZgMYUjH5Zrn+49MGgAooooAKKKKACiiigAooooAKAMnFFKjbW6UATxONhA6jpWrZXMbq4umVl2YCk4Ix9Ky4yN2QOtTKgwQFycZoA39DgsbqTZdPtUv8ozxweMn0r1KCLTk8DX32Z0uposcKTuiHPKjo3Tv6V5n4ftrS8WGMZ+0bgu3PP4V9BfDn4azjRJXULaNeLz57EGUEHHrgc/rQB8v6+M3RYSExk5/eABh6g4qLQ7GO9vdkz7Ihgsfau7+MPhC88H6/La3xg2TbpYzCxYYPI5IHPNcj4cvbay+0G8VuU+Uj1waANTXTpWl2UcFjDM87DHmN93+dZcHh3V7vT/7Wgtke2ZZZF2zJvdYuZGVCdxCg5JA6Vn6hd/armR05i/hrr9E8X2dr4Tg0Oa3lDG3voZLqKJTLC0xUoY2JztO0q68ZVjQBykOm6lcaTc6xDbSPp9rMkEs/G1HcEqD9cH9PUVR+dmJbOa7nRvE+n2OhroUmmy/YZrGWG5uNx3mdyHEgTdtO10iAJ52qfWuWsNJuL5yVkgBxzkn/CgDOgiaWTGcfMOW6VsWmnRbZGmm81xyip0pJdFltlczXFuoB67j/hSWdrbyS/vL+3QD/aP+FAFyOK1fi/kARAP3KdaW1hsJbhms7SR4oxzsJJ/U1FMdLtPl3fbX6gRk4H8qotqtwVkhtSsMRONmMkfjQBa1G4jV2UIFB+6jkhh9cVlm4ZGyrKT3HYfSopQcnzGy9NA7ntQBbhuS0g8xgc/pVm4kQxFQzMxI+YAYArLJH8NOVyxHoKALDRFYgyj7pPJ71G13N9maAN8kh3FcDginTzEoqr92q+c0AOli2KhWVHYjOF7VGemT171ZsfI+0p9rRngJyyg88Uy5KCeUwKyw7jsHXCnoD+FAENFFFABRRRQAc9q0LSYpEFDis+nh8dKALOpSeZ5fO7Gc1THQU933DmmUAFFFFABRRRQAUUUUAFFFFABRgnvRSqpYgAZOeKAJouMHPStCwkt/M3uMgcNg81SaKSLZ5qYU96uxiEbSgJAHIFAHVaBFYzX9vNbRShkIOfQ+vWvoLw947FpZ2FjfRma0CrHMGwpCnADLjrjnNeCeEzFIhaAiCYAgtKflx39ea6jTr54LhoZP3kyjdFJGMqB36/hQB7T8QvAVr4+0O3vtDkik8qNgFldhjgYHGfSvmrxN4TPh/UGstWYRspP3eVPsD1r1XT/iRqvhmyEUJaFJSTlkU+Z7c/X9a5fxvrun+KJLe5uE2X7583JxuzjnGcetAHkcumbrlzBIqwkkLuPWnoDYuNyK7Z5OTgVt6naWsO0YZlDfKAfesi/8ryzyRzwvpQBFNeJLNkqGwPu5wKrTXQD7oo/KPfBJ/nUUvyODjgioWYt0NAEjzs4OWOTUBxk+9LgnrTSDmgAKqcZHSnKSp+U7QaSun8AWCaje6xAbUXUo0i7khj2b28wINpUf3h2xQBzTDvnJpvP4V3ngzw9DrdrqGiarCNPv7KWPUmmmTy5BarxcKc4PCFZAP9k461x+s3cV/q95dW1sltBNKzxQRjCxIT8qgewxQBT6ggA08RsFAPQ96ckW8fvHCLUsvk/JHGGdRjc1ADViZQPlLDHaoyAXIyFx61cETXTRW9hBJK54wBzmrF3o11ZhBfKsMjDIgP3sUAUIowVZmPGCqn+dIs720MkUbBEk4bjO7/Oat+SpUKoO1eT9aqzIN+SMDoKAIXhkjiSSRCiOflY96Yf8/SnoIxKnJC5+YryffANLN5W8+SzsmeC4AP6UAR0UUUAFFFFACUtFFABRRRQAUUUUAFFFFABRRRQAUqZ3Db1zxSUDggjrQB1ej3Wm3ulvZaojLdhsRSg8D9fp2qzbaO7Fksmiu0HVY2OfxrkIy68jByckV0fh2+vbS5E9tLkrj5VUEj86ANtbAoiWyu1hfN9xWGVP4nJqe2/tLSzvu2R2j5VwOD69qTVNb/tVoWv3WSeMYwow6/gOKzr7UUG2FGdosfNkDIx6UAXtf8R/2nZxQ3EJ84HCEfhXNvL5MitIp83t9KjuLpBPhScHpkc02e9ygUgHHQ0AJeXjznYBjFVmknZdpx8vSo55Q+SoINQxMwbO5eetAEk6syhpOMVCB83yVLjeSJHXafSrVlGfNCZQL2YnigCx4etIl1CK41HTGu7FWzIm9l3D6gg12HiTUPBN3YrDpegHTZEQhszyOWbHX5mNUNMsrh0ZY7q3MRU5XJ/wrnfEdsYLnaqKoyMupJz+dAGNNt85xGRsBIXHpSLuU7lJBHcHFOdMHO4GmhgSQvJ9qABmZmyzMT6k5NJ3FHY+3X2rTsdC1K+h86C0ke37y4+UUAUIklmlWNNzP2CgVsWegzth7srAg+YBvvOfYdK1NA0v7DNh5wbtvuqgyF+ua9H8C/DPVPEF8b++aK1sI2DtJMSu/vlcCgDD8HacdFsptQWzaOd+IXlJy3X5gOmOlc94lubR7mSaaU3N7MxaYJwF5/D3zXqfxYv9C0XR/wCx7G5W+v449nyH5Y+MGvn25uGlkLSkvjoDxj06elAFxrxV8wjByMLjsO1UZNzgt0BNVyTnqDnmnksQPQUANZaImRQytCshbgEsQR+VIzZpp5BBHGKAJWhkSESGMohPfpxUROTmn26O+2KLgk9ua0tc0HUNFW1fUIGjS6jWWJz0ZWAIP60AZVFHr7frRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRT1AJ9qAHQKSck4q4JXSPIO5Rx8vWqhj5znK+lPjDPKBFu3YxigCdZpBhyNqnv3NPN26ruwCKRvOtI2+Vo2frx1qjIRJll++etAFsyxzEDo3rVryIVh3u/UVmxqxAyDipJXUxhEzkUANLKsjFeRTJHVl6YPakyw4bvTcY5U0APt0J6AVYjDJIPMOyOqeCTnNPBkZggPI6cUAdNaMqQBkuh5fUrjmrUWlLrkFy9jEGa2CmaWWdIkTc21clmA5PFc7BJqBjKRAsoGMBRXY+BbfVYNL12GLSvtNxfJAsImgWSMFJQ5LKfbpweaAMyx8F6nerfeZDHAtjObWYXEyxFJQCSmCck4B6VF/wiWYwbq/s7Vc8faXZcfTANd3Z2GvDw/q1jqS3cGo39/8AbXuXso7gS5jZWHzEFWJOciuasfhp4s1eURrYvIo+ZinQD1NAFVoPDuh2ybbhdWv+o+zsdiH68H9K1NL1Hxd4rVNF0G3ne3+6YkiQhQeBz1rufB37PGuXUkU+rTQWtsCGwzHdj24r1G6v/B3wl0trazn3a1LHsZ0JYlgMcgnA5PYUAYHw4+GGh+C9PXWPHkqDUpAJFSSRl8vHJyBj1FWPHXxL0O30qTT9GaDyW3CRkYsNvY5PPTNeP+O/H83iTUHNy8ksa7l3OqrgH/d+lefarKShCALEeQR3HagC54r1S3vLqU2DApIxYsOQT+NcuQeQSKkllc8E5FQ55oAAQODTtxx1pppMCgBaBnqOgFFFACxvsdZI2wwNXNR1K71JYxdyGZYVCINoG0DgDiqQOKDycnrQAZ7A/hRRk4x2ooAKKKKACiiigAooooAKKKKACiiigAoUZBzRmlBGcmgCWKXyhhxxUkUo85XiJD9uKg8tm+cDK0+NinNAG1PfpLY+TcqRLxhugrCmUK5KMMZq1JIJEAbrVRuSaALVrM6jgbl9BUdzJvclRtI7VEkhQYFNY5OfWgBSS3WlHPApvSnIyg5YE0AGOtT2waMGQMFPtzSRBmJZPu+9WLaJ5WIF1BGO4lJH8hQB0vhjxFd2CZgmcMeN3lqQBXo3hPxjPFdx3Go3jGBSCwEaD+leQpFPER5N1FJ7R8j9RVi6urlYQsjleOwFAH1LB8YvByBEmhmnmAAZhgYx6/NVq8+NHhy3jR9MtrneBkuFUgfm1fIiLI7oQ3Ge4rZt7O4vYxH5qsoHQUAenePvi9qWr3jpps/lWxXBwik/jkcV5bfandahMZZ7kEBizZA5/So5LGK1mMcr7X781Vu1t4zy7MB0xQBNe6hAtuBbxbZD99yetYlzK8333BFJfSbyBGpCe9VtxHFAAwwcCm0pOaSgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBKUHFFFAEiyuowDxUqSxOpSTIPrVal4x8w57UAPcKv3Tn3phOaT3NJmgB1Hem5ozQA4nNKhweabRQBLv4IBwDSIyKw3DimcUAj0oA1ba7skj5jffj/Peq1xNHI27ax9Aaqbm7MBUiuc4cg+lAGhp9/HZ8zR7lPYGtePW4/IJtLVo9w5bOf5muciCEgyyAL6VeiubOPKOz4x2HWgB7kzSPIC7OfQCqVxJKMByfxAqY38Ue7yEbB9az5pjK5cnqelABI7NgE8UwnIxSZzRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRyegzRjPTrQAUVJHBLJFJJFGzpHjeV/gz6/kajxwPfp70AFFGGIJCkgdT6U+GJ5i3lKX2jJwOlADKKstYXS2v2lreRbfO3zCOM1WweKACigjA54FPjieVlCISzHAA70AMoqze2F3ZPGt3byRNINyhh1B6VWHO7JwQcEd/rQAUUHgZ7etBGCB3IzigAoo4GSxx9aBz05oAKKBzn2o/GgAooIwMn7vrR1+7z9KACij0HQk4pQCSQvJzgAd6AG55pRz1p0YzJtP3h19quQWNxePssoXnb/YoApE0lacugarFGzy2E6qoySQKzdjZYFSCpwRjpQAlFORHkcJGpZjwAB3rUTw3rLxJIum3BR/unA5/WgDJoq7qWl3umSxx6hbSW7uNyhx1qj/POKAFqewtpL29ht7cFp5XEcfpuJwKgrW8KSpH4n0l5WASK7ick8cBgaALFz4bezuGjvdU02C5B+ZJnYEEfRaRvDc76dcX1re2d5HAw83yGY7c5x1A9DWp4u0TVNQ8RajdWVhLNBNM7o6YwQWJGOan0iwutJ8H+IY7+BrZrhoCqv1bG/OPzFAHDkEMQQQQehooIAY4BAzRQAUUUUAFFFFACHGDuGQKfbtGksUkiLJFuAZATnFNBx0oPJzQB6VpVx4bXSZLRbm2todVQLJDLI263kjHDt14JckcnociuY1u40KzvzDpVhHdRQosb3DSuBJJ0Zhg/dJHHT8K5vH880pOTk0AapvtObDnQ4Co6kzyAfzqePxJeWgzparZQdFUAOPzbJrD75o/i3d6AN6bxfrsyqsl7uC8lREmAPXpVY6tDLukuNOgnnPPnGR1OfXA4rLz1pO9AGoupW7/67TLeUg/eMrjA9ODVj/hJLu3AXTo1sYB/Cg8zP4tmsPNAODnvQB0lv4mF28UPiWEX9khJVR8jIT1I24yenBPanCy0DVdTEOnXV1bNMQsSXCqFDHgDIJOPeuZzwR69aVWKkFeCORQB6Jrej6SNNtbJ7yG1uNNVmvJgxKy5xtVM/wAXytjgdeawvtHhWEoiWt7OQMtJJhSx9cBsYrmXkZ2LMck03J49qAOqW/8ACq5K6bdO3puP/wAVWXNqGmtM5h0aEJk43TyZx781k9896KAN6x1HRCxW80hVXu0Uzls/QnFWvtvhbP8AyDrr/vo//FVy46EUUAdUL3worFhpt3uIwCGP6fNUd7rGlW/kjQ9PaCYqwuGnY5dTjjGSAOvIrme1B6Y7UAb922j6hFbnTsafd4InM7ExOeOh5Pr2FaXhfwtFd3S3NzJaX+lWreZeLbyP8ijnBOB94A9+1cd2+hzV/T9XvtPtbu3tJ/Lhu12zLtB3jn1HHU9KAN/xV4dSxupb2zeGDTLg+ZaxuxLGPrgdc4BGcmsa21e90wj7HMIwRwdoP8xVO4vrm5hhimk3RwjCDAGB/kCq5cnqaAN1PGGtoWxfgk+kSf4U1vFWsEf8fSoe5Ma8/pWHnmjvmgDb/wCEr1g8LeBsdhEmP5VUv9ZvtRRReXCuAegAH8hWfmlBIGBQBsWutsbZLbUbcXtmjYCsSuz6EYJP1puvXOlXC2w0m1lt3UHzfMJOemMcngc1kevvQScAdhQAUE4X5jhTxz29aKASDkdaAAksACxbaMLzgYoJ3L03be2fzpDzxSg4IPpQAYx+POPSij196KACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAo6UVahsLueISQwOyHPIHpQBVoqVraeMnzY3UjjmoyCD0oASig0UAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Subcostal four-chamber view from a two-dimensional echocardiogram shows a moderate-sized pericardial effusion (PE) in a patient with normal hemodynamics at cardiac catheterization. The effusion surrounds the right atrium (RA), right ventricle (RV) and left ventricle (LV).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ralph Shabetai, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24190=[""].join("\n");
var outline_f23_39_24190=null;
var title_f23_39_24191="Approach to fluid management in adult with hypovolemia";
var content_f23_39_24191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Approach to fluid management in adult with hypovolemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 525px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Regina C LaRocque, MD, MPH, and Mark Pietroni, MA, MBBChir, FRCP, DTM&amp;H.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_39_24191=[""].join("\n");
var outline_f23_39_24191=null;
